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ABSTRACT 
In this thesis several aspects related to the production and subsequent 
modification of the peptide sequences within food matrices have been studied, taking 
into account the influence of technological treatments, and the modifications once they 
are ingested, including gastrointestinal digestion, absorption and metabolism. Liquid 
chromatography coupled to tandem mass spectrometry with different analyzers (ion 
trap, Q-TOF, MALDI TOF/TOF) has been used to perform sequencing and 
quantification of peptides within different dairy matrices (fermented milk, cheese, 
gastrointestinal digests) or biological samples (plasma). Special attention has been 
paid to the β-casein region 126-140, which is a well conserved domain among different 
species and hosts several active sequences, such as LHLPLP, f(133-138) , and 
HLPLP, f(134-138).  
The production of active compounds and the impact of the packaging conditions 
on peptides have been also evaluated in this thesis. An alternative was provided to 
produce active hydrolysates, containing the antihypertensive peptides from β-casein, 
f(134-138), HLPLP, and f(133-138), LHLPLP, by casein fermentation using two food-
grade yeast strains of Debaryomyces hansenii. In addition, the peptide profile of two 
cheeses packed using different technologies, vacuum and modified atmosphere, was 
studied during the shelf life of the product. No marked qualitative differences could be 
found in the peptide profile regarding the packaging technique and storage time, 
although the relative abundance of the peptides was different in both packaging 
systems. Once the production of active compounds and the impact of the packaging 
conditions on peptides have been evaluated, the peptidome generated through 
digestion under different conditions of several dairy matrices was studied. Skimmed 
milk powder (SMP) and a highly proteolysed blue cheese were subjected to static 
gastrointestinal digestion in order to assess the influence of the proteolytic state of the 
matrix in the release of peptides. Several regions of β-casein were shown to be 
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resistant to digestion i.e. 60-93, 128-140 and 193-209, in both matrices. The 
differences found among cheese and milk were attributed to the initial state of 
proteolysis of cheese, which hosted several precursor fragments for bioactive peptides, 
i.e. LHLPLP, before digestion, in contrast to SMP. On the other hand, the impact of 
heat treatment on the release of peptides during gastric digestion of heated and 
unheated milk has been studied using a dynamic digester, which represents next step 
after static models to better reproduce physiological conditions. The heat treatment 
elicited an increase in the resistance of casein fraction to digestion by pepsin, in 
contrast to β-Lg, which became more susceptible. Some resistant domains from β-
casein (76-93, 126-140 and 190-209) were identified regardless the heat treatment, 
where the active sequences LHLPLP and HLPLP are located. Later on, an 
antihypertensive sequence included in the resistant domain of β-casein 126-140, i.e. 
HLPLP, f(134-138), was demonstrated for the first time to be absorbed into blood 
circulation in rats after its oral administration. The kinetic parameters of HLPLP after 
oral and intravenous administration were determined, being the effective absorption 
around 5.18 %, based on the quantification of the intact penta-peptide in plasma. 
However, it was found that several derived fragments, HLPL β-casein f(134-137) and 
LPLP β-casein f(135-138), were rapidly formed in plasma after both types of 
administration, and therefore, the absorption of the peptide is probably higher. The 
degradation of the penta-peptide by the action of plasma peptidases was confirmed by 
in vitro incubation of HLPLP in plasma, where several fragments i.e. HLPL, LPLP and 
HLP were released, and the antihypertensive activity of these fragments was 
demonstrated in a SHR model.   
Subsequently, the implication of opioid receptors in the mechanism of action of 
two antihypertensive peptides from αs1-casein (RYLGY, f(90-94) and AYFYPEL, f(143-
149)) and of a casein hydrolysate, containing these, was shown by the co-
administration of naloxone. The antihypertensive activity of YFYPEL, αs1-casein f(144-
Abstract 
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149) also present in the hydrolysate, was demonstrated for the first time, but its 
mechanism of action did not seem to involve opioid receptors. 
The application and optimisation of peptidomic techniques has permitted to 
characterise the peptide fraction within dairy matrices and to evaluate the influence of 
the technological treatments, the changes during digestion, absorption, metabolism, 
and ultimately estimate the in vivo bioavailability of an active sequence. 
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RESUMEN 
En esta tesis se abordan varios aspectos relacionados con la producción y las 
modificaciones de la fracción peptídica en matrices alimentarias, teniendo en cuenta la 
influencia de los tratamientos tecnológicos, y los cambios que sufren tras ser ingeridas, 
incluyendo la digestión gastrointestinal, absorción y metabolismo. Se ha utilizado 
cromatografía de líquidos acoplada a espectrometría de masas en tándem con 
distintos analizadores (trampa de iones, Q-TOF, MALDI TOF/TOF) para llevar a cabo 
tanto la secuenciación como la cuantificación de péptidos en distintos productos 
lácteos (leche fermentada, quesos, digeridos gastrointestinales) o muestras biológicas 
(plasma). Se ha prestado especial atención a la región (126-140) de la β-caseína, 
donde se encuentran incluidas algunas secuencias activas de interés, por ejemplo 
LHLPLP, f(133-138) y HLPLP, f(134-138). 
Se propone una alternativa para la producción de hidrolizados activos que 
contienen los péptidos antihipertensivos de la β-caseína f(134-138), HLPLP, and f(133-
138), LHLPLP, mediante la fermentación de caseína comercial con dos cepas de 
levaduras de Debaryomyces hansenii de grado alimentario. Se evaluaron en quesos 
semicurados el efecto del envasado, a vacío y en atmósfera modificada, en el perfil 
peptídico durante su vida útil. No se encontraron diferencias cualitativas destacables 
en el perfil peptídico de los quesos respecto al tipo de envasado pero sí en la 
intensidad relativa de los péptidos identificados. Una vez se hubo examinado la 
producción de secuencias activas y el impacto del envasado en el perfil peptídico, se 
estudió el peptidoma generado durante la digestión de varios productos lácteos, 
utilizando distintas condiciones. Se comparó el peptidoma obtenido al someter leche 
en polvo y queso azul a un proceso de digestión gastrointestinal estática, con el fin de 
evaluar la influencia del estado proteolítico de la matriz en la formación de péptidos. 
Se observó la resistencia a la digestión de ciertas regiones de la β-caseína, 
concretamente los residuos 60-93, 128-140 y 193-209, tanto en los digeridos de leche 
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en polvo como de queso. Sin embargo, también se observaron diferencias que pueden 
ser atribuidas al estado proteolítico inicial del queso, que antes de su digestión ya 
contenía fragmentos precursores de algunos péptidos activos estudiados como el 
péptido LHLPLP. Por otra parte, se estudió la formación de péptidos, en leche con 
distinto tratamiento térmico, a lo largo de la digestión gástrica empleando un digestor 
dinámico, cuyo uso representa un nivel más sofisticado con respecto a los modelos 
estáticos para reproducir las condiciones fisiológicas. Se pudo concluir que el 
tratamiento térmico provoca un aumento de la resistencia de las caseínas a la 
digestión por pepsina, en contraposición a la β-Lactoglobulina, que resultó ser más 
susceptible. Se identificaron algunos dominios de la β-caseína resistentes a la 
digestión gástrica independientemente del tratamiento térmico, por ejemplo las 
regiones 76-93, 126-140 y 190-209, una de las cuales alberga las secuencias activas 
LHLPLP y HLPLP, mencionadas anteriormente. Más adelante, se demuestra por 
primera vez que una secuencia antihipertensiva perteneciente al dominio de la β-
caseína 126-140, resistente a la digestión, HLPLP f(134-138), se absorbe al torrente 
sanguíneo de ratas tras su administración oral. Además, se calcularon los parámetros 
farmacocinéticos de absorción y eliminación de dicho péptido. Su absorción total 
efectiva, determinada en base a la cantidad intacta del pentapéptido fue estimada en 
5.18%. Sin embargo, se constató que tras su administración intravenosa y oral se 
formaban rápidamente varios fragmentos in vivo derivados de él como el HLPL, β-
caseína f(134-137) y LPLP β-caseína f(135-138), por lo que la absorción efectiva 
probablemente es mayor a la calculada. La incubación del péptido HLPLP in vitro 
permitió confirmar la degradación del péptido HLPLP por acción de las peptidasas 
plasmáticas, encontrándose los fragmentos HLPL, LPLP y HLP, que presentaron 
actividad antihipertensiva en un modelo de ratas espontáneamente hipertensas.  
Asimismo, se muestra que los receptores opioides están implicados en la 
actividad antihipertensiva de los péptidos RYLGY, αs1-caseína f(90-94) y AYFYPEL, 
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αs1-caseína f(143-149) y el hidrolizado activo que los contiene, a través de su 
coadministración con naloxona. Se ha demostrado por primera vez la actividad 
antihipertensiva del péptido YFYPEL αs1-caseína f(144-149), presente también en el 
hidrolizado, pero cuyo mecanismo de acción no parece implicar receptores opioides. 
La aplicación y optimización de las técnicas peptidómicas ha permitido realizar 
una caracterización de la fracción peptídica de distintos productos lácteos y evaluar la 
influencia de los tratamientos tecnológicos, los cambios durante la digestión, absorción 
y metabolismo, llegando a estimar la biodisponibilidad in vivo de una secuencia activa. 
 10 
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ABBREVIATIONS 
ACE: Angiotensin Converting-Enzyme 
α-La: α-Lactalbumin 
β-Lg: β-Lactoglobulin 
CPP: Caseinophosphopeptides 
CM: Casomorphins 
Cmax: Maximum Concentration 
CMP: Caseinomacropeptide 
ESI: Electrospray ionization 
GRAS: Generally recognized as safe 
HPLC: High performance liquid chromatography 
IT: Ion trap 
LF: Lactoferrin 
MALDI-TOF: Matrix-assisted laser desorption/ionization-time of flight 
MS: Mass scpectrometry 
MS/MS: Tandem mass spectrometry 
N: Nitrogen 
NO: Nitric oxide 
Q-TOF: Quadrupole-time of flight 
SDF: Simulated duodenal fluid 
SGF: Simulated gastric fluid 
SHR: Spontaneously hypertensive rat 
SMP: Skimmed milk powder 
Tmax: Time required to reach the maximum concentration 
UHT: Ultra high temperature 
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OBJECTIVES AND WORK PLAN 
In the last decades, there has been an increasing interest on protein 
hydrolysates produced by enzymatic hydrolysis or by fermentation, containing 
biologically active peptides, such as, opioid (Teschemacher et al., 2003), 
antihypertensive (Martínez-Maqueda et al., 2012), antimicrobial (López-Expósito et al., 
2008); or to improve mineral bioavailability (Phelan et al., 2009). When assessing the 
bioactivity of a given compound, i.e food-derived peptide, using animal models, the 
peptide is usually orally administered, and an observed effect is associated to its 
administration. However, the different phenomena occurring from the ingestion of the 
bioactive compound to the observation of the physiological effect remains unknown in 
most cases. Thus, it is crucial to explore the events occurring either before food 
ingestion (i.e. stability during shelf-life of the product) or once ingested, i.e., during 
gastrointestinal digestion, absorption, metabolism, mechanism of action, in order to 
elucidate the relationship between a bioactive compound and a given biological effect 
and also to identify the active form of this compound.  
With this in mind, the primary objectives of the research were: 
 
Objective 1 
Application of a peptidomic strategy to the identification of peptides during production, 
shelf-life of the product and changes during digestion. Concretely, this first objective 
comprises three partial objectives: 
1. Targeted search of antihypertensive peptides in casein fermented by yeasts 
2. Evolution of the peptide profile of cheese during shelf-life when different 
packaging technologies are used (vacuum and modified atmosphere). 
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3. Evaluation of the changes undergone by dairy proteins during in vitro 
simulated gastrointestinal digestion to assess (i) the impact of proteolysis 
degree of the dairy matrix on the final digestome and (ii) the impact of heat 
treatment of milk protein on the subsequent release of peptides during 
dynamic gastric digestion. 
 
To carry out these partial objectives (1, 2 and 3), this working plan was followed: 
 
 
Semi-hard cheese
(MODIFIED ATMOSHPERE 
PACKAGING)
Zymography
CASEIN
Debaryomyces hansenii
Kluyveromyces lactis
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Targeted analysis: 
Antihypertensive peptides
Casein
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HPLC-
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28ºC, 
100 rpm
6 days
ACE assay
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quantification
Partial Objective 1
Whole peptide
profile
WaterSoluble
Extract
(WSE)
HPLC-
ESI-ITUltrafiltration< 3000 Da
Semi-hard cheese
(VACUUM PACKAGING)
Partial Objective 2
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Scheme 1. Working plan objective 1 
 
 
Objective 2 
The aim of this study was to characterize whether the β-casein-derived peptapeptide 
HLPLP is bioavailable in rats, and to calculate the main kinetic parameters of 
absorption and elimination. Furthermore, the stability of the peptide in plasma was 
studied, as well as, the antihypertensive activity of the derived fragments. 
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Sequencing
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i
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Scheme 2. Working plan objective 2 
 
 
Objective 3 
To evaluate the involvement of the opioid system in the mechanism of action of the 
active peptides [RYLGY f(90-94), AYFYPEL f(143-149) and YFYPEL f(144-149)] and 
an antihypertensive casein hydrolysate containing them. 
To carry out these objectives, this working plan was followed: 
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Scheme 3. Working plan objective 3 
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In the last years, much research has been done regarding the health effects of 
food proteins and on the biologically active peptides included in their sequences. There 
is evidence on different physiological processes occurring in the body mediated by 
endogenous peptides that can act as hormones or signalling peptides. Food proteins 
can lead to the release of peptides structurally similar to those found endogenously. 
Therefore, they could act as agonist or antagonist at the same target as their 
endogenous homologous peptides (Meisel et al., 1998). Therefore, recent research has 
been focused on the biological effect produced by peptides, such as, opioid 
(Teschemacher et al., 2003), antimicrobial (Agyei et al., 2012; López-Expósito et al., 
2008), or antihypertensive (Martínez-Maqueda et al., 2012).  
Likewise, much effort has been dedicated to the investigation of foodstuff itself, and to 
the processing thereof to produce certain bioactive sequences within the matrix, by 
fermentation or hydrolysis (Korhonen, 2009.) However, little information is available 
about the changes that active sequences undergo from ingestion to arrival at target 
organ. Therefore, it is important to understand these changes, since it would permit to 
establish a relationship with bioactivity, and attribute it to a certain compound. For 
instance, one of the most important parameters to consider when studying a bioactive 
compound is its bioavailability. From the nutritional perspective it is defined as the 
fraction thereof available to be employed in physiological functions or stored by the 
organism. This term includes another one, less extended, called bioaccesibility, which 
is the portion of the compound of interest released from the food matrix in its soluble 
form, becoming absorbable (Fernández-García et al., 2009). Both concepts are mostly 
determined by the process that food should undergo upon ingestion, gastrointestinal 
digestion. Digestion process provokes important modifications on foodstuff, and 
especially on food proteins, which determines the release, among others, of peptides 
encrypted in the proteins sequences. In order to exert their physiological effect, these 
peptides need to be available for absorption and subsequent use by the organism, or 
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for interaction with intestinal receptors (Shimizu et al., 2007; Shimizu, 2010). However, 
few studies have been carried out on the absorption of food-derived peptides, and their 
detection in plasma. Once it has been shown that a certain peptide is absorbed into 
blood circulation and could reach target organ, it is important to evaluate its 
metabolism, distribution, elimination and mechanism of action, to elucidate how and at 
which dose the peptide induces a positive effect on the organism, in order to establish 
a relationship between food and health. Up to date, no food-derived peptide has been 
approved by the EFSA, because the evidence presented was not sufficient to establish 
a cause and effect relationship between their consumption and a given health claim, 
such as, the maintenance of normal blood pressure. Therefore, there is a need to shed 
some light into the factors affecting the food from its ingestion to the final physiological 
effect of a peptide, which also involves the identification of the active form in vivo and 
the elucidation of its mechanism of action (Figure 1). 
 
 
Figure 1. Path from ingestion to physiological effect. 
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1.1 Milk composition 
Milk is an oil/water emulsion containing numerous substances, either in 
dissolution or in colloidal state. In addition to carbohydrates, lipids, water and minerals, 
milk contains proteins. The amount of the latter present in ovine milk is 4.75-7.20%, in 
caprine milk 2.6-4.1% and in bovine milk 2.5-3.5%. In all cases the total content of 
proteins depends on the breed, on individual animal variations, on lactating stage, and 
on nutritional and health state of the animal (for review see Raynal-Ljutovac y col., 
2008; Dalgleish, 1993). 
The protein composition of milk can be divided in two groups: whey proteins 
and caseins. The whey proteins are mainly comprised by 4 units: β-Lactoglobulin (β-
Lg), α-Lactalbumin (α-La), seralbumin, and immunoglobulins (Ig). In addition, other 
minor proteins are present in milk, such as, Lactoferrin (LF), proteose peptone 
(fragments from N-terminal end of β-casein), enzymes and globular proteins from fat 
globule membrane. Whey proteins are globular proteins that undergo heat-induced 
denaturation. Moreover, they are not susceptible of phosphorylation, they are not labile 
to calcium and they display intramolecular disulfide bonds that stabilise their structure. 
The two major whey proteins are β-Lg and α-La. The first one is the most abundant one 
in ovine, caprine and bovine whey, although is not present in human milk.  
The casein fraction comprises 4 proteins: αs1-, αs2-, к-, and β-casein. Another 
minor protein exists in the casein fraction, γ-casein, generated by the action of 
proteolytic enzymes on β-casein. The total content of casein, as well as the relative 
ratio of each protein is characteristic for each species. In the case of ovine milk, the 
casein fraction is present at 45 g/L, being the percentages of caseins 33-35%, 8-14%, 
30-38% and 14-17% for αs1-, αs2-, β- and к-casein, respectively. In bovine milk, the 
amount of caseins is 29 g/L and the different caseins represent 37.6-39.5%, 7.8-12.1%, 
33.4-44.6% and 9.5-19.7%, respectively. On the other hand, the content of caseins in 
caprine milk can vary from 27 g/L to 32 g/L, depending on the genetic polymorphism of 
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αs1-casein, and the amount of them is 18-21%, 11-13%, 48-63% and 8-15%, 
respectively. Overall, caprine milk contains less αs1-casein compared to other 
ruminant’s milk (Bramanti et al., 2003; Raynal-Ljutovac y col., 2008). The caseins are 
proteins that may be phosphorylated in Serine residues and precipitate at pH 4.6 (could 
slightly change depending on the species), whereas the whey proteins are soluble at 
this pH value. Moreover, caseins are found in micellar structures. These structures are 
supramolecular protein aggregates containing caseins combined with calcium 
phosphate, magnesium, potassium, sodium and little amount of citrate (Fox, 1992).  
 
1.2  Gastrointestinal digestion of milk proteins. Application of peptidomic-based 
techniques 
 
Upon ingestion, food undergoes complex chemical and physical changes 
mediated by peristaltic movements and the different enzymes involved in 
gastrointestinal digestion that will finally disintegrate food. As a result of the specific or 
unspecific action of enzymes on food, macro- and micronutrients are released, and 
when they finally reach the small intestine, the absorption process occurs, mainly at the 
jejunum (Langerholc y col., 2011). In the case of proteins, they are differently 
susceptible to proteases depending on their conformation, the presence of cross-
linkages between protein chains, fixed metals, antinutritional factors, like trypsin or 
chymotrypsin inhibitors, particle size of proteins ingested or biological differences 
between individuals. Milk proteins belong to the easily utilized class of proteins with a 
digestibility of 95% (Damodaran, 1997). 
Given the undeniably important role of digestion on food components that finally 
will influence health, it is essential to know how food proteins are degraded during this 
process. The in vivo experiments provide the most valuable information in this sense. 
Intervention studies have been carried out in humans in order to evaluate digestion of 
milk proteins (bovine unless otherwise indicated). Nevertheless, animal models have 
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been widely used as a preliminary approach on the study of in vivo digestion of milk 
proteins. Porcine models are one of the most commonly used models, to whom 
cannulas at stomach and jejunum are usually placed to collect the effluents (Figure 2); 
although reports exist on the use of rats or calves at this aim. 
 
 
Figure 2. Cannulated pig.  
 
1.2.1. Human studies on digestion of milk proteins 
Several studies have been conducted in humans to study the in vivo digestion of 
milk proteins. Milk proteins have high oro-ileal digestibility, and protein quality, 
assessed in terms of the net postprandial protein utilization in healthy humans (Bos et 
al., 1999). The influence of diet composition on the postprandial utilization of milk 
proteins has been pointed out (Gaudichon et al., 1999). Indeed, in this work the 
ingestion of milk supplemented with sucrose delayed the absorption of protein longer 
than supplementation with milk fat, but digestibility of proteins remained unchanged. In 
addition, the different supplementation modified the metabolic utilization of nitrogen (N) 
while the N absorption did not vary. Moreover, a study in patients with a high 
jejunostomy revealed that the digestion of milk proteins seemed to be incomplete in the 
upper jejunum; thus, the lower part of jejunum and the ileum play a key role to 
accomplish complete digestion and absorption processes (Mahé et al., 1991a). In 
addition, in this study they detected 64% and 44% of β-Lg and α-La, respectively, in an 
intact antigenic form at jejunum. Troost et al. (2001) reported over 62% of intact LF 
after gastric digestion in humans, during which the iron saturation of LF did not 
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influence significantly the degradation of the protein. The hydrolysis of 15N-labeled 
protein in milk and yogurt was evaluated in humans (Gaudichon et al. 1995). They 
observed that the fermentation process only modified the gastric emptying rate but not 
the level of hydrolysis of the protein, the endogenous N stimulation or the digestibility 
rate. Likewise, Mahé et al. (1991b; 1995) observed different behavior for β-Lg, caseins, 
skim milk and yogurt in the intestine of healthy humans, due to differences in their 
gastric emptying rates. On the other hand, Calbet et al. (2004) observed similar values 
of gastric emptying after the administration of casein, whey proteins and their 
corresponding hydrolysates to humans; as well as the amino acids absorption values, 
except in the case of casein, which showed slower rates. In addition, these authors 
observed that the hydrolysates compared to the whole protein solutions induced an 
increase of 50% of gastric secretion and of glucose-dependent insulinotropic 
polipeptide (GIP), a gut peptide that counterbalance the secretagogue effect of amino 
acids. The basal gastro-jejunal secretions have been demonstrated to be stable in 
composition, which are partly comprised of proteins with rapid rate of synthesis 
(Gaudichon et al., 1994a). Moreover, the influence of the protein amount on the 
digestion kinetics of 15N labeled β-Lg and casein has been also evaluated in humans 
(Mahé et al., 1996). In this study, they reported differences in the amino acid delivery 
and in the nature of products present in lumen between both proteins. This fact could 
be attributted to the different gastric emptying, which occurs as peptides for casein, and 
for β-Lg mainly in intact form. These two proteins have been described as “slow” and 
“fast” proteins, respectively, in regard of the kinetics of hydrolysis during digestion and 
the amino acid absorption rate (Boirie et al., 1997). This may have been elicited by the 
coagulation of casein in the stomach leading to a longer retention, in contrast to β-Lg, 
which is soluble and can be rapidly emptied from stomach. Dangin et al. (2001) 
observed that “fast”-protein meal produced a strong, rapid and transient increase in 
aminoacidemia, L-1-13leucine flux and oxidation vs. the “slow”-protein meal, which 
increased these parameters, but they were maintained longer over time. Furthermore, 
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kinetics of dietary amino acid delivery from different food proteins could ultimately 
influence the anabolic responses in the body since “slow” digested proteins can induce 
better postprandial use of dietary N (Lacroix et al., 2006a). Likewise, Deglaire et al. 
(2009a) evaluated the postprandial utilization of proteins after ingestion of two diets 
based on intact and hydrolyzed casein in humans. The hydrolyzed casein diet elicited 
faster absorption rate, which led to stronger and earlier hyperaminoacidemia and 
hyperinsulinemia, and resulted in less N peripheral availability for anabolic use after its 
ingestion compared to casein ingestion. Thus, the fast supply of amino acids favors the 
splanchnic use of N at the expense of their anabolic use in peripheral tissues such as 
muscle, as it was previously reported for the fast soluble milk or soy proteins compared 
to caseins in humans (Fouillet et al., 2006; 2002).  
Some studies on the characterization of the resulting products from milk protein 
digestion in humans have been reported, as shown in table 1, where the peptides 
identified within in vivo digests can be observed. The management and analysis of 
samples from in vivo digestion is difficult. Nevertheless, several examples can be found 
on the identification of peptides released from in vivo digestion of milk proteins, 
although few studies have reported information about the whole profile of in vivo 
digests in humans. Among the human trials conducted on this topic, in 1985, Svedverg 
et al. identified immunoreactive material from β-casomorphins (β-CM)-4, 6 y 7, 
originated from β-casein fragment (f)(60-63), f(60-65) y f(60-66), respectively in small 
intestine of humans. All of these sequences had been previously reported as opioid 
peptides (Brantl et al., 1981). Later on, Chabance et al. (1998) conducted a human 
trial, at stomach and duodenal level, and in which several peptides derived from the 
casein fraction, could be recorded, after ingestion of milk or yogurt. After milk ingestion, 
a total of 26 peptides were identified from αs1-, αs2-, β and к-casein in gastric contents, 
in contrast to eight peptides found after yogurt ingestion (from αs1-, β and к-casein). In 
both effluents the caseinomacropeptide (CMP) [f(106-169) from к-casein) and its N-
terminal part i.e. f(106-117), MAIPPKKNQDKT, were found, which results from the 
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cleavage of the peptide bond Phe105-Met106, commonly known to be cleaved by pepsin 
during gastric phase, and their resistance during intestinal phase. In duodenal content 
the peptides were shorter than in stomach, and the sequences belonged to αs1-, β and 
к-casein, and as well as to LF. Among these sequences, some active peptides from 
αs1-casein could be identified, such as the antihypertensive peptide AYFYPEL, f(143-
149), found in the stomach content. The peptide YFYPEL, f(144-149), known as 
antioxidant (Suetsuna et al., 2000) or stimulant of mucin secretion and expression 
(Martínez-Maqueda et al., 2013); and VAPFPEVF f(25-32) as angiotensin converting-
enzyme (ACE)-inhibitor (Contreras et al., 2009), were found in duodenal fluids, and the 
latter one also in stomach content. Moreover, several fragments from the β-casein 
domain comprised between residues 29-48 were found in stomach content, which 
suggested the resistance of this region to gastric digestion. Later on, reports appeared 
on the identification of the CMP in digestive fluids isolated from jejunum of humans 
after consumption of casein, yogurt and whey proteins (Ledoux et al., 1999).  
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Table 1. Peptides sequences from β- and αs1-casein identified in gastrointestinal effluents from adult humans 
Sequence Protein fragment Location Substrate Reference 
RELEELNVPGEI β-CN 1-12 Stomach; duodenum; jejunum Milk; CN1 Chabance et al., 1998; Boutrou et al., 2013 
RELEELNVPGEIVE* 
(19 fragments included in this domain) 
β-CN 1-14 Jejunum CN Boutrou et al., 2013 
LNVPGEIVE β-CN 6-17 Stomach Milk Chabance et al., 1998 
NVPGEIVE β-CN 6-14 Jejunum CN Boutrou et al., 2013 
LNVPGEIVELS β-CN 7-14 Jejunum CN Boutrou et al., 2013 
NVPGEIVEL β-CN 7-16 Duodenum Milk Chabance et al., 1998 
NVPGEIVELSS β-CN 7-18 Duodenum Milk Chabance et al., 1998 
KIEKFQSEEQQQ β-CN 29-40 Stomach Milk Chabance et al., 1998 
KIEKFQSEEQQQT β-CN 29-41 Stomach Milk Chabance et al., 1998 
IEKFQSEEQQQT β-CN 30-41 Stomach Milk Chabance et al., 1998 
FQSEEQQQTED β-CN 33-44 Stomach Milk Chabance et al., 1998 
FQSEEQQQTEDELQDK β-CN 33-48 Jejunum CN Boutrou et al., 2013 
TEDELQDKIHPF* 
(6 fragments included in this domain) 
β-CN 41-52 Jejunum CN Boutrou et al., 2013 
DKIHPF β-CN 47-52 Jejunum CN Boutrou et al., 2013 
SLVYPFPGPIPNSL* 
(22 fragments included in this domain) 
β-CN 57-70 Jejunum CN Boutrou et al., 2013 
YPFP (β-CM 4) β-CN 60-63 Duodenum Milk Svedverg  et al., 1985; 
YPFPGP (β-CM 6) β-CN 60-65 Duodenum; jejunum Milk; CN Svedverg  et al., 1985; Boutrou et al., 2013 
YPFPGPI (β-CM 7) β-CN 60-66 Duodenum; jejunum Milk; CN Svedverg  et al., 1985; Boutrou et al., 2013 
PGPIPN β-CN 63-68 Jejunum CN Boutrou et al., 2013 
YPFPGPI (β-CM 9) β-CN 60-68 Jejunum CN Boutrou et al., 2013 
PNSLPQNIPPLTQTPVVVPPFLQPEV* 
(12 fragments included in this domain) 
β-CN 67-92 Jejunum CN Boutrou et al., 2013 
SLPQNIPPLTQT β-CN 69-80 Duodenum; jejunum Milk; CN Chabance et al., 1998; Boutrou et al., 2013 
VPPFLQPEV β-CN 84-92 Duodenum Milk Chabance et al., 1998 
VPPFLQPEVM β-CN 84-93 Duodenum Milk Chabance et al., 1998 
GVSKVKEAMAPK β-CN 94-105 Stomach yogurt Chabance et al., 1998 
HKEMPFPKY* 
(5 fragments included in this domain) 
β-CN 106-114 Jejunum CN Boutrou et al., 2013 
EMPFPKY β-CN 108-114 Jejunum CN Boutrou et al., 2013 
HKEMPFPKYPVQPFT β-CN 106-120 Stomach Milk Chabance et al., 1998 
KEMPFPKY β-CN 107-114 Stomach Milk Chabance et al., 1998 
YPVQPF β-CN 114-118 Duodenum Milk Chabance et al., 1998 
YPVQPFTESQS* β-CN 114-124 Jejunum CN Boutrou et al., 2013 
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(8 fragments included in this domain) 
TLTDVENLHLPLPLL* 
(24 fragments included in this domain) 
β-CN 128-140 Jejunum CN Boutrou et al., 2013 
LHLPLP β-CN 133-138 Jejunum CN Boutrou et al., 2013 
WMHQPHQPLPPTVMFPPQSVL* 
(26 fragments included in this domain) 
 
β-CN 144-163 Jejunum CN Boutrou et al., 2013 
HQPHQPLPPTVM β-CN 145-156 Duodenum Milk Chabance et al., 1998 
VMFPPQSVLSL β-CN 155-165 Duodenum Milk Chabance et al., 1998 
SLSQSKVLPVPVPE β-CN 164-175 Stomach Milk; yogurt Chabance et al., 1998 
SKVLPVPVQK* 
(6 fragments included in this domain) 
β-CN 168-176 Jejunum CN Boutrou et al., 2013 
KAVPYPQRMPIQ* 
(4 fragments included in this domain) 
β-CN 176-187 Jejunum CN Boutrou et al., 2013 
FLLYQEPVLGPVRGPFPIIV* 
(29 fragments included in this domain) 
β-CN 190-209 Jejunum CN Boutrou et al., 2013 
HPIKHQGLPQEV αs1-CN 4-15 Stomach; jejunum Milk; CN Chabance et al., 1998; Boutrou et al., 2013 
HPIKHQGLPQEVLNENLL* 
(9 fragments included in this domain) 
αs1-CN 4-21 Jejunum CN Boutrou et al., 2013 
EVLNE αs1-CN 14-18 Duodenum Milk Chabance et al., 1998 
FFVAPFPEVFG* 
(15 fragments included in this domain) 
αs1-CN 23-33 Jejunum CN Boutrou et al., 2013 
FVAPFPEVF αs1-CN 24-32 Jejunum CN Boutrou et al., 2013 
VAPFPEVF αs1-CN 25-32 Stomach; duodenum; jejunum Milk; CN Chabance et al., 1998; Boutrou et al., 2013 
FVAPFPEVFGKE αs1-CN 25-34 Stomach yogurt Chabance et al., 1998 
FPEVFGKE αs1-CN 28-35 Duodenum Milk Chabance et al., 1998 
EKVNELSKDIGSEST αs1-CN 35-49 Stomach Milk Chabance et al., 1998 
DQAMEDI αs1-CN 51-57 Jejunum CN Boutrou et al., 2013 
AMEDIKQMEAE αs1-CN 53-63 Jejunum CN Boutrou et al., 2013 
EIVPNSVEQKHIQ αs1-CN 70-82 Stomach yogurt Chabance et al., 1998 
HIQKEDVPSERY* 
(5 fragments included in this domain) 
αs1-CN 80-91 Jejunum CN Boutrou et al., 2013 
YLGYLEQ αs1-CN 91-97 Jejunum CN Boutrou et al., 2013 
YLGYLEQL αs1-CN 91-98 Jejunum CN Boutrou et al., 2013 
YKVPQLEIVPNSAEERLH* 
(25 fragments included in this domain) 
αs1-CN 104-121 Jejunum CN Boutrou et al., 2013 
VPQLEIVPN αs1-CN 106-114 Duodenum; jejunum Milk; CN Chabance et al., 1998; Boutrou et al., 2013 
VPQLEIVPNSAEER αs1-CN 106-119 Jejunum CN Boutrou et al., 2013 
LHSMKEGIHAQQ αs1-CN 120-131 Stomach Milk Chabance et al., 1998 
EGIHAQQKEPMIGVNN* αs1-CN 125-140 jejunum CN Boutrou et al., 2013 
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(8 fragments included in this domain) 
EPMIGV αs1-CN 133-138 Duodenum Milk Chabance et al., 1998 
AYFYPEL αs1-CN 143-149 Stomach Milk Chabance et al., 1998 
AYFYPELFRQF αs1-CN 143-149 Stomach yogurt Chabance et al., 1998 
YFYPEL αs1-CN 144-149 Duodenum Milk Chabance et al., 1998 
QLDAYPS αs1-CN 155-161 Jejunum CN Boutrou et al., 2013 
YYVPLGTQYTDAPSFSDIPNPI* 
(14 fragments included in this domain) 
αs1-CN 165-186 Jejunum CN Boutrou et al., 2013 
SDIPNPIGSENS αs1-CN 180-191 Stomach yogurt Chabance et al., 1998 
GSENSEKTTMPLW αs1-CN 187-199 Jejunum CN Boutrou et al., 2013 
TDAPSFSDIPN αs1-CN 174-184 Duodenum Milk Chabance et al., 1998 
1CN: casein;  *Protein domain where several peptides have been identified in samples, not specifically indicated in order to simplify the tables, unless they had been previously described as active 
sequences, in which case they have been highlighted separately;  In bold: active sequences (commented in the text).
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The improvement of the analytical techniques, such as mass spectrometry (MS), 
combined with a suitable preparation of these samples has permitted to obtain greater 
amount of information with respect to the identification of peptides. In this regard, in 
2013, the detection of 347 and 146 peptides from casein and whey protein, 
respectively, in jejunal fluids gathered from humans after ingestion of these proteins 
was possible by the use of a nanoLC-Q-TOF (Boutrou et al., 2013). Several identified 
sequences were known as bioactive peptides, for instance, the immunomodulator β-
casein peptide f(63-68), PGPIPN (Migliore-Samour et al., 1989), the antihypertensive 
peptide LHLPLP, β-casein f(133-138) (Miguel et al., 2006); or the к-casein sequence 
KNQDK, f(112-116), known as antithrombotic peptide (Bal Dit Sollier et al., 1996). In 
this study, various peptides were quantified in the effluents, and some β-CMs [f(57-, 
58-, 59, and 60-66)] were present in sufficient amount to elicit their physiological effect. 
Overall, several cores from β- and αs1-casein seem to be resistant to digestion in adult 
humans as it can be observed in Table 1, since numerous fragments were identified 
during gastrointestinal digestion of milk proteins i.e. β-casein 1-14, 57-70, 67-92, 128-
140, 144-163, and the C-terminal part of the protein [region 190-209]. The resistant 
domains from αs1-casein seemed to be 23-33, 104-121 and 165-186. Indeed, several 
active sequences above mentioned belong to some of these regions of the protein (57-
70 and 128-140) i.e LHLPLP, PGPIPN or some β-CMs (Boutrou et al., 2013). 
Interestingly, β-CMs 6 and 7 are coincident peptides detected after milk (Svedverg et 
al., 1985) and casein (Boutrou et al., 2013) ingestion, regardless of the food matrix. 
Moreover, as it can be observed in Table 1, various peptides are present throughout 
the whole gastrointestinal track since they were generated in stomach and also 
identified in duodenum after milk ingestion (Chabance et al., 1998), being also found in 
jejunum after casein ingestion (Boutrou et al., 2013), for instance β-casein f(1-12) and 
αs1-casein f(25-32).   
Recently, a peptidomic analysis of human milk from 3 mothers and the stomach 
contents from their 4 to 12-day newborns after feeding was carried out using a nano-
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LC-Q-TOF (Dallas et al., 2014.) This study revealed approximately 135 peptides 
exclusively detected in the “intact” milk, due to the over-activity of plasmin system 
proteolysis in mammary gland. This fact is believed to arise from an evolutionary 
selected natural mechanism capable to compensate the early immaturity of the human 
newborn gastro-intestinal system. On the other hand, 586 distinct peptides were 
identified in stomach contents from the infants. Overall, 64 peptides were common for 
both “intact” milk and gastric digest. Most of these peptides found either in intact milk or 
in gastric samples belonged to β-casein, which indicates a protein-selective 
degradation within milk or in stomach, since this protein does not represent even half of 
milk proteins. Several of these sequences were coincident or displayed structural 
similarities to some previously described bioactive peptides. For instance KVLPIPQ, 
from human β-casein, with Ile/Val replacement compared the known antihypertensive 
sequence KVLPVPQ (Maeno et al., 1996), and YPYY from human β-casein, which 
matches with the opioid antagonist (casoxin-B) from bovine к-casein (Chiba et al., 
1989). These results suggest that gastric digestion occurs within the first weeks of life 
in the infant, releasing peptides that can exert biological activities. 
 
1.2.2. Milk protein digestion in animal models 
Among the studies on animal models, Miranda & Pelissier (1983) studied the in 
vivo digestion of milk proteins in rats after ingestion of raw milk. The proteins α-La and 
β-Lg were not much susceptible of hydrolysis during gastric digestion, even after 240 
min. Likely, whey proteins were also shown to be resistant to gastric digestion in calves 
(Yvon et al., 1985). Later on, the amount of N in the digests remaining in the stomach 
of neonatal pigs suggested that whey proteins were emptied from stomach faster than 
caseins (Newport et al., 1985). Later on, Moughan et al. (1991) studied the rate of 
gastric emptying and the postprandial change on pH values in calves fed infant formula 
containing either intact bovine proteins or a hydrolysate thereof. The type of diet did not 
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affect the pH after ingestion, however, the gastric emptying occurred faster in the case 
of the hydrolysate vs intact protein (12% and 22% of hydrolysate and intact protein, 
respectively, remaining in the stomach, after 3 hours). The gastric emptying was 
claimed to be a major factor controlling the absorption kinetics of milk 15N-labeled 
protein during a study conducted in mini-pigs fed milk and yogurt (Gaudichon et al. 
1994b). In this study, milk proteins were observed to be rapidly absorbed once they 
reached the intestine. Overall, the pig is a suitable model to predict differences among 
dietary protein digestibility in men, showing good inter-species correlation in terms of 
true N and amino acid digestibility (Deglaire et al., 2009b). Besides, it is monogastric 
(incontrast to ruminants), and omnivore like humans.  
 
In regard to the characterisation of in vivo digests of milk proteins, some reports 
have been published on the peptides present in the gastrointestinal tract in animals 
(Table 2). In 1986, the β-casein f(60-70), known as pro-CM YPFPGPIPNSL, was found 
in intestinal content of mini-pigs after ingestion of casein, finally adopting the name of 
β-CM-11, due to its opioid activity (Meisel, 1986). This sequence was later on identified 
in distal jejunal effluents from mini-pig after ingestion of casein, in addition to the 
caseinphosphopeptide (CPP), f(66-74), from αS1-casein with three phosphoserines 
(Meisel & Frister, 1988; 1989). Several peptides originated from casein were detected 
in the stomach contents of calves after ingestion of a diet based on milk or casein 
(Yvon & Pelissier, 1987). Among them, two active sequences from αS1-casein can be 
pointed out: the antihypertensive peptide AYFYPEL, f(143-149) (Contreras et al., 
2009); Isracidine, RPKHPIKHQGLPQEVLNENLLRF, f(1-23), known as antibacterial 
peptide (Lahov & Regelson, 1996); and the immunomodulatory peptide from β-casein,  
YQEPVLQPVRGPFPIIV, f(193-209) (Coste et al., 1992). In 1991, the presence of 
various phosphopeptides derived from casein [β-casein f(1-28) (4 maximum 
phosphorylation sites, 4P), β-casein f(33-48)1P, αs1-casein f(43-58)2P, αs1-casein f(59-
79)5P and αs2-casein f(46-70)4P] was reported in duodenum, jejunum and ileum of rats 
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fed whey proteins, casein and CPPs (Brommage et al., 1991). The CPP f(59-79) 
showed good calcium binding properties, favored by the presence of the phosphoseryl 
cluster (SpSpSpEE) in its sequence (Cross et al., 2005). However, it is known that the 
intestinal epithelium has a strong phosphatase activity, and CPPs are easily de-
phosphorylated in neutral or slightly alkaline conditions (Bader et al., 1984; Moss et al., 
1992). A year later, Scanff et al. (1992), could identify the CMP f(106-169) from κ-
casein, in fluids gathered from stomach of calves. In addition, they also identified a 
precursor peptide of β-CMs [f(58-93)], and a CPP derived from αs1-casein [f(110-
142)1P].  
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Table 2. Peptide sequences from β- and αs1-casein identified within in vivo digests from animals 
Sequence Protein fragment Location; animal Substrate Reference 
RELEELNVPGEIVESLSSSEES… 
…ITRINK β-CN 1-28 Duodenum, jejunum and ileum (rats) CN
1
, CPPs Brommage et al., 1991 
NVPGEI β-CN 7-12 Jejunum (piglets) IF2 Bouzerzour et al., 2012 
NVPGEIVE β-CN 7-13 Jejunum (piglets) IF Bouzerzour et al., 2012 
NVPGEIVESLSSSEESIT β-CN 7-24 Ileum (rats) CPPs Hirayama et al., 1992 
FQSEEQQQTEDELQDK β-CN 33-48 Duodenum, jejunum and ileum (rats) CN, CPPs Brommage et al., 1991 
LVYPFPGPIPNSLPQNIPPLTQTP… 
…VVVPPFLQPEVM β-CN 58-93 Stomach (Calves) Milk Scanff et al., 1992 
YPFPGPI (β-CM 7) β-CN 60-66 Jejunum (piglets) IF Bouzerzour et al., 2012 
YPFPGPIPNSL (β-CM 11) β-CN 60-70 Duodenum;Jejunum (minipigs) CN Meisel et al., 1986;1989 
PGPIPN β-CN 63-68 Jejunum (piglets) IF Bouzerzour et al., 2012 
NIPPLT β-CN 73-78 Jejunum (piglets) IF Bouzerzour et al., 2012 
IPPLTQTP β-CN 74-81 Jejunum (piglets) IF Bouzerzour et al., 2012 
IPPLTQTPVVVP β-CN 74-85 Jejunum (piglets) IF Bouzerzour et al., 2012 
PLTQTPV β-CN 76-82 Ileum (piglets) IF Bouzerzour et al., 2012 
PLTQTPVV β-CN 76-83 Ileum (piglets) IF Bouzerzour et al., 2012 
TPVVVP β-CN 80-85 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPP β-CN 80-86 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPPFL β-CN 80-88 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPPF β-CN 80-87 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPPFLQ β-CN 80-89 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPPFLQP β-CN 80-90 Jejunum (piglets) IF Bouzerzour et al., 2012 
TPVVVPPFLQPEV β-CN 80-92 Jejunum (piglets) IF Bouzerzour et al., 2012 
PVVVP β-CN 81-85 Jejunum (piglets) IF Bouzerzour et al., 2012 
PVVVPP β-CN 81-86 Ileum (piglets) IF Bouzerzour et al., 2012 
PVVVPPFLQ β-CN 81-89 Jejunum (piglets) IF Bouzerzour et al., 2012 
VVVP β-CN 82-85 Jejunum (piglets) IF Bouzerzour et al., 2012 
VVVPP β-CN 82-86 Ileum (piglets) IF Bouzerzour et al., 2012 
VVVPPFLQPEV β-CN 82-92 Jejunum (piglets) IF Bouzerzour et al., 2012 
VVPPF β-CN 83-87 Jejunum (piglets) IF Bouzerzour et al., 2012 
VVPPFL β-CN 83-88 Jejunum (piglets) IF Bouzerzour et al., 2012 
PPFLQP β-CN 85-90 Jejunum (piglets) IF Bouzerzour et al., 2012 
PFLQP β-CN 86-90 Jejunum (piglets) IF Bouzerzour et al., 2012 
PFLQPE β-CN 86-91 Jejunum (piglets) IF Bouzerzour et al., 2012 
PFLQPEV β-CN 86-92 Jejunum (piglets) IF Bouzerzour et al., 2012 
FLQP β-CN 87-90 Jejunum (piglets) IF Bouzerzour et al., 2012 
QPEV β-CN 89-92 Jejunum (piglets) IF Bouzerzour et al., 2012 
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QPEVMGVSSK β-CN 89-98 Ileum (piglets) IF Bouzerzour et al., 2012 
VMGVSSKV β-CN 92-99 Ileum (piglets) IF Bouzerzour et al., 2012 
KVKE β-CN 97-100 Ileum (piglets) IF Bouzerzour et al., 2012 
TLTDVENLHLPLPL β-CN 128-139 Stomach (Calves) CN Yvon & Pelissier, 1987 
QSWMHQPHQPLPP β-CN 141-153 Jejunum (piglets) IF Bouzerzour et al., 2012 
WMHQPHQPLPP β-CN 143-153 Jejunum (piglets) IF Bouzerzour et al., 2012 
QPHQPLP β-CN 146-152 Jejunum (piglets) IF Bouzerzour et al., 2012 
QPHQPLPP β-CN 146-153 Jejunum (piglets) IF Bouzerzour et al., 2012 
VLSLSQSK β-CN 162-169 Ileum (piglets) IF Bouzerzour et al., 2012 
SKVL β-CN 168-171 Jejunum (piglets) IF Bouzerzour et al., 2012 
QRMPIQA β-CN 182-188 Jejunum (piglets) IF Bouzerzour et al., 2012 
LLYQEPVLG β-CN 191-199 Jejunum (piglets) IF Bouzerzour et al., 2012 
LYQEPVLG β-CN 192-199 Jejunum (piglets) IF Bouzerzour et al., 2012 
YQEPVLGPVRGPFPIIV β-CN 193-209 Stomach (Calves) CN;milk Yvon & Pelissier, 1987; Scanff et al., 1992 
RPKHPIKHQGLPQEVLNENLLRF αs1-CN 1-23 Stomach (Calves) CN Yvon & Pelissier, 1987 
KHQGLPQEVLNENLLRFF αs1-CN 7-24 Ileum (rat) CPPs Hirayama et al., 1992 
LRF αs1-CN 21-23 Stomach (Calves) CN Yvon & Pelissier, 1987 
DIGSESTEDQAMEDIK αs1-CN 43-58 Duodenum, jejunum and ileum (rats) CN, CPPs Brommage et al., 1991 
TEDQAMEDIK αs1-CN 49-58 Jejunum (piglets) IF Bouzerzour et al., 2012 
QAMEDIK αs1-CN 52-58 Jejunum (piglets) IF Bouzerzour et al., 2012 
QMEAESISSSEEIVPNSVEQK αs1-CN 59-79 Duodenum, jejunum and ileum (rats) CN, CPPs Brommage et al., 1991 
EAESISSSEEIVPN αs1-CN 61-74 Ileum (rat) CPPs Hirayama et al., 1992 
ISSSEEI αs1-CN 65-71 Jejunum (piglets) IF Bouzerzour et al., 2012 
SSSEEIVPN αs1-CN 66-74 Jejunum (minipigs) CN Meisel et al., 1989 
SSEEIVPN αs1-CN 67-74 Jejunum (piglets) IF Bouzerzour et al., 2012 
SEEIVPN αs1-CN 68-74 Jejunum (piglets) IF Bouzerzour et al., 2012 
LGY αs1-CN 92-95 Stomach (Calves) CN Yvon & Pelissier, 1987 
EIVPNSAEERLHSMKEGIHAQQK… 
…EPMIGVNQEL αs1-CN 110-142 Stomach (Calves) Milk Scanff et al., 1992 
AYFYPEL αs1-CN 143-149 Stomach (Calves) CN Yvon & Pelissier, 1987 
YQL αs1-CN 154-156 Stomach (Calves) CN: milk Yvon & Pelissier, 1987; Scanff et al., 1992 
DAYPSGAW αs1-CN 157-164 Stomach (Calves) CN; milk Yvon & Pelissier, 1987; Scanff et al., 1992 
YYVPL αs1-CN 165-169 Stomach (Calves) CN Yvon & Pelissier, 1987 
YYVPLGTQYTDAPSF αs1-CN 165-179 Stomach (Calves) CN Yvon & Pelissier, 1987 
YYVPLGTQYTDAPSFSDIPNPI… 
…GSENSEKTTMPLW αs1-CN 165-199 Stomach (Calves) CN Yvon & Pelissier, 1987 
FSDIPNPIG 
 
αs1-CN 179-187 Jejunum (piglets) IF Bouzerzour et al., 2012 
SDIPNPIGSENSEKTTMPLW αs1-CN 180-199 Stomach (Calves)  Milk Scanff et al., 1992 
1
 CN: casein; 2 IF: Infant Formula; In bold: active sequences (commented in the text) 
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The same year, Hirayama et al. (1992) found only two CPPs, f(61-74) from αS1-
casein and f(7-24) from β-casein, in the intestine of rats after ingestion of CPPs. 
Furthermore, CMP was found in the stomach and duodenum of rats fed a diet 
containing 48% of Phe-CMP-1P (Fosset et al., 2002), and in addition, the presence of 
some derived peptide fragments was reported. For instance, CMP-1P and Phe-CMP, 
both from variants A and B. Recently, in 2012, Bouzerzour et al. could keep track of 
numerous milk peptides that reached ileum and jejunum of piglets fed infant formula at 
different times postprandial using a nano- LC-Q-TOF. They reported the region 
comprised between residues 74 and 91 from β-casein, as one of the most resistant 
domains to digestion, as shown in table 2. Indeed, the peptide TPVVVPPFLQP, f(80-
90), which had previously shown ACE inhibitor activity (Abubakar et al., 1998), was 
identified. As well, the opioid sequence β-CM 7 was detected in jejunum of piglets. 
Furthermore, the same technique was employed to identify approximately 3000-4000 
sequences in duodenal effluents of mini-pigs fed raw (Figure 3 and 4) and heated milk, 
and their corresponding rennet gels (Barbé et al., 2014). In this study, the structure of 
dairy matrices had little influence on the cleavage sites of peptides, but mainly affected 
the number of sequences. Approximately 29 of them were previously reported bioactive 
peptides. However, a peptide mapping of the whole peptide profile was provided, giving 
information about the pattern and kinetic of peptide release in vivo. Some resistant 
cores of the β- and αs1-casein can be observed in the Figures 3 and 4, respectively. For 
instance, β-casein domains 30-60 and the C-terminal part of the protein comprised 
between residues 170-209. In the case of αs1-casein, the N-terminal region (residues 1-
20), especially at very short times of digestion, the core composed of residues 110-140 
and the C-terminal part of the protein, gave rise to numerous peptides.  
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Figure 3. β-casein peptides identified in duodenal effluents of mini-pigs fed raw milk 
(Barbé et al., 2014) 
 
 
Figure 4. αs1-casein peptides identified in duodenal effluents of mini-pigs fed raw milk 
(Barbé et al., 2014) 
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In summary, although during the last years the information available on the 
identification of peptides released through in vivo digestion of milk proteins in humans 
or in animal models has increased, little is known about the concentration available in 
small intestine. The information provided by in vivo digestion studies is valuable, on 
one hand, because the presence of certain peptides in small intestine indicates that 
they are actually generated through in vivo digestion, and they can reach small 
intestine, where they may be transported through the epithelium to plasma or interact 
with intestinal receptors in situ. However, the mere presence of the peptide would not 
always elicit their biological activity, but they need to be in sufficient amount. Therefore, 
in addition to the identification of the sequences it is important to evaluate if the 
peptides formed during digestion are released in physiological concentrations. This has 
only been reported in few cases. On the other hand, this information obtained from in 
vivo digestion trials could be used to validate and develop the in vitro digestion models. 
It has to be underlined that these studies concern bioaccesibility of peptides, although 
not their bioavailability and systemic distribution. In this regard, they could undergo 
further hydrolysis by the peptidases under the mucus of intestinal layer, or intracellular 
or plasma degradation.  
 
 
1.2.3. In vitro digestion of milk proteins 
The in vivo digestion trials performed in animals or in humans provide the most 
physiologically relevant results. Nevertheless, these studies are associated to 
significant ethical implications, and they are also expensive and time consuming. Thus, 
this had led to the development of different in vitro approaches, which has given as a 
result the development of different models of simulated gastrointestinal digestion. A 
great variety of these in vitro models have been employed in the last years in order to 
evaluate the structural and chemical changes that take place during food digestion (Hur 
et al., 2011; Wickham et al., 2009; Guerra et al., 2012); and whose differences mainly 
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lie on the number of steps of digestion, type of fluids (enzymes, salts, buffers) in each 
step, or the type of mixing. Likewise, other aspects have been proposed as important 
parameters to be considered when studying digestion: i) sequential secretion of 
enzymes at physiological concentrations, ii) suitable pH for the enzymes, and the use 
of cofactors in the process, such as bile salts, iii) removal of digestion products, iv) 
adequate mixing at each step and vi) physiological transit time for each step of 
digestion (Minekus et al., 1995). Two types of in vitro digestion models exist, the static 
and the dynamic models. The dynamic models can perform continuous changes in pH 
and sequential secretion of gastric or pancreatic juices containing the enzymes; they 
also consider the gastric emptying, or the removal of digestion products. Overall, the 
dynamic digestion models reproduce better the physiological conditions occurring in 
vivo (Guerra et al., 2012). 
In vitro digestibility of milk proteins (bovine origin unless otherwise specified) has 
been widely assessed by static digestion models. The β-Lg was shown to be resistant 
to gastric digestion simulating physiological adult conditions (pH around 2), and 
susceptible to duodenal phase, although being less degraded in presence of 
phosphatidylcholine (Mandalari et al., 2009). This protein has been proved to be 
resistant to pepsin when subjected to adult and infant digestion models, in contrast to 
β-casein (Dupont et al., 2010a), as also observed in the previous work. In addition, in 
this study numerous peptides could be identified, giving information about the peptide 
profile generated throughout digestion using nano-LC-Electrospray ionization (ESI)-Q-
TOF. Other whey proteins, such as α-La, have been shown to be partly resistant to 
gastric digestion (Picariello et al., 2010), although more susceptible than β-Lg. The 
reason why is the conformational transition of α-La. This protein at pH lower that 3 
partially loses its terciary compact structure leading to a lax conformation, where some 
residues (hydrophobic) become exposed to the medium and more accessible to the 
proteases, although it keeps some traits of the molten globule (Yang et al., 2006). 
Nevertheless, milk proteins from different species such as equine, bovine, caprine and 
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human show differences in digestibility (Inglingstad et al., 2010). Overall, the proteins 
from equine milk were found to be rapidly digested compared to the others. 
Nonetheless, the pH of gastric digestion is an important factor which significantly 
influences the hydrolysis of milk proteins. LF and caseins from donkey’s milk was 
markedly more susceptible to digestion with human gastrointestinal fluids at pH 2 
compared to pH 4 since pepsin is more active; as it also occurred in the case of β-Lg, 
although in the latter case this effect was not as pronounced (Tidona et al., 2011). 
Nonetheless, β-Lg from donkey’s milk was found quite resistant to digestion; it suffered 
more degradation compared to that from bovine or goat’s milk (Almaas et al., 2006; 
Almaas et al., 2008). Interestingly, in the latter study, caprine α-La was shown to be 
very resistant to digestion with human juices, however, it was fully degraded by 
commercial enzymes.  
Some works using MS-based techniques have focused on targeted analysis of 
certain sequences generated through digestion, and other studies have been 
untargeted to obtain information about the whole peptide profile. In this sense, the 
formation of active peptides was reported during digestion of human milk and infant 
formulas using two-step model by adding pepsin for the gastric phase and pancreatin 
for the duodenal step (Hernández-Ledesma et al., 2007). In this work, the peptides 
HLPLP and WSVPQPK that showed ACE-inhibitory activity and antioxidant activity, 
were identified in human milk digests by HPLC-ESI-IT. Likely, Beaufort cheese was 
digested using pepsin for gastric phase, also followed by incubation with pancreatin, 
although they employed nano-LC-MS/MS for the identification of the peptides, in this 
case targeted at CPPs (Adt et al., 2011). Most of the CPPs found in this cheese digest 
were monophosphorylated. Furthermore, other authors have studied the formation and 
resistance of CPPs through gastrointestinal digestion after the addition of pepsin and 
subsequent incubation with pancreatin-bile extract solution, analysed by HPLC-ESI-IT 
(García-Nebot et al., 2010; Miquel et al., 2005). Cheese ripening and proteolytic 
systems involved in the elaboration of dairy products are the processes that more likely 
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could lead to the formation of β-CM 7, from β-casein. However, the potential of 
gastrointestinal digestion (pepsin and Corolase PP®) to release this sequence in 
different dairy products, regardless the type of matrix has been pointed out i.e 10 
cheeses, 4 liquid milks, 4 fermented milks, 7 infant formulas, 4 dried-milk products (De 
Noni & Cattaneo, 2010). Some studies have applied the MS-based techniques to 
reveal the whole peptide profile generated during in vitro digestion. For instance, 
Picariello et al. (2010) have reported the use of nano-LC-Q-TOF and MALDI-TOF to 
map the peptides generated through a multi-step in vitro digestion. In this study, the 
resistance of β-Lg f125-135 to digestion was underlined due to the importance for 
cow’s milk allergy. On the other hand, Eriksen et al. (2010) detected more extensive 
hydrolysis of the peptide profile from β-Lg digested with porcine enzymes compared to 
human fluids by nano-LC-ESI-Q-TOF, despite no noticeable differences were found in 
SDS-PAGE analysis. Likely, Almaas et al. (2011) performed an in vitro digestion on 
caprine whey proteins with human gastrointestinal juices. The analysis by nano-LC-Q-
TOF revealed that only two peptides matched with the profile previously described with 
non-human enzymes. These results suggest that the human enzymes are more 
complex and have different cleavage sites compared to non-human enzymes. 
Likewise, the same technique was used to analyze two types of Norwegian cheeses 
digested with human gastrointestinal juices following a three-step model, including oral, 
gastric and duodenal phase (Qureshi et al., 2013). This work reported the depletion of 
Pro after gastric digestion, while no changes were detected for some others such Phe, 
Lys, Tyr, Arg, Leu or Trp. Conversely, the duodenal phase provoked an increase of 
these residues. Furlund et al. (2013) identified several peptides released during LF 
digestion with gastrointestinal human juices and also after gastric digestion in human 
volunteers, where some of the sequences matched in vivo and in vitro, using nano-LC-
Q-TOF. The study revealed that gastric pH and the activity of human gastrointestinal 
juices significantly influenced the formation of peptides. There is evidence about the 
importance of another step during digestion, which few authors actually take into 
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account; this is the use of brush border enzymes (Petrilli et al., 1984; Oshawa et al., 
2008; Picariello et al., 2010). This step would finally simulate the fraction of peptides 
that could really be transported intact through intestinal epithelium. Given the variety of 
in vitro models and the fact that none has been commonly accepted, there is a need of 
correlating in vivo-in vitro data to validate and develop a model that simulate as closely 
as possible the physiological conditions. In this regard, an in vitro model was 
developed using a correlation with data obtained from in vivo digestion of proteins, 
lipids and carbohydrates present in literature (Kopf-Bolanz et al., 2012). In this study it 
is noteworthy to highlight the preparation of the digestive fluids at physiological final 
concentration of ions, the application of three steps, starting with oral phase, where 
lysozyme was included; moreover, mucins I and II were added to the digestive fluids. 
Recently, a standardized harmonized in vitro static model (Figure 5) has been 
developed in the framework of Infogest COST Action (Minekus et al., 2014).  
 
 
   Figure 5. Digestion scheme. Oral, gastric and intestinal steps (Minekus et al., 2014). 
 
Some of the dynamic systems used for milk protein digestion are bi- or multi-
compartmental models. Among the dynamic digestion models, the mono-
compartmental are normally focused on the gastric step (Kong et al., 2010; Mercuri et 
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- Enzymes: Trypsin, Chymotrypsin, 
lipase and pancreatic α-amylase.
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-Simulated gastric fluid: K+, Na+, Cl-, H2PO4-, 
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- Phospholipids
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al., 2011; Hoebler et al., 2002), although they consider the gastric emptying and the 
gradual decrease of pH. There is evidence of the existence of some devices developed 
to simulate digestion and the movement in small intestine, to face the transport 
phenomena occurring in the lumen and the influence of the concentration of species 
available for absorption (Tharakan et al., 2010). A semi-continuous digestion model 
was described by Vermeirssen et al. (2003a), where the pH was controlled by pH stat 
and a pump carried the content from stomach to intestinal vessel, and out of the latter 
at the end of digestion. The performance of this device was compared with that of 
batch digestion in order to achieve the best conditions for the generation of ACE-
inhibitory peptides from whey and pea proteins. They count with systems to simulate 
the gastric and intestinal steps, usually small intestine. They can control the pH in 
stomach and small intestine, the gastric emptying, and usually also the intestinal 
transit. Figure 6 shows an example of a model with gastric and intestinal stirred 
compartments. Moreover, Minekus et al. (1995) developed a model (TIM-1) with 4 
compartments representing stomach, duodenum, jejunum and ileum, and, in addition, 
possessed a system of passive transport provided with a dialysis membrane. The 
conditions for the performance of this device were based on those obtained in healthy 
humans in terms of meal transit time from stomach (milk and yogurt; Marteau et al., 
1990; 1991), pH (yogurt; Marteau et al., 1991), bile-salt concentrations and glucose 
absorption. The results showed good mimicking of the in vivo data in regard of the 
gastric and ileal delivery of blue dextran, used as substrate in this study. Almost all the 
glucose (96%) that reached duodenum was absorbed through the dialysis membrane. 
In addition, the bile-salts were found to be within the correct range, and the pH values 
simulated correctly the pre-set curve based on in vivo data. This system reproduced 
very closely the in vivo conditions occurring in man based on the above mentioned 
parameters. 
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Figure 6. Bi-compartmental dynamic digester available at STLO-INRA (Rennes).  
 
The correlation between in vitro and vivo data for milk proteins in dynamic 
digestion systems has been done in few studies. For instance, Yvon et al. (1992) 
performed a correlation of in vitro with in vivo data obtained from animal experiments to 
create an in vitro dynamic tool for gastric digestion of milk by controlling the emptying 
rate, the pH, the nature of enzymes, and the ratio of substrate/enzyme. In this study, 
the rate of pH decrease was 2-fold faster in vitro compared to in vivo experiments. In 
addition, the percentage of the intake (in terms of fresh matter) leaving the stomach 
recovered after 6 h during in vivo experiments was achieved in half of the time in the 
case of in vitro digestion. However, a wide variability of data was found in vivo for these 
parameters. In this comparison, the nitrogen emptying rate was similar between in vivo 
and in vitro, suggesting a close in vitro simulation of the clotting process in vivo. 
Similarly, Ménard et al. (2014) developed a gastrointestinal dynamic digestion model 
for infant formula through the comparison of in vivo and in vitro data. The hydrolysis 
kinetics of caseins and β-Lg resulted similar in both in vivo and in vitro experiments, 
although the percentage (%) of immunoreactive β-Lg present in the small intestine was 
higher in the in vitro model. Good correlation was found for food transit and for casein 
and β-Lg concentrations in stomach and intestine between in vivo and in vitro 
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experiments. Differences in the kinetics of proteolysis of both proteins were found. 
Casein was hydrolysed faster than β-Lg, which remained intact in stomach even after 
120 min, as previously found in static models in vitro.  
 
In summary, the dynamic models are important tools not only applicable from 
nutritional point of view (Martin et al., 2012; Yvon et al., 1992), but also from the 
toxicological and pharmacological perspective. In addition, they represent a model to 
assess the potential risk of allergens present in food stuff, since they allow a more 
realistic evaluation of the interactions thereof with the food matrix and the manner in 
which they are degraded (Wickham et al., 2009). Although some static models have 
been employed in pharmacological studies, as an initial approach on the development 
and testing of drugs, the advantages of the dynamic models have made of them the 
model of choice. The dynamic device TIM has been used in pharmacological trials in 
order to evaluate the effect of the dosage form, the transit time on the behavior of 
drugs (Blanquet-Diot et al., 2012; Blanquet et al., 2004), of the feeding state and the 
interaction with food (Brouwers y col., 2011; Souliman et al., 2006). Likewise, the 
bioaccesibility of some contaminants has been studied by the application of TIM-1, and 
compared to that obtained by using a static model (Torres-Escribano y col., 2011). 
Nevertheless, other dynamic models have been used to assess the effect of the 
dosage form of drugs (Mercuri y col., 2011). However, although these models have 
been used to evaluate the behavior certain food components through digestion 
process, few information is available focused on the resulting products, such peptides, 
released during dynamic digestion of milk proteins.  
 
1.2.4 Influence of food processing on gastrointestinal digestion of milk proteins 
Food processing could influence the behavior of milk proteins during digestion 
and subsequent formation of peptides. Heat treatment, homogenization, vacuum 
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concentration and drying are some of the most common treatments applied to dairy 
products in industry (Schuck et al., 2013). Other kinds of processes have been less 
extended, such as high pressure application (Pedras et al., 2014). Heat treatment 
affects the structural and nutritional characteristics of food proteins. Indeed, these 
modifications may result in a loss of amino acid bioavailability, such as Lys or Met, and 
of protein efficiency ratios; and even proteolysis can occur during heat treatment (Guo 
et al., 1999). Likewise, Maillard reaction induced by heat treatment in presence of 
carbohydrates leads to the blockage of Lys and the subsequent loss of its 
bioavailability, and could depend on the type and extent of treatment (Finot et al., 
1981). In this regard, blocked Lys would not be recognized by digestive enzymes, for 
instance trypsin. Heat treatment or drying could also produce the formation of non-
natural amino acids, i.e. isopeptide bonds in lysinoalanine or lantionine, which are no 
longer substrate of digestive proteases. In addition, casein and whey proteins 
aggregates induced by heat have been reported in some studies (Patel et al., 2006; 
Jean et al., 2006). The proteins usually involved in these aggregates are β-Lg (higher 
proportion) and α-La with к- and αS2-casein, depending on the size of aggregates, the 
amount of к-casein available and the casein/whey protein ration in the product 
(Guyomarc'h et al., 2003). These modifications have been reported to change the 
behavior of milk proteins during digestion, in vivo and in vitro. Moreover, they affect the 
profile of bioactive peptides generated through digestion, since different protein bonds 
will be available for the action of the gastrointestinal enzymes (Meisel et al., 1998), or 
they could have toxicological implications from the point of view of food allergies (Mills 
et al., 2009). In regard to physiological parameters, heat treatment applied to milk 
resulted in an increase of the gastric emptying rate of caseins in rats (Miranda & 
Pelissier, 1987). Likewise, the effect of technological treatments on digestion of milk 
proteins was evaluated in the stomach of calves after ingestion of raw and pasteurized 
milks and yogurt (Scanff et al., 1990). In this study, the heat treatment on the liquid 
milks produced a slower coagulation; in yogurt, the kinetic of casein digestion was 
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slower compared to that observed for the liquid milks; and the β-Lg was not susceptible 
of gastric hydrolysis in any case. Recently, the heat treatment was reported to be 
important factor influencing the digestion kinetics of milk proteins and the subsequent 
amino acids absorption in mini-pigs (Barbé et al., 2013). Proteomic analyses of raw, 
pasteurized, sterilized and ultra-high temperature (UHT) milks subjected to in vivo (rat 
pup model) and in vitro digestion revealed higher lactulosyl-lysine content in milks with 
higher heat treatment (sterilized and UHT milks), which implied a decrease of α–La, β-
Lg and casein digestibility (Wada et al., 2014). These authors suggest that the 
improvement of the digestibility of certain proteins produced by heat-induced 
denaturation would be offset by other modifications, such as non-enzymatic 
posttranslational modifications i.e Maillard reaction, that finally led to a decrease in 
digestibility. The nutritional consequences of the heat treatment have also been pointed 
out by other authors. For instance, the bioavailability of different raw products such as 
caseins, whey protein and microfiltered milks, was not significantly different in rats 
compared to different heat-treated milks, despite their differences in the distribution of 
N between them; and the different postprandial N metabolism found only for spray-
dried milk (Lacroix et al., 2003; 2006b). The UHT treatment on milk influenced the 
digestive kinetics and the postprandial metabolism of milk proteins in humans, leading 
to a higher transfer of dietary N into serum amino acids and proteins, and to body urea 
after ingestion compared to other processes, such pasteurization or microfiltration, due 
to the heat-induced modifications of proteins (Lacroix et al., 2008; 2006c). The effect of 
heating on milk proteins digestion has also been described in vitro, for instance, an 
increased resistance of caseins with the heat treatment was observed in infant 
formulas subjected to different processes (Dupont et al., 2010b); or in different dairy 
matrices, such as raw, pasteurised and sterilised milks, and yogurt subjected to 
digestion using an infant model (Dupont et al., 2010c). Furthermore, digestion of 
caprine and bovine proteins was affected by the heat treatment, although the 
application of different heat-treatment processes did not cause any difference in the 
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degradation of caprine proteins, in contrast to bovine ones (Almaas et al., 2006). The 
authors explained this discrepancy due to the higher resistance of bovine vs caprine β-
Lg to digestion, differences in composition and tertiary structure between the proteins 
from both species. The protein degradation of different technologically processed 
matrices i.e. raw, pasteurized, UHT, yogurt, cheeses, kefir etc was monitored before 
and after in vitro gastrointestinal digestion (Kopf-Bolanz et al., 2014). In this study, β-Lg 
was differently degraded during gastric phase in fermented or unfermented matrices, 
an also depending on type of heat-treatment. This protein was fully degraded by pepsin 
in fermented products while in heated milks it could be still detected; and after the 
intestinal step was completely hydrolysed. The peptidomic analysis revealed the impact 
of the heat-treatment on β-Lg behavior, but it was not that evident on αs1-casein; and 
showed that the higher the heat-treatment, the higher the number of peptides released 
from β-Lg. Although it is known, that β-Lg is resistant to digestion by pepsin at low pH 
there is also evidence that under certain conditions it can be susceptible to hydrolysis 
by this enzyme. Heating at temperatures higher than 90ºC, and especially at 100ºC 
induces conformational changes in this protein, which provokes the exposure of the 
hydrophobic regions, increasing its susceptibility to hydrolysis by pepsin (Guo et al., 
1995; Peram et al., 2013). Likewise, other conditions have been described to increase 
the susceptibility of this protein to gastric digestion, for instance heating at low pH or 
under pressure, presence of alcohols and esterification (Bateman et al., 2010; 
Dalgalarrondo et al., 1995; Chobert et al., 1995; Zeece et al., 2008).  
 
1.2.5 Influence of digestion on biological activity of peptides and proteins  
 
Gastrointestinal digestion is a key step to evaluate the arrival of a peptide in its 
active form to duodenum or jejunum, where they could be transported through the 
intestinal epithelium, reach blood and be distributed to target organs; or interact in situ 
with gastrointestinal receptors. If some of these peptides are generated in sufficient 
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concentration, they can be physiologically and metabolically relevant as signals 
implicated in the control of the gastric and intestinal motility, pancreatic secretion, food 
intake, and in the ethiology of autoimmune diseases or food allergies. Likewise, the 
evaluation of the formation of epitopes involved in food allergies by means of digestion 
assessment has gained interest in the last years (Whickham et al., 2009; Benedé et al., 
2014). Indeed, an in vitro digestion method was developed to evaluate the potential of 
a protein to become a food allergen by pepsin hydrolysis (Astwood et al., 1996). This 
method was incorporated to the protocol of assessment of possible allergen risk from 
novel food (FAO-WHO, 2001). 
Digestion does not only affect the formation or release of peptides, when they 
were present in the food matrix, as it is the case of cheese fermented products, they 
can be further hydrolyzed during digestion (Korhonen, 2009; Sforza et al., 2012; 
Griffiths et al., 2013). In this regard, peptides can be either stable to digestion or be 
hydrolyzed, and the latter fact could imply the decrease or increase of bioactivity. For 
example, in vitro digestion produced the hydrolysis of the ACE-inhibitor sequence 
[(Lactokinin from β-Lg f(142-148)] to negligible concentrations, leading to the 
subsequent loss of its potential hypotensive effect in vivo (Walsh et al., 2004). Likely, 
the partial digestion and fragmentation of α-La led to a reduction in its activity, which 
had been demonstrated to inhibit proliferation of adenocarcinoma cell lines (Caco-2 
and HT29) in its monomeric form (Brück et al., 2014). On the contrary, the release of 
the active form of certain sequences may occur during gastrointestinal digestion. 
Maeno et al. (1996), observed that the sequence KLPVPQ, f(169-175), from β-casein, 
possessed a low in vitro ACE-inhibitory activity, but produced a significant blood 
depressor effect after its oral administration to spontaneously hypertensive rats (SHR). 
This sequence was shown to lose the Gln at C-terminal end during simulated 
gastrointestinal digestion, giving rise to KLPVP, which had in vivo blood pressure 
lowering effect, as well as, in vitro ACE-inhibitory activity. On the other hand, in vitro 
digestion, in batch (non-optimal, physiological and prolonged-physiological conditions) 
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and semi-continuous, was studied regarding the ACE-inhibitory activity of peptides 
(Vermeirssen et al., 2003b). In this study, batch digestion, using physiological 
conditions, led to the highest ACE-inhibitory activity, with no correlation between the 
degree of proteolysis and such activity, since the highest proteolysis degree was 
achieved when longer incubation in physiological conditions was applied (prolonged-
physiological conditions). This suggests that the generation of ACE-inhibitory peptides 
reached saturation point, at which the equilibrium between formation and degradation 
of active peptides occurred. Thus, physiological conditions were enough to obtain 
maximal ACE-inhibitory activity. In addition, when physiological conditions were 
reproduced in the semi-continuous system, no significant differences were observed in 
the degree of proteolysis and the values of ACE inhibition compared to batch 
physiological conditions. Therefore, the ACE-inhibitory activity of whey hydrolysates 
may be controlled by the conditions of in vitro gastrointestinal digestion, influencing the 
bioavailability of the peptides. Likewise, two Norwegian cheeses (Gamalost and 
Norvegia) were subjected to gastrointestinal digestion with human’s fluids and 
Gamalost cheese increased its ACE-inhibitory activity after gastric digestion but 
somewhat it decreased after duodenal phase (Qureshi et al., 2013). Conversely, the 
ACE-inhibitory activity of Norvegia cheese followed an increasing trend through both 
steps, but lower values were observed compared to the other cheese. On the other 
hand, Oshawa et al. (2008) demonstrated the resistance of the antihypertensive β-
casein peptides IPP and VPP to simulated gastrointestinal digestion with pepsin and 
pancreatin, or trypsin and chymotrypsin, followed by incubation with brush border 
enzymes expressed by Caco-2 cells. Likely, Quirós et al. (2009) demonstrated the 
resistance of the antihypertensive β-casein f(133-138), to in vitro gastrointestinal 
digestion. However, this sequence was further hydrolyzed by the brush border 
enzymes during incubation with Caco-2 cell culture, releasing the penta-peptide f(134-
138), HLPLP (Quirós et al., 2008), the latter retaining antihypertensive activity (Miguel 
et al., 2010). The antihypertensive sequences RYLGY, AYFYPEL [αs1-casein f(90-95) 
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and f(143-149), respectively)] and YQKFPQY [αs2-casein f(89-95)] were subjected to in 
vitro gastrointestinal digestion and the first two sequences were partly hydrolyzed, 
although the latter one was totally degraded (Contreras et al., 2013). After digestion, 
the two αs1-casein peptides maintained similar ACE-activity. In addition, some of the 
derived fragments maintained moderate ACE-inhibitory activity, which could explain the 
ACE-inhibitory activity of digests. Moreover, the peptide fragments derived from 
RYLGY showed antihypertensive activity suggesting that digestion could contribute to 
the effect of the precursor sequence through these fragments. Likely, the bovine LF 
digested with human gastric juice showed higher inhibition of Echovirus 5 replication 
than the native bovine protein, regardless the gastric digestion conditions, suggesting 
the release of peptides with antiviral activity (Furlund et al., 2012). However, they 
observed the strongest antiviral activity for the fraction of LF digested pH at 2.5 (doing 
fast decrease of pH instead of gradual), simulating adult gastric digestion and non-
buffering conditions, which led to complete degradation of the protein. Moreover, 
Tidona et al. (2011) observed higher antimicrobial activity against Escherichia coli 
10208355 and Listeria monocytogenes 2230/92 in digested donkey’s milk compared to 
the undigested one. These results were due to the synergic effect of the generated 
peptides and intact proteins resistant to digestion process, as lysozyme.  
The information obtained from these studies would not only be valuable to the 
application on the field of food, but also could be extended to the prevention and 
treatment of chronic diseases by nutraceuticals (Erdmann et al., 2008) or to the 
assessment of bioavailability of drugs (Brouwers y col., 2011).  
 
1.3 Absorption, distribution, metabolism, and elimination of bioactive peptides 
 
Once the resistance of certain peptides to digestion and their transport through 
the intestinal epithelium have been assessed, it is essential to evaluate the 
bioavailability properties of the peptides of interest. This term has been defined in a 
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previous section from nutritional point of view, as the fraction of the nutrient or bioactive 
available to be used in physiological functions or to be stored. Nevertheless, this term 
may adopt other meanings, for instance from pharmacological point of view. The Food 
and Drug Administration defines this term as “the rate and extent to which the active 
ingredient or active moiety is absorbed from a drug product and becomes available at 
the site of action” (Food and Drug Administration, 2013). This term includes the 
availability of the nutrient for absorption, distribution, metabolism and elimination. 
However, because of the difficulty, for practical and ethical reasons, to carry out these 
kind of trials, it is usually defined as the portion of the compound that reaches 
bloodstream (Fernández-García et al., 2009). Nonetheless, it has to be underlined that 
some active compounds can interact in situ with intestinal receptors present in the 
epithelium, being the absorption process a secondary factor for the active compound to 
exert the physiological effect. 
Few studies have been performed on the absorption of bioactive peptides 
derived from milk proteins. Given the complexity of the biological samples, the 
technique of analysis needs to be sensitive in order to detect peptides in plasma. This 
is the case of the method developed by van Platerink et al. (2006), based on MS-based 
technique, and whose sensitivity and selectivity permitted the detection and 
quantification of small amounts of 17 peptides in plasma, achieving limits of detection 
of 0.01 ng mL-1 and of quantification from 0.05 to 0.2 ng mL-1 . By using this method, 
the tri-peptide IPP was detected in plasma from humans after ingestion of a milk 
beverage enriched in tri-peptides, containing IPP among others (Foltz et al., 2007). The 
ingestion of the beverage produced an increase in the plasma concentration of IPP, 
whose maximum concentration (Cmax) was 1.6-fold that obtained after placebo 
ingestion. They observed that the time required to reach Cmax (Tmax) tended to be 
shorter after the ingestion of the enriched milk beverage compared to the placebo 
drink. The pharmacokinetic parameters of this peptide, IPP, were modified when the 
milk beverage was administered 30 min after a meal. In this case, greater values of 
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area under the curve (1.3 fold) and of half-time (1.5 fold) were observed compared to 
those obtained in fasted state; however, Tmax and Cmax were not affected by the feeding 
state of subjects. Later on, a pharmacokinetic study was carried out after intragastric 
and intravenous administration of the antihypertensive peptides IPP, LPP and VPP in 
pigs (van der Pijl et al., 2008). In this study they demonstrated the absorption of the 
three peptides after its intragastric administration to pigs, with different half-times of 
absorption between 2 and 4.6 min. No significant differences were found between the 
peptides, neither in the times of absorption, nor in Tmax and half-time of elimination. 
However, significant differences were reported in Cmax between IPP and LPP vs VPP; 
as well as in the half-time of elimination of the peptides after intravenous 
administration. In any case, the effective absorption of the peptides exceeded 0.1%, 
and considering that half-time of absorption and elimination did not exceed 5 and 15 
min, respectively, an acute effect of the peptides under these conditions was 
concluded. Matsui et al. (2002a) studied the absorption and elimination kinetics of the 
peptide VY in normotensive humans after ingestion of a beverage containing the di-
peptide. They found the peptide in plasma samples collected from subjects, reaching 
the maximum peak of absorption 2 h postprandial, and it was dose-dependent. The 
half-time of elimination was estimated at 3.1 h. This sequence is known to have blood 
depressor effect in humans with mild hypertension (Kawasaki et al., 2000). However, 
despite the detection of the intact peptide in plasma (Matsui et al., 2002a), the values 
of blood pressure of these normotensive male subjects did not change during the 
pharmacokinetic study. The same authors (Matsui et al., 2002b) found the di-peptide 
VY in plasma of subjects with mild hypertension after ingestion of the milk beverage 
containing the peptide. In this case, they obtained similar concentration values of the 
peptide in plasma as in the previous study. Therefore, it was demonstrated that the 
absorption process of this peptide was no affected by the physiological state of 
subjects; however, no changes in blood pressure were reported. These results point 
out the difficulty of establishing the physiological ranges for the administration of 
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peptides correlated to their biological effect in vivo and to their pharmacokinetic 
parameters. Nevertheless, although little is known about these aspects, these trials are 
essential to understand the behavior of peptides in the organism to establish a clear 
relationship between activity and bioavailable fraction.   
Moreover, once the absorption of a peptide is demonstrated, it is important to 
evaluate its resistance to plasma peptidases with the goal of assessing its metabolism, 
since it can play a key role in the manifestation of the effect in vivo (Vermeirssen et al., 
2004). In this regard, some authors have evaluated the impact of plasma peptidases on 
the stability of peptides during in vitro incubation of the peptides. For instance, the 
peptide IVY was incubated in rat and human plasma in vitro, releasing the active 
peptide fragment VY (Matsui et al., 2000). Likewise, Quirós et al. (2008) also 
performed an incubation in vitro of the β-casein f(134-138) in human plasma in order to 
assess its resistance to plasma peptidases, once they had demonstrated its transport 
through a Caco-2 cell monolayer. However, little information in this regard has been 
reported in vivo. For instance, studies focused on the metabolism and the distribution 
of active peptides have been carried out in different rat organs (lung, kidney, aorta, 
heart and brain). Indeed, the tri-peptides VPP and IPP were found in abdominal aorta 
of rats, after the ingestion of fermented milk that contained those sequences (Masuda 
et al., 1996).    
Overall, few studies have been focused on the absorption, metabolism, 
distribution and elimination of food-derived peptides and little is known about 
pharmacokinetic properties of peptides derived from milk proteins. However, there is a 
need to deepen into this field, to clear up some of the questions that remain unknown 
and that are important factors when dealing with bioactive peptides. This information is 
valuable in order to achieve a broader knowledge on the behavior of peptides in the 
organism and with the final aim of establishing a direct relationship with health.    
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1.4 Mechanism of action of antihypertensive peptides 
 
The antihypertensive effect of food-derived peptides has been widely studied 
(Martínez-Maqueda et al., 2012; Ricci-Cabello et al., 2012; Jäkala et al., 2010). Several 
milk-derived peptides have demonstrated antihypertensive activity in mild-hypertensive 
subjects, as reported in a meta-analysis carried out with 17 clinical trials (for review see 
Pripp et al., 2008). One of the systems involved in the control of blood pressure is the 
rennin-angiotensin system (Figure 7), where the ACE is included. This enzyme is 
responsible for the conversion of the deca-peptide angiotensin I in the octa-peptide 
angiotensin II, a vasoconstrictor. By a separate parallel pathway, ACE is also 
implicated in the inactivation of bradikinin, which possess vasodilator activity. Most of 
the peptides derived from milk proteins with a reported activity related to the reduction 
of blood pressure have been described as ACE inhibitors. However, other systems are 
involved in blood pressure regulation. The systems endothelin-converting enzyme and 
the kinin-nitric oxide are also involved in this function, by the release of vaso-regulatory 
peptides, independent from ACE, and of nitric oxide (NO), a vasodilator antiplatelet 
agent. Nevertheless, ACE is also related to the endothelial NO synthase. The latter 
enzyme is activated by angiotensin II, and the production of NO inhibits the action of 
ACE by negative feedback (Phelan & Kerins, 2011).  
The relationship that in the last years has been outlined for the food-derived 
peptides and the cardiovascular health lies on the blood pressure lowering effect 
mediated by several pathways. Among the wide range of antihypertensive peptides, 
IPP and VPP are two of the most studied ones, in regard to the Renin Angiotensin-
system. These peptides have been described as ACE-inhibitors in vitro (Nakamura et 
al., 1995a), and their antihypertensive activity has been proven in rats after single oral 
administration (Nakamura et al., 1995b) and long-term intake (Sipola et al., 2001; 
2002a), as well as in humans (for review see meta-analysis Xu et al., 2008; Qin et al., 
2013; Cicero et al., 2013). 
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Figure 7. Renin-angiotensin and Kalikrein-kinin pathway (Phelan and Kerins, 2011). 
 
For instance, a reduction in vascular reactivity to angiotensin I and II in mesenteric 
arteries from rats was observed after their incubation with IPP and VPP (Jakäla et al., 
2009a). Moreover, a decrease in plasmatic ACE activity was observed after their 
administration to SHR, although no significant differences were reported (Jakäla et al., 
2009b). Likewise, these tri-peptides were found intact in abdominal aorta of rats after 
the ingestion of fermented milk containing those sequences, and the values of ACE 
activity in this tissue decreased compared to the control (Masuda et al., 1996). 
Furthermore, there is evidence about the improvement of endothelial function induced 
by these food-derived tri-peptides (IPP and VPP), and also by whey peptide NOP-47, 
where NO was involved (Ballard et al., 2009; Hirota et al., 2011). Indeed, IPP and VPP 
produced a significant increase in the endothelial NO synthase gene after their 
administration to SHR during five days (Yamaguchi et al, 2009). Likely, a peptic casein 
hydrolysate, containing two antihypertensive peptides, RYLGY and AYFYPEL, that 
also showed ACE-inhibitory activity (Contreras et al., 2009), later on improved the 
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endothelial function in aortic and mesenteric rings, and increased the expression of 
endothelial NO synthase in aorta (Sánchez et al., 2011).  
The interaction of peptides with opioid receptors has been suggested as an 
alternative mechanism of action on the regulation of blood pressure. The presence of 
opioid receptors, as well as endogenous opioid peptides has been demonstrated in 
different organs of peripheral cardiovascular system (Schultz et al., 2001). Some 
studies have reported the involvement of endogenous opioid peptides in the regulation 
of blood pressure (Siren et al., 1992; Czapla et al., 1998). The endogenous opioid 
peptides interact with opioid receptors (µ, δ y κ), whose stimulation may induce direct 
or indirect functional changes on heart or cardiomyocytes (Barron et al., 1999). The 
administration of the opioid agonist morphine, with high affinity for µ receptors, induced 
a depressor response mediated by interactions with opioid receptor (Randich et al., 
1993). Nevertheless, it seems that morphine may also interact with δ and κ receptors 
(Ela et al., 1997). Evidence on this subject has led to consider that the interaction of 
these opioid receptors with the cardiovascular system is also related to the release of 
NO. In this sense, it has been demonstrated that morphine produced endothelial-
dependent relaxation in aortic rings from rats, associated to the release of NO, and it 
was reverted by naloxone (Stefano et al., 1995). In this regard, little information is 
available on peptides derived from milk proteins whose antihypertensive activity has 
been related to the opioid system. For instance, the blood lowering effect of the milk-
derived peptide α-Lactorphin [α-La f(50-53)], has been related to the opioid system, as 
agonist of µ opioid receptors (Nurminen et al., 2000). The evaluation of the participation 
of opioid receptors in the regulation of cardiovascular system is complex, due to the 
high number of them present either centrally or peripherally. In this respect, it has been 
demonstrated that α-Lactorphin, in contrast to morphine, does not exert its 
antihypertensive effect mediated by central opioid receptors (Ijäs et al., 2004). 
Moreover, this peptide was shown to improve endothelial function associated to the 
release of NO (Sipola et al., 2002b). 
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1.5 Peptidomic-based techniques for quantification and monitoring of peptides in food 
matrices  
The application of MS to identify peptides, usually preceded of high resolution 
separation techniques, has become one of the indisputable tools when dealing with 
bioactive peptides, in terms of discovery, bioavailability and monitoring through 
different processes. Given its development during the last years, and its versatility, it is 
one of the election techniques, over other analytical choices.  
In the field of the biologically active peptides, these techniques have had an 
enormous application to monitor the production of peptides by fermentation or by 
hydrolysis, to check their stability or to establish their bioavailability. Some peptidomic 
analyses are focused on targeted or untargeted products present in the food matrix due 
when manufactured i.e cheese ripening. For instance, a study aimed at seeking 
particular bioactive sequences in cheeses using an IT as mass analyzer (Bütikofer et 
al., 2007). Sometimes, the objective was to perform a mapping of peptides conferring 
bitter flavor to cheese (Toelstede et al., 2008). In addition, some products, such as 
human milk may undergo proteolysis in the mammary gland, and as a consequence, 
numerous peptides with antimicrobial properties can be formed, which could have 
further health implications for the neonate (Dallas et al., 2013). Two antihypertensive 
peptides from αs1-casein, RYLGY, f(90-94) and AYFYPEL, f(143-149) were monitored 
for a scaled-up production of an antihypertensive casein hydrolysate by HPLC-ESI-IT 
(Contreras et al., 2010). In addition, Quirós et al. (2006) developed and validated a 
mass spectrometry method based on the same instrument to quantify the 
antihypertensive sequence LHLPLP, f(133-138) present in a complex matrix, such as 
fermented milk produced by Enterococcus faecalis that caused hypotensive effect after 
single oral (Muguerza et al., 2006) and long-term administration (Miguel et al., 2005). 
Likewise, fermentation by yeasts such as Kluyveromyces marxianus has been 
proposed as an alternative to enzymatic hydrolysis to produce antihypertensive 
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peptides from α-lactalbumin and β-lactoglobulin (Hamme et al., 2009). In this sense, 
various antihypertensive peptides generated by Kluyveromyces marxianus from LF 
substrate were identified using HPLC-ESI-IT (García-Tejedor et al., 2013). However, 
little information is available about the peptide profile of these hydrolysates sequenced 
by MS-based techniques. 
MS techniques are useful tools to monitor the stability of the peptides through 
technological processes (heat treatment, packaging, storage, drying etc). In addition, 
food processing may induce changes in the profile of peptides present in food matrices. 
For instance, the release of peptides during cheese proteolysis (Piraino et al., 2007); or 
a detailed study on the evolution of peptide fraction along 24 months of aging (Sforza 
et al., 2012). On the other hand, food processing such heat-treatment can induce 
modifications of proteins, such as glycosylation that may have an influence on the 
bioavailability of certain amino acids involved in these changes. The pattern of protein 
glycosylation is susceptible of detection by MS-based techniques (Siciliano et al., 2013; 
Montgomery et al., 2013). Some technological processes could also modify the 
concentration of bioactive peptides in food. In this regard, the application of MS-based 
techniques to quantify and monitor food-derived bioactive peptides has been pointed 
out as a suitable tool (Contreras et al., 2008). The stability of two antihypertensive 
peptides (RYLGY and AYFYPEL), present in a peptic casein hydrolysate, to drying and 
storage was assessed by HPLC-ESI-IT (Contreras et al., 2011). 
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Nutrition exerts an important life-long environmental impact on
human health, and this interplay between nutrition and health has
been known for centuries (Kussmann, Panchaud, & Affolter, 2010).
171L. Sánchez-Rivera et al. / Food Research International 63 (2014) 170–181The quality of a dietary protein source depends not only on the
amino acid composition, their digestion, absorption, and availability
for subsequent anabolism, but also on the peptides that are released
(Awati et al., 2009). Many physiological functions in the organism
are mediated by peptides, acting as neurotransmitters, hormones
or antibiotics (Hruby & Balse, 2000). Because peptides from food
sources can be structurally similar to these endogenous peptides, it
is reasonable that they can interact with the same receptors and play a
role asmodiﬁers of food intake, growth factors, immune regulators, or an-
timicrobials in the host organism (Kamau et al., 2010;Meisel, 1998). Bio-
active peptides can be released in vivo, during gastrointestinal digestion,
by the action of host or microbial enzymes but theymay also be originat-
ed in vitro, whether it be from ripening, fermentation (naturally occur-
ring enzymatic reactions) or targeted food hydrolysis with selected
enzymes. Besides, preparation of bioactive peptides can be performed
using recombinant DNA technology or chemical synthesis (Hernández-
Ledesma, Contreras, & Recio, 2011). Once they are released in the body,
bioactive peptides may act as regulatory compounds with hormone-like
activity, exhibiting a wide range of biological functions, including antihy-
pertensive, antioxidant, opioid, antimicrobial, and immunostimulating
activities (Hartmann & Meisel, 2007). Although other animal as well as
plant proteins contain potential bioactive sequences, milk proteins are
currently the main source of biologically active peptides. Thus, they ac-
count for most of the researches on bioactive peptides that apply
peptidomics. This review will focus on studies dealing with peptides
from milk and related dairy products.
The food peptidome can be deﬁned as the whole peptide pool
present in food products or raw materials, or obtained during pro-
cessing and storage. Food peptidomics can be considered a subﬁeld
of the food proteomics focused on composition, interactions, and
properties of peptides present in a food matrix (Gagnaire, Jardin,
Jan, & Lortal, 2009). Some issues are common between the food pro-
teomics and food peptidomics ﬁelds, like the occurrence of non-
sequenced proteins, which makes mandatory to use de novo sequenc-
ing. This approach can be also helpful for identifying new single
amino acid polymorphisms.Workingwith complexmatrices is inherent
to these ﬁelds aswell. However, while in food proteomics a certain cov-
erage is enough to ﬁnd the selected protein, in the case of food
peptidomics, peptides may be unique (variants or modiﬁcations)
whereasmany similar species can be found in the studiedmatrices. Fur-
thermore, food peptides are released by the action of various unspeciﬁc
and speciﬁc proteases, as opposed to the tryptic peptides generated in
the proteomic experiments (Panchaud, Affolter, & Kussmann, 2012).
An additional difﬁculty arises from the need to follow up these speciﬁcYear
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Fig. 1. Number of publications including the topic “bioactive peptide” in the 2002–2012
period. Web of Science®.molecules not only in the food matrix but also upon ingestion and
absorption.
In biomarker proteomics, identiﬁcation and quantiﬁcation rely on
several peptides that can unambiguously be inferred back to one parent
protein sequence accounting for the key biological activity. By contrast,
bioactive peptides are the active molecules per se and their identiﬁca-
tion relies on the detection of this particular sequence in its full length
(Panchaud et al., 2012). Furthermore, their quantiﬁcation is needed
when the effective dose has to be calculated. Peptidomics can also
have a role in biomarker search. For instance, a peptidomic approach
has permitted to identify peptide panels which discriminate between
two bacterial causes of infection in bovine mastitis, as it has been re-
cently reported (Mansor et al., 2013). In human milk, the identiﬁcation
of the complete set of peptides naturally occurring suggests that protein
cleavages in themammary gland are not random events and represents
the ﬁrst step in understanding where and when milk peptides exert
speciﬁc functions (Dallas et al., 2013).
In the past ten years, the identiﬁcation and characterization of bioac-
tive peptides have become emerging research subjects as shown by the
increasing number of publicationswith the term “bioactive peptides” as
topic (Fig. 1). As a result of its analytical versatility and power for struc-
ture elucidation and, to a lesser extent, quantiﬁcation, mass spectrome-
try (MS) has developed into the major contributor to proteome and
peptidome-wide assessment in food (Kussmann et al., 2010). This is a
review in the ﬁelds of discovery, bioavailability, and monitoring of
dairy bioactive peptides emphasizing those contributions where
peptidomics has constituted an indispensable tool to achieve the
objective.
2. Peptide discovery
Nowadays, the research focused toward the discovery of new dairy
bioactive peptides continues mostly based on empirical strategies, in-
cluding advanced analytical techniques as MS in different conﬁgura-
tions. Despite the current prevalence of empirical approaches, in the
last years emerging bioinformatic tools have achieved an increasing
importance in the discovery of dairy bioactive peptides, through the
prediction of their biological activity and the optimization of the empir-
ical procedure.
2.1. Empirical approaches
The use of high-resolution separation techniques along with the en-
hanced peptide identiﬁcation, resulting from the combination of MS
methods and databases, support the present peptidomics status regard-
ing the empirical discovery of dairy bioactive peptides. Usually, the em-
pirical approach involves a series of steps: 1) release of the bioactive
sequences; 2) initial screening for a targeted bioactivity; 3) puriﬁcation
and separation; 4) further determination of biological activity; 5) pep-
tide identiﬁcation by MS; 6) in vitro and in vivo validation of biological
activity. A representative example of this workﬂow is found in the dis-
covery of casein (CN)-derived peptides with antihypertensive proper-
ties (Contreras, Carrón, Montero, Ramos, & Recio, 2009). Initially,
peptic hydrolysis of CN was carried out, its angiotensin-converting en-
zyme (ACE)-inhibitory activity was monitored at different intervals of
time and the antihypertensive activity was also veriﬁed in an animal
model. Once the activity was determined, the hydrolysate was ﬁrstly
subjected to ultraﬁltration and later fractionated by semi-preparative
reverse phase high performance liquid chromatography (RP-HPLC).
Those chromatographic fractions with relevant ACE-inhibitory activity
were analyzed by RP-HPLC coupled to tandem MS (MS/MS) and the
peptides comprised in the active fractions were identiﬁed. Finally, the
ACE-inhibitory activity was veriﬁed for selected peptides, besides the
veriﬁcation of their in vivo antihypertensive activity.
In addition to in vitro enzymatic hydrolysis, the release of bioactive
peptides from the parent dairy proteinsmay occur during gastrointestinal
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mentation (mainly by lactic acid bacteria because their advanced proteo-
lytic system), and food manufacturing (ripening and cooking)
(Rutherfurd-Markwick, 2012). The variety of enzymes becomes wider
in recent years due to the increasing use of non-digestive enzymes like
microbial- and vegetable-derived enzymes (Choi, Sabikhi, Hassan, &
Anand, 2012).
The complexity of the dairy hydrolysates, fermented products, or di-
gests and the analytical limitations of the equipment make necessary
the implementation of pretreatments to remove interfering compo-
nents and concentrate peptides with the aim of obtaining a successful
separation and identiﬁcation (Poliwoda & Wieczorek, 2009). The pep-
tide extraction using homogenization in water or organic solvents is
mandatory for the study of bioactive peptides from cheeses, followed
by a deproteinization step through selective precipitation, ﬁltration,
and/or centrifugation, as occurs in the search of ACE-inhibitory peptides
in different Cheddar cheeses (Ong & Shah, 2008) or fermented milk
(Pihlanto, Virtanen, & Korhonen, 2010). Acid precipitation can be also
used like a preliminary sub-fractionation, as performed by Ferranti
et al. (2004) during the study of the bioactive peptide occurrence in
human milk. Regarding the sample fractionation step, ultraﬁltration
with different molecular cut-off membranes, the use of solid phase ex-
traction cartridges, low pressure liquid chromatography, and RP-HPLC
at semi-preparative scale represent the main techniques employed
(Martínez-Maqueda, Hernández-Ledesma, Amigo, Miralles, & Gómez-
Ruiz, 2013). The combination of techniques based on different selectiv-
ities is recommended in support of optimizing the bioactive peptide
identiﬁcation. For instance, in the determination of ACE-inhibitory pep-
tides derived from yak milk CN, the serial ultraﬁltrations (10 & 6 kDa)
were further fractionated by low pressure size exclusion chromatogra-
phy (SEC) and ﬁnally by RP-HPLC (Jiang, Chen, Ren, Luo, & Zeng,
2007). Similarly, in the fractionation of antibacterial peptides from
ovine αs2-CN, the use of low pressure ion exchange chromatography
(IEX) was followed by semi-preparative RP-HPLC (López-Expósito,
Gómez-Ruiz, Amigo, & Recio, 2006).
The large number of peptides contained in studied samples usually
leads their prior separation before identiﬁcation by MS. HPLC in their
different modes have become the preferred technique to the separation
of peptides because its versatility, efﬁciency, and automation capabili-
ties (Hernández-Ledesma, Martínez-Maqueda, Miralles, Amigo, &
Gómez-Ruiz, 2013). RP-HPLC constitutes the most employed method
to analyze milk-derived bioactive peptides, highlighted by its ability to
effectively separate small peptides (Recio & López-Fandiño, 2010),
that is a common characteristic of most bioactive peptides (Roberts,
Burney, Black, & Zaloga, 1999). Nevertheless, other HPLC modes have
been also used in bioactive peptide separation such as IEX, SEC, hydro-
philic interaction chromatography (HILIC), hydrophobic interaction
chromatography, and afﬁnity chromatography (Hernández-Ledesma
et al., 2013). A representative example is found in the promising appli-
cation of use metal oxide afﬁnity chromatography in the ﬁeld of
“phosphopeptidomics” (Leitner, 2010). Sometimes, it is mandatory
the implementation of more than one HPLC step, that is orthogonal
combination of separation techniques, occurring that the last dimension
is usually RP-HPLC (D'siva & Mine, 2010; Sandra et al., 2009). On the
other hand, capillary electrophoresis (CE) represents another separa-
tion option supported by its versatility and low consumption of sample,
reagent, and time (Herrero, Ibañez, & Cifuentes, 2008; Kašička, 2012).
Català-Clariana, Benavente, Giménez, Barbosa, and Sanz-Nebot (2010)
identiﬁed several bioactive peptides in infant milk formulas using CE-
MS. Miniaturized techniques like capillary electromigration chromatog-
raphy and nano liquid chromatography (nanoLC) represent a promising
separation strategy that may be increasingly applied to empirical dis-
covery of bioactive peptides given their optimized design (Issaq, Chan,
Blonder, Ye, & Veenstra, 2009). Direct nanoLC-MS was carried out by
Zhu and FitzGerald (2010) to identify caseinophosphopeptides (CPPs)
generated via tryptic hydrolysis of CN.MS has been notably developed over the last decade, becoming the
undisputed tool in bioactive peptide identiﬁcation, reducing the use of
other identiﬁcation techniques like amino acid analyzers or protein se-
quencers (Picariello, Mamone, Addeo, & Ferranti, 2012). Occasionally
MS is complemented with some traditional identiﬁcation methods as
shown by Pihlanto et al. (2010) who carried out the identiﬁcation of
ACE-inhibitory peptides in fermented milk by using matrix-assisted
laser desorption ionization-time of ﬂight (MALDI-TOF) and Edman deg-
radation sequencing. Beneﬁts associated with MS equipment involve
sensitive and accurate mass information, likely structure elucidation
and short time analysis (D'siva & Mine, 2010). Nowadays, the quantity
of available MS conﬁgurations is higher, featuring enhanced different
capabilities (Hernández-Ledesma et al., 2013) and depending mainly
on the combination of the ionization source and mass analyzer (Recio
& López-Fandiño, 2010). Fast atom bombardment practically represents
an extinct ionization methodology over the last decade, despite its ap-
plication was crucial for the discovery of several milk-derived bioactive
peptides such as CPPs, ACE-inhibitory, opioid, and antioxidant peptides
(Contreras, López-Expósito, Hernández-Ledesma, Ramos, & Recio,
2008). The emergence of the electrospray (ESI) displaced previous ion-
izationmethods and presently continues being the predominant ioniza-
tion choice, as shown in Table 1. The ease of on-line couplingwith HPLC
entails a crucial beneﬁt that has been extensively exploited like in the
discovery of novel antihypertensive peptides from a peptic hydrolysis
of lactoferrin (Ruiz-Giménez et al., 2012) and the identiﬁcation of
ACE-inhibitory peptides in Mexican Fresco cheese (Torres-Llanez,
González-Córdova, Hernandez-Mendoza, Garcia, & Vallejo-Cordoba,
2011). Both studies used ESI as ionization source and ion trap mass an-
alyzer (IT). The progression of ESI technology is today a fact with the in-
creasing implementation of miniaturized instrumentation such as
nano-ESI which allowsworkingwith small samples and buffer volumes,
e.g., the discovery of dipeptidyl peptidase IV (DPP IV)-inhibitory pep-
tides from Gouda cheese using nanoESI-IT (Uenishi, Kabuki, Seto,
Serizawa, & Nakajima, 2012). ESI also permits the appropriate on-line
couplingwith CE as proved in the characterization of bioactive peptides
in infantmilk formulas by ESI-IT and ESI-TOF, where the effectiveness of
both mass analyzers was additionally evaluated (Català-Clariana et al.,
2010). The combination of more than one mass analyzer seeks the en-
hancement of the identiﬁcation through their particular advantages
and several existing MS conﬁgurations are a sign of this reasoning like
the combination of quadrupole (Q) and TOF mass analyzers used in
the discovery of a novel peptide with mucin stimulatory activity
(Plaisancié et al., 2013) or during the development of an at-linemethod
for the identiﬁcation of ACE-inhibitory peptides (van Platerink, Janssen,
&Haverkamp, 2007).MALDI constitutes another broadly employed ion-
ization source that exhibits signiﬁcant differences compared to ESI, i.e.,
higher sensitivity, single charged ions, and lower susceptibility to salt
and impurities although does not allow on-line chromatographic cou-
pling (Mamone, Picariello, Caira, Addeo, & Ferranti, 2009).MALDI is nor-
mally presented with TOF (MALDI-TOF) and is especially focused to the
identiﬁcation of longer peptides (Saavedra, Hebert, Minahk, & Ferranti,
2013). The use ofMALDI-TOF in the identiﬁcation ofmilk-derived bioac-
tive peptides is clearly demonstrated through the examples included in
Table 1, like the identiﬁcation of ACE-inhibitory peptides in Idiazabal
cheese (Sagardia, Iloro, Elortza & Bald, 2013) or antimicrobial peptides
in a peptic hydrolysate of lactoferrin (Chan & Li-Chan, 2007). Regarding
small peptide identiﬁcation, MALDI matrix might interfere the analysis
due to the appearance of matrix signals at low masses. Nevertheless a
suitable method named NALDI (nanostructure laser desorption/ioniza-
tion) without matrix has been recently introduced and could represent
a potential option for lowmass peptide analysis (Saavedra et al., 2013).
Analysis of peptides inmilk has been already carried out byNALDI (Kütt,
Malbe, & Stagsted, 2011) although future development in bioactive pep-
tide ﬁeld is expected.
Once performed the identiﬁcation of the peptides potentially re-
sponsible for the observed activity, the veriﬁcation of the in vitro or
Table 1
Examples of mass spectrometry application for dairy bioactive peptide discovery.
Origina Activity Ion
source
Mass analyzer Reference
Fermented milk ACE-inhibitory
Antihypertensive
ESI IT Quirós et al. (2007)
Fermented caprine whey ACE-inhibitory ESI IT Didelot et al. (2006)
Commercial caprine keﬁr ACE-inhibitory
Antimicrobial
Antioxidant
ESI IT Quirós et al. (2005)
Different Spanish cheeses ACE-inhibitory ESI IT Gómez-Ruiz, Taborda, Amigo, Recio, and Ramos (2006)
Mexican Fresco cheese ACE-inhibitory ESI IT Torres-Llanez et al. (2011)
Different Italian cheeses Antimicrobial ESI IT Losito et al. (2006), Rizzello et al. (2005)
Fermentation of sodium caseinate ACE-inhibitory ESI IT Hayes et al. (2007), Robert, Razaname, Mutter, and Juillerat (2004)
Hydrolysis of milk proteins with thermolysin ACE-inhibitory ESI IT Otte, Shalaby, Zakora, Pripp, & El-Shabrawy (2007)
Ovine κ-CN and whole CN hydrolysed with digestive
enzymes
ACE-inhibitory ESI IT Gómez-Ruiz, Ramos, & Recio (2007)
In vitro gastrointestinal digestion of human milk ACE-inhibitory
Antioxidant
ESI IT Hernández-Ledesma et al. (2007)
WPC hydrolysate from Cynara cardunculus ACE-inhibitory ESI IT Tavares et al. (2011)
Chymosin and peptic hydrolysis of CN Antibacterial ESI IT McCann et al. (2005, 2006)
Peptic hydrolysis of ovine αS2-CN and bovine κ-CN Antibacterial ESI IT López-Expósito, Gómez-Ruiz, et al. (2006), López-Expósito, Minervini,
Amigo, and Recio (2006)
Peptic hydrolysis of lactoferrin Antihypertensive ESI IT Ruiz-Giménez et al. (2012)
Peptic hydrolysis of CN Antihypertensive ESI IT Contreras et al. (2009)
Hydrolysis of α-LA and β-LG with Corolase PP™ Antioxidant ESI IT Hernández-Ledesma, Dávalos, Bartolomé, and Amigo (2005)
Tryptic hydrolysis of WPC DPP-IV inhibito-
ry
ESI IT Silveira et al. (2013)
Tryptic hydrolysis of WPC Mucin secretory ESI IT Martínez-Maqueda, Miralles, Ramos, and Recio (2013)
Infant milk formula Several activities ESI IT & TOF Català-Clariana et al. (2010)
Tryptic hydrolysis of ovine β-LG and milk yogurts ACE-inhibitory ESI QTOF Chobert et al. (2005)
Commercial hydrolysed caseinate ACE-inhibitory ESI QTOF van Platerink et al. (2007)
Yogurt Mucin secretory ESI QTOF Plaisancié et al. (2013)
Commercial antihypertensive yogurt Several activities ESI TOF Kunda et al. (2012)
Gouda cheese DPP-IV inhibito-
ry
nanoESI IT Uenishi et al. (2012)
Mozzarella cheese whey Antioxidant
Cytomodulatory
ESI &
MALDI
(ESI)-IT &
(MALDI)-TOF
De Simone et al. (2009)
CN hydrolysatedwith a proteinase from Lactobacillus
helveticus PR4
ACE-inhibitory
Antibacterial
MALDI TOF Minervini et al. (2003)
Fermented milk ACE-inhibitory
Antihypertensive
MALDI TOF Pihlanto et al. (2010)
Sodium caseinate fermented with Lactobacillus
acidophilus DPC 6026
Antimicrobial MALDI TOF Hayes, Ross, Fitzgerald, Hill, and Stanton (2006)
Peptic hydrolysis of lactoferrin Antimicrobial MALDI TOF Chan and Li-Chan (2007)
Idiazabal cheese ACE-inhibitory MALDI TOF Sagardia, Iloro, et al. (2013)
Tryptic hydrolysis of milk proteins Phosphopeptides MALDI TOF Lo, Chen, Chen, and Chen (2007), Wang, Chen, Wu, Guo, and Xia (2007)
α-LA, α -lactalbumin; CN, casein; β-LG: β -lactoglobulin; WPC: whey protein concentrate; ACE: angiotensin-converting enzyme; DPP-IV: dipeptidyl peptidase IV; ESI: electrospray;
MALDI: Matrix-assisted laser desorption/ionization; IT: ion trap; TOF: time-of-ﬂight; QTOF, quadrupole-time-of-ﬂight.
a Unless indicated, milk proteins from bovine origin.
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establish their bioactivity. This step is generally performed in peptide
discovery studies. For instance, in a recent report, the DPP-IV inhibitory
activity of two novel β-lactoglobulin (β-LG)-derived peptides was veri-
ﬁed by determining the activity of the synthetic sequences (Silveira,
Martínez-Maqueda, Recio, &Hernández-Ledesma, 2013). Same strategy
was followed to identify two novel antioxidant peptides after screening
the activity of eight synthetic peptides found in the simulated gastroin-
testinal digestion of human milk (Tsopmo et al., 2011). Furthermore,
peptidomics can be helpful in the study of related issues as the bioavail-
ability or the bioactive peptide monitoring, according to the following
sections.
2.2. Bioinformatic-driven approaches
The recent development and combination of computational tools
and bioactive peptide databases have led to a growing importance of
bioinformatic-driven approaches or in silico analysis in the bioactive
peptide discovery. Unlike empirical approaches that typically involve a
signiﬁcant expense, bioinformatics provide a cost-effective strategythrough the reduction of different steps of the traditional workﬂow
(Saavedra et al., 2013). Major contribution of in silico analysis in bioac-
tive peptide ﬁeld is related to the prediction of biological activity and
the evaluation of food proteins as potential precursors, as observed in
the in silico analysis of 34 proteins as potential sources of DPP-IV inhib-
itory peptides (Lacroix & Li-Chan, 2012). Furthermore, bioinformatic-
driven studies are often supported by the possibility of predicting the
proteolysis of dietary proteins due to the knowledge of the speciﬁc
cleavage site of certain enzymes (Panchaud et al., 2012). The prediction
of peptide activity is closely related to the study of interactions between
target receptor and the peptide structure. Fig. 2 exhibits how two con-
formers of a β-CN peptide interact in different ways with the ACE active
site, which results in different inhibitory behavior (Gómez-Ruiz, Recio,
& Belloque, 2004). In recent years, the quantitative structure activity re-
lationshipmodel (QSAR) has reached a notable occurrence in the bioac-
tive peptide discovery as reviewed by Carrasco-Castilla, Hernández-
Álvarez, Jiménez-Martínez, Gutiérrez-López, and Dávila-Ortiz (2012).
QSAR analysis is based on elucidating structure–activity relationships
by physicochemical descriptors to predict biological activities of other
peptide sequences. QSAR approaches have been successfully used in
Fig. 2.Models showing the interactions between a peptide inhibitor, with trans- and cis-Pro at the C-terminal end (light gray), and the active site of the angiotensin-I-converting enzyme
(dark gray). Model modiﬁed from the crystal coordinates of Drosophila angiotensin-I-converting enzyme bound to lisinopril (Protein Data Bank, PDB code 1J36) (11), modeled with DS
Viewer Pro 5.0 (Accelrys). H-bonds are labeledwith dashed lines. Carboxyl groups (CO andCOO\) are labeled in black. The change of trans-Pro to cis-Pro results in the displacement of the
CO group of the previous residue of the inhibitor (labeled with an arrow) to the opposite side of the peptide chain, losing its original H-bonding with the enzyme.
Reprinted with permission from Gómez-Ruiz, Recio, & Belloque, 2004. Copyright © 2004 American Chemical Society.
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tripeptides (Sagardia, Roa-Ureta, & Bald, 2013; Toropova et al., 2012),
or for the evaluation of different food proteins as ACE-inhibitory peptide
precursors (Gu, Majumder, & Wu, 2011). The antioxidant activity has
also been evaluated via QSAR analysis, as Li and Li (2013) developed
via 17 physicochemical descriptors or Li, Li, He, and Qian (2011) per-
formed focusing on the second C-amino terminal position, as well as
in the prediction of antimicrobial peptides (Shu et al., 2013). QSAR ap-
proaches broadly exploit the peptide and protein databases, which
may include extensive information like bioactivity, physicochemical
parameters, references, and more. Among bioactive peptide data-
bases, BIOPEP emerges as one of the most valued with more than
2500 entries classiﬁed according to speciﬁc biological activities
and the opportunity of in silico proteolysis of more than 700 pro-
teins (Minkiewicz, Dziuba, Iwaniak, Dziuba, & Darewicz, 2008).
Other databases are Pepbank, BioPD, and SwePep as reviewed by
Carrasco-Castilla et al. (2012).
The remarkable improvement of computational tools and analytical
equipments, including MS, has supported the growing applicability of
chemometrical analysis to different topics related to food bioactive dis-
covery (Minkiewicz, Dziuba, Darewicz, et al., 2008). The response sur-
face methodology (RSM) has demonstrated to be very useful in the
optimization of proteolysis variables such as time, temperature, pH, en-
zyme or bacterial strain as well as substrate ratio when searching for a
speciﬁc activity (Carrasco-Castilla et al., 2012). For instance, the produc-
tion of antioxidant hydrolysates from a whey protein concentrate with
thermolysin (Contreras, Hernández-Ledesma, Amigo, Martín-Álvarez,
& Recio, 2011) and the fermentation of sour milk by Lactobacillus
helveticus to get ACE-inhibitory activity (Pan&Guo, 2010)were assisted
by RSM prior to the bioactive peptide identiﬁcation. Chemometrics, as
the art of extracting chemically relevant information from processes
and transforming it into valuable data, can also be helpful in the bioac-
tive peptide identiﬁcation by predicting retention (HPLC) or migration
(CE) times on the basis of the knowledge of peptide physicochemical
properties and the use of complex algorithms. Recent examples of the
use of semi-empirical models of elution time prediction to improve
the peptide identiﬁcation reliability are found in the study of hypoaller-
genic infant milk formulas by CE–ESI-TOF (Català-Clariana, Benavente,Giménez, Barbosa, & Sanz-Nebot, 2013), as well as, a functional yogurt
by microLC–ESI-TOF (Kunda et al., 2012).
3. Bioavailability
When studying the effect that an active compound could have in our
organism, it is important to assure that the active form reaches the tar-
get organ. For this purpose, stability to digestion has to be assessed and,
if it is absorbed, it is also important to evaluate its distribution,
metabolism, and excretion, in order to establish thebioavailability prop-
erties of a selected peptide (Foltz, van der Pijl, & Duchateau, 2010).
3.1. Modiﬁcations during gastrointestinal digestion
The ingested food composed of complex molecules is digested
through physical and chemical processes followed by absorption of
the reﬁned macro- and micronutrients, which mainly takes place in
the duodenum and upper jejunum (Langerholc, Maragkoudakis,
Wollgast, Gradisnik, & Cencic, 2011). Digestion process determines the
formation of peptides derived from food proteins, which can be physio-
logically and metabolically relevant for the digestion process itself, but
also for novel food formulation, concerning not only nutritional but
also technological and toxicological aspects, such as, identiﬁcation of
potential epitopes involved in allergies (Wickham, Faulks, & Mills,
2009).
The MS application, normally preceded of high-resolution separa-
tion techniques, is becoming a useful tool for the study of digestion pro-
cesses, since it allows to obtain not only descriptive-type results but also
the identiﬁcation of resulting products. Several authors have recently
employed this technique to characterize the products formed during di-
gestion of different milk proteins, as bovine (Dupont, Mandalari, Molle,
Jardin, Léonil, et al., 2010; Picariello et al., 2010), ovine (Gómez-Ruiz,
Ramos, & Recio, 2004a), caprine (Almaas et al., 2011), donkey
(Bermeosolo-Bidasolo, Ramos, & Gomez-Ruiz, 2011), and human
(Hernández-Ledesma, Quiros, Amigo, & Recio, 2007). The identiﬁcation
by MS can be targeted at some products of interest through digestion
(potential epitopes, bioactive monitoring, stability of certain regions);
or exhaustive untargeted analysis, intended to elucidate the kinetics of
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models. Some authors have used this targeted identiﬁcation to assess
the stability of several peptides during digestion, for instance tomonitor
their ACE-inhibitory activity in cheese (Gómez-Ruiz et al., 2004a), or to
follow the generation of antioxidant and ACE-inhibitory peptides in
human milk and infant formulas digested in vitro with porcine pepsin
and pancreatin (Hernández-Ledesma et al., 2007). De Noni and
Cattaneo (2010) studied the occurrence and stability of β-
casomorphins (β-CMs) 5 and 7 in dairy products during in vitro gastro-
intestinal digestion using porcine pepsin followed by the addition of
Corolase PP™. Likewise, the survival of certain antihypertensive regions
of β-CN (e.g. f(133–138) mature protein sequence always considered),
which turned out to be resistant to in vitro digestion, was evaluated
by Quirós, Contreras, Ramos, Amigo, and Recio (2009) by using a two-
stage hydrolysis with porcine pepsin and Corolase PP™. However, pep-
tides can be hydrolyzed during gastrointestinal digestion and either
maintain their activity, decrease it, or increase it. As an example of the
latter case, the antihypertensive sequence KLPVPQ, which had a low
in vitro activity, showed higher activity by losing its C-terminal Gln res-
idue after in vitro digestion with pancreatin (Maeno, Yamamoto, &
Takano, 1996).
Other authors have used MS-based techniques to identify phos-
phopeptide formation during gastrointestinal digestion. For in-
stance, the resistance of CPPs to in vitro gastrointestinal digestion
was monitored when they were incorporated into milk-based fruit
beverage or into a fruit beverage using two enzymatic solutions for
digestion: porcine pepsin and pancreatin-bile solution (García-
Nebot, Alegría, Barberá, Contreras, & Recio, 2010). Likewise, Miquel
et al. (2005) carried out the identiﬁcation of CPPs generated in differ-
ent infant formulas after in vitro gastrointestinal digestion using
porcine pepsin from gastric mucosa, followed by the addition of pan-
creatin from porcine pancreas and bile extract. Also, Adt et al. (2011)
studied the content of CPPs in Beaufort cheese using selective precip-
itation before and after subjecting cheese to digestion with pepsin
acid solution followed by incubation with pancreatin. They
highlighted the increase of CPPs after digestion with gastrointestinal
enzymes, being most of them, monophosphorylated.
The untargeted analysis to characterize gastrointestinal digests by
using MS-based techniques has also been reported by several authors.
The peptide proﬁle of two Norwegian cheeses before and after in vitro
gastrointestinal digestion with human enzymes was compared by
Qureshi, Vegarud, Abrahamsen, and Skeie (2013) using nanoLC–ESI-
QTOF. In this study, digestion was performed using a three-stage
model that included the incubation of the samples in a Stomacher to
mimic the chewing step, followed by the addition of human gastric
and duodenal juices. It was reported the resistance of some peptides, al-
though others seemed to be totally degraded and disappeared after di-
gestion. Also, it was pointed out that generation of free amino acids
was affected during this process. Gastric digestion caused a signiﬁcant
decrease on Pro content. Whereas the aromatic amino acids such as
Tyr, Phe, and Trp; the positively charged ones (Arg and Lys); and Leu
did not undergo any changes. On the contrary, duodenal digestion pro-
duced a signiﬁcant increase on these amino acids. Recently, Sánchez-
Rivera et al. (in press) studied the peptidome of a proteolyzed cheese
(Valdeón) and skim milk powder after a two stage in vitro static
digestion by adding porcine pepsin, followed by trypsin, chymotrypsin,
lipases and bile salts, using RP-HPLC–ESI-IT. The great homology of the
digests found in this study suggests that the gastrointestinal digestion
could bring closer the proﬁle of resulting products whose matrices
differed in their proteolytic state. However, regarding the occurrence
of bioactive sequences, there are exceptions attributed to peptide pre-
cursor differences that are in accordance with the different biological
activity observed. Eriksen et al. (2010) used a nanoLC–ESI-QTOF to com-
pare the peptide formation from caprine whey proteins after two-step
static in vitro digestion with human gastric and duodenal juices and
porcine enzymes (pepsin and Corolase PP™). Although there was nota great difference at protein digestion level revealed through SDS-
PAGE assays, it was reported in this study that, the peptide proﬁles of
β-LG revealed differences and showed a more extensive digestion by
porcine enzymes than by human ones under the same conditions. Like-
ly, the comparison of protein digestion patterns for two in vitro static di-
gestions models, infant and adult, have been assessed using nanoLC–
ESI-QTOF byDupont, Mandalari, Molle, Jardin, Léonil, et al. (2010). Like-
wise, the peptide survival during an in vitro multi-step static digestion
model of milk proteins was studied by Picariello et al. (2010), by using
MALDI-TOF, nanoESI-QTOF, and nanoLC–ESI-QTOF. CPP-enriched frac-
tions obtained with a TiO2 column were analyzed in this study in
order to increase protein coverage. Furthermore, the authors highlight-
ed the relevance of certain regions of β-LG, resistant to proteolysis and
their implications for cow's milk allergy. There are some valuable
in vivo studies conducted to understand the breakdown of proteins,
and its kinetics during digestion. Bouzerzour et al. (2012) conducted a
study on digestion of infant formula in piglets, in order to evaluate pro-
tein digestion kinetics and peptide release. The β-CN region between
residues 74 and 91 was reported to be resistant to proteolysis during
these experiments, which was in agreement with in vitro studies of in-
fant digestion carried outwith different dairymatrices such as raw, pas-
teurized, sterilized milks and yogurt (Dupont, Mandalari, Molle, Jardin,
Role-Répécaud, et al., 2010). Also, some authors have characterized
human digests after ingestion of milk or yogurt (Chabance et al.,
1998). Sequences f(25–32) and f(143–149) from αs1-CN were identi-
ﬁed by Edman degradation using an automated gas-phase sequencer.
Likewise, more recently, Boutrou et al. (2013) conducted an in vivo
study in humans to assess the release of peptides after ingestion of CN
or whey protein. A total of 356 peptides from β-CN and 165 from
whey proteins were identiﬁed in jejunum. The amount of several pep-
tides found postprandial, (i.e. different β-CN including β-CN f(60–66)
and f(108–113)) was claimed to be enough to allow these peptides to
exert their biological activity, known to have opioid and antihyperten-
sive activity, respectively. In order to evaluate the effect that a dietary
peptide could exert in the organism, the digestion process is to be as
close as possible to in vivo physiological parameters. In this sense,
Kopf-Bolanz et al. (2012) validated an in vitro digestion model of pas-
teurized milk using RP-HPLC–ESI-IT by the comparison of results to
human physiological data from studies related to the intestinal peptide
transport, digestion of emulsiﬁed triglycerides and starch digestibility.
In this study, the results were found to be consistent since the devel-
oped method gave macronutrients degradation values similar to those
found in human. Altogether, there are some common traits resulting
from these in vitro static digestion studies. β-LG and α-lactalbumin
are more resistant to digestion than other milk proteins (Dupont,
Mandalari, Molle, Jardin, Léonil, et al., 2010; Picariello et al., 2010).
There are some regions that also appear to be resistant like those con-
taining phosphorylated fragments as proved by García-Nebot et al.
(2010), previously reported in other studies (Hirayama, Toyota,
Hidaka, & Naito, 1992). Likewise, hydrophobic and Pro-rich regions re-
sist digestion, in agreement with previous observations (Hausch, Shan,
Santiago, Gray, & Khosla, 2002), while neutral and basic amino acids
are rapidly hydrolyzed. Some of these Pro-rich domains are well con-
served between species, and interestingly, some sequences reported
as bioactive are included in these regions.
3.2. Modiﬁcations during absorption
In the intestinal epithelium, the absorptive enterocytes and the gob-
let cells are the two main cellular types. The apical side of the
enterocytes is characterized by a brush border which contains several
enzymes and which increases the surface for nutrient absorption. The
goblet cells secrete mucus, which covers the apical membrane of intes-
tinal cells and partially limitsmolecule absorption (Meaney&O'Driscoll,
1999). Any food peptide in the intestinal lumenmust transverse this en-
vironment prior to absorption. Peptidomics has emerged as an
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food peptides in this environment.
Models physiologically close to human intestinal absorption are, in as-
cendant order, cell linemodels, excised tissuesmounted onUssing cham-
ber (animal, ex vivo), and intestinal perfused loops (animal, in situ).
3.2.1. Peptidomics in cell line models
Cell linemodels offer a suitable alternative for in vivo animal testing.
Their main advantage is their simplicity, interlaboratory repeatability,
and large-scale testing capacity. Due to their reliability they have be-
come an indispensable tool for the elucidation of intestinal absorption
mechanisms. Most of the current intestinal cell line models are using
transformed cell lines, among them the Caco-2 model being the most
widely used (Langerholc et al., 2011).
For stability experiments, the digestion can be continued by a brush
border phase, in order tomimic the ﬁrst contactwith the intestinal wall.
For oligopeptides, it is known that susceptibility to brush border pepti-
dases controls the apical-to-basolateral transepithelial transport rate
(Shimizu, Tsunogai, & Arai, 1997). In the case of absorption of the anti-
hypertensive β-CN peptide LHLPLP, using Caco-2 cell layers, it was
shown that the hexapeptide was partly hydrolyzed by brush border
peptidases that cleaved the peptide bond between Leu and His, releas-
ing the pentapeptide HLPLP, which undergoes a rapid transport to the
basolateral chamber. The unequivocal determination of this short form
by RP-HPLC–ESI-IT conﬁrmed that the peptide must ﬁrst be hydrolyzed
by peptidases before absorption occurs. As no other sequences were de-
tected, it was suggested that HLPLP is probably the minimum activeform of the peptide (Quirós, Dávalos, Lasunción, Ramos, & Recio,
2008). The presence of Prowithin the sequence can have a protective ef-
fect from the action of peptidases. This was also the explanation for the
survival of a relatively long CN fragment, the 17-residues peptide
f(193–209) from β-CN, which was not signiﬁcantly hydrolyzed by
brush border exopeptidases, as shown on its quantiﬁcation in the apical
solutions of a Caco-2 monolayer using RP-HPLC–ESI with triple quadru-
pole (QqQ) as mass analyzer (Regazzo et al., 2010).
The use of Caco-2 cell model has some limitations, such as the ab-
sence of amucus layer, to be tighter compared to human small intestine,
low expression of uptake transporters, and over-expression of P-
glycoprotein. The additional presence of mucin-secreting goblet cells
in co-cultures with Caco-2 might modulate the tightness of the mono-
layer and form amucus gel layerwhichmimics physiological conditions
(Hilgendorf et al., 2000). Using a co-culture 75% Caco-2/25% HT29-MTX,
the antihypertensive peptides from αs1-CN RYLGY, AYFYPEL, and two
derived fragments, RYLG and AYFYPE, identiﬁed after treatment with
pepsin and Corolase PP™ showed that they can survive the action of in-
testinal peptidases, cross the mucus layer, and be absorbed intact
through the intestinal epithelium, because they were detected in the
basolateral solution (Fig. 3). The use of a powerful identiﬁcation tech-
nique, RP-HPLC-ESI-IT, showed also that released fragments from
these peptides could be transepithelially absorbed and they could,
therefore, exert physiological effects (Contreras, Sancho, Recio, & Mills,
2012).
A recent work has characterized the entire panel of peptides pro-
duced from CN and whey proteins that survive in vitro sequential
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chymotrypsin, elastase and carboxypeptidase) and translocate across
the Caco-2 cell monolayer (Picariello et al., 2013). The combination of
RP-HPLC in conventional and microscale ﬂow and MS analyzers
(MALDI-TOF and ESI-QTOF) together with the use of synthetic peptides,
as the gastrointestinal-resistant model peptides, permitted a reliable
peptide monitoring. The presence of some of the previously described
bioactive peptides of milk on the basolateral side of the Caco-2 mono-
layer was negligible. For instance, the β-CMs were not detected,
although it has been reported that synthetic human β-CMs can translo-
cate across Caco-2 monolayers (Iwan et al., 2008). By contrast, some
CPPs from the regions 104–119 of αs1-CN and 33–52 of β-CN were
shown to translocate across the intestinal epithelium model. Besides,
resistant regions from β-LG f(40–60) and f(125–135) were also detect-
ed in considerable amounts.
With the aim to construct a structural diverse database for dipep-
tides, assessing their intestinal stability, permeability to Caco-2 cells
and ACE-inhibitory activity, QSAR modeling was applied to a total of
228 synthetic dipeptides. Quantiﬁcation of dipeptides derived from di-
gestion and transport experimentswas performedwith amultiple reac-
tion ion monitoring (MRM) method on a QqQ combined with previous
HILIC separation. No signiﬁcant correlation models were found for in-
testinal permeability with peptide structure. However, the intestinal
stability of 12 peptides was predicted (Foltz, Van Buren, Klaffke, &
Duchateau, 2009).
3.2.2. Peptidomics in ex vivo and in situ models
The Ussing chamber technique utilizes small intestinal tissue sheets
that are mounted between two (luminal and serosal)buffer containing
reservoirs with supply of gases to mimic physiological conditions. The
test compound is added to either themucosal or the serosal side of the tis-
sue to study transport in the absorptive or secretory direction,
respectively.
By using segments of rabbit distal ileummounted on Ussing chamber,
the transfer of theβ-CNderived opioid peptidemorphiceptin (YPFP-NH2)
was monitored. The observed peptide degradation was followed by RP-
HPLC, and therefore no information about the released fragments was
possible (Mahé, Tomé, Dumontier, & Desjeux, 1989). In contrast, using
rat intestinal segments, the apparent permeability of the antihypertensive
β-CN peptides VPP and IPP has been selectively calculated in the cell
media by the use of a MRM method (Foltz et al., 2008). The authors
showed that the values of Peyer's patches for VPP were more than three
times greater than those of jejunal and duodenal segments, which can
be due to lower peptidase activity and a leakier epithelium.
In situ perfusion of intestinal segments of rodents (rats or rabbits) is
frequently used to study the permeability and absorption kinetics of
drugs. Themain advantage of in situmodels is the integration of the dy-
namic components of themesenteric blood circulation, themucus layer,
and all the other factors present in the intestinal content (Antunes,
Andrade, Ferreira, Nielsen, & Sarmento, 2013).
By using a ligated segment of rat duodenum, Bouhallab et al. (1999)
demonstrated that the CPP from β-CN f(1–25), whether to iron com-
plexed or not, is hydrolyzed by the digestive enzymes including prote-
ases/peptidases and phosphatases during duodenal transit. Each HPLC
peak contained several ions corresponding to endogenous components
of the lumen but QqQ MS permitted to attribute signals to β-CN
f(1–25)-derived peptides. At least ﬁve peptidic bonds of β-CN f(1–25)
were cleaved and successive dephosphorylation of the β-CN f(15–25)
was observed. This pointed out the need to know the relationship be-
tween the positive role of this CPP in iron availability and its susceptibil-
ity to digestive enzymes. Subsequently, Ani-Kibangou et al. (2005)
demonstrated that the inhibition of alkaline phosphatase improved
the absorption of CPP-bound iron.
Comparison of the three absorption models, the Caco-2 cells, Ussing
chamberwith ex vivo different rat intestinal segments, and in situ intes-
tinal perfusion model in rat has been performed for the transport of IPPandVPP, (Foltz et al., 2008). The intestinal permeability of both peptides
augmented with increasing physiological relevance of the model.
Therefore, the previous observation that Caco-2 cell model underesti-
mates intestinal peptide permeability was supported by the 5 to 20-
fold higher permeability across intact excised intestinal tissues and in
the closed perfused loop model.
3.3. Absorption, distribution, metabolism, and excretion (ADME)
Once the stability of peptides to digestion, and the permeability by
cellularmodels have been evaluated, ADME studies need to be conduct-
ed, in order to determine the course of potential biologically active pep-
tides in the organism. The absorption of the dipeptide VY into human
circulatory blood has been reported (Matsui et al., 2002). The plasma
levels increased with dosage and after single oral administration of a
VY-containing drink. The maximum absorption occurred at 2 h post-
prandial and the elimination half-time of VY was estimated at 3.1 h.
The application of MS-based techniques has permitted the develop-
ment of selective and sensitive methods for the quantiﬁcation of
peptides and monitor small changes in plasma. This is the case of an
atmospheric pressure ionization MRM method to quantify 17 ACE-
inhibitory peptides (2, 3, and 5 residues) in human plasma samples col-
lected after ingestion of a peptide-enriched drink. The limit of detection
achieved was reported to be 0.01 ng mL−1, and the quantiﬁcation limit
was estimated between 0.05 and 0.2 ng mL−1 (van Platerink, Janssen,
Horsten, & Haverkamp, 2006). Other authors have also applied a MRM
method to assess the bioavailability of IPP and seven other ACE-
inhibitory peptides contained in a peptide-enriched beverage, and the
inﬂuence of meal intake on the bioavailability of IPP (Foltz et al.,
2007). The maximum peptide concentration in plasma after ingestion
of the peptide-enriched beverage was 897 ± 157 pM.When the bever-
age was consumed after a meal, the maximum concentration of IPP
compared to the placebo treatment was higher than that obtained in
the fasted state. van der Pijl, Kies, Ten Have, Duchateau, and Deutz
(2008) reported the kinetics of Pro-rich tripeptides (IPP, LPP, and
VPP) in pig, administrated intravenously or intragastrically. This study
revealed that, in the ﬁrst case, the elimination half-times were signiﬁ-
cantly different between the three peptides, being higher for IPP than
those obtained for the others. However, no difference in elimination
half-time was found after intragastric administration of peptides. The
maximum concentration detected was 10 nM and the absolute absorp-
tion was estimated to be 0.1% when administrated with saline solution.
However, the absorption and elimination half-times were maximally 5
and 15 min respectively, suggesting an acute effect of the peptides
under these conditions.
4. Peptidomics for bioactive peptide monitoring
4.1. Peptide occurrence in dairy products
Many commercial dairy products have been shown to contain re-
ported bioactive peptides, which are mainly released during fermenta-
tion with starter cultures, ripening, and other manufacturing processes
(e.g., thermal treatment or storage steps) (Hernández-Ledesma et al.,
2011). Furthermore, peptides can be found in the milk as result of the
natural proteolysis of milk proteins. Some peptidomic studies are con-
ducted to monitor speciﬁc peptides of known activity while others are
intended to provide a panel of identiﬁed peptides, among which bioac-
tive sequences can be recognized.
Dallas et al. (2013) recently identiﬁed over 300 peptides in human
milk by nanoLC–ESI-QTOF and veriﬁed that a large group of them
showed sequence overlap with reported antimicrobial and immuno-
modulatory peptides. Also, MALDI-TOF and nanoLC–ESI-linear IT were
used to analyze the peptidome proﬁle of drying-off cow milk and
study the in situ proteolysis (Ho et al., 2010). Among202 identiﬁed pep-
tides, ﬁve of them have been reported to possess bioactivity, i.e., opioid,
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rence of the opioid peptide β-CM-7 was identiﬁed and quantiﬁed
(14 μg L−1) in commercial milk by using an optimized nano-ESI-IT
method (Juan-García, Font, Juan, & Picó, 2009).
Cheese constitutes one of the major sources of bioactive peptides
among commercial dairy products due to the proteolytic activities devel-
oped on milk proteins during cheese ripening by rennet, microbial ﬂora,
and natural milk proteases and peptidases. López-Expósito, Amigo, and
Recio (2012) recently reviewed the healthy role of cheeses since their re-
markable content in bioactive peptides, especially antihypertensive, CPP,
and opioid peptides. For instance, the ACE-inhibitory peptides VPP and
IPPwere found in several commercially available cheeses at physiological
relevant concentrations by using linear IT (Bütikofer, Meyer, Sieber,
Walther, & Wechsler, 2008; Bütikofer, Meyer, Sieber, & Wechsler,
2007). Similarly, Ong and Shah (2008) determined the release of several
ACE-inhibitory peptides in Cheddar cheeses made with different starter
cultures by the use of RP-HPLC in conjunction with MALDI-TOF. More-
over, peptides with ACE-inhibitory and antihypertensive activities were
detected by RP-HPLC–ESI-IT in Manchego cheese (Gómez-Ruiz, Ramos,
& Recio, 2004b). In a Mexican unripened cheese variety but
manufactured with speciﬁc strains of lactic acid bacteria, ACE-inhibitory
peptides were also identiﬁed through the analysis of the water extract
(b3 kDa) by nanoLC–ESI-IT (Torres-Llanez et al., 2011). On the other
hand, largeCPPswere found in semi-hardHerrgård cheese byperforming
RP-HPLC–ESI-IT analysis after IEX separation (Ardö, Lilbæk, Kristiansen,
Zakora, & Otte, Shalaby, Zakora, Pripp, & El-Shabrawy (2007). Regarding
opioid peptides, De Noni and Cattaneo (2010) quantiﬁed β-CM-7 in dif-
ferent cheese varieties by using RP-HPLC–ESI-IT and they detected con-
centrations of 0.15 mg kg−1 in Brie cheese.
Fermented milks, yogurts, and keﬁr are another important group of
commercial dairy products that can include bioactive peptides in their
composition due to themilk-protein proteolysis bymicrobial fermenta-
tion (Muro Urista, Álvarez Fernández, Riera Rodriguez, Arana Cuenca, &
Téllez Jurado, 2011). For instance, Hernández-Ledesma, Miralles,
Amigo, Ramos, and Recio (2005) identiﬁed three reported potent ACE-
inhibitory peptides, VPP, NIPPLTQTPV, and RY, in a commercial
fermented milk after performing RP-HPLC–ESI-IT analysis of certain ac-
tive fractions. Besides, some identiﬁed peptides showed sequenceswith
a high similarity to other described ACE-inhibitory, immunomodulato-
ry, and antioxidant peptides. In another study, Quirós, Hernández-
Ledesma, Ramos, Amigo, and Recio (2005) described the occurrence of
two ACE-inhibitory peptides, PYVRYL and LVYPFTGPIPN, in a commer-
cial keﬁr made from caprine milk following the peptide identiﬁcation
by analogous MS analysis. Interestingly, Jarmołowska and Krawczuk
(2012) detected the opioid peptides β-CM-7, lactoferroxin A, casoxin
6, and casoxin C in two commercially available yogurts and one keﬁr.
In this case, ELISA assays were employed instead of MS analysis. On
the other hand, the application of microLC–ESI-TOF to the peptidome
analysis of a functional antihypertensive yogurt demonstrated, in addi-
tion to ACE-inhibitory and antihypertensive peptides, the occurrence of
other bioactive peptideswith different activities as antioxidant, antibac-
terial, opioid or antithrombotic (Kunda et al., 2012).
4.2. Peptide stability during industrial processing
The effect of processing may inﬂuence the ﬁnal activity of the pep-
tides in real food systems. The ﬁnal extent of amino acid modiﬁcations
and changes in bioactivity will largely depend on the composition of
the food matrix in which the peptide is present, the processing condi-
tions, and the peptide structure (López-Fandiño, Otte, & van Camp,
2006). However, little is known about the effects of processing and stor-
age on bioactive peptides incorporated into foods. Recently, some stud-
ies have reported for speciﬁc bioactive peptides their limited
commercial utilization in fermented foods due to their partial or total
degradation along fermentation process depending on the peptide se-
quence, the strain, and pH. Paul and Somkuti (2009) studied thedegradation of the antimicrobial (RRWQWRMKKLG) and antihyperten-
sive (FFVAPFPEVFGK) peptides, derived from lactoferrin andαs1-CN, re-
spectively, in the presence of the yogurt starter cultures Streptococcus
thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The moni-
toring by RP-HPLC in conjunctionwithMALDI-TOF showed their higher
resistance at pH 4.5 compared to that at pH 7. Likewise, the degradation
of the antimicrobial peptides casocidin and isracidin was followed in
conditions that mimic yogurt fermentation (Somkuti & Paul, 2010).
The results indicate that the peptide addition should take place at the
end of fermentation or by blending into drinkable yogurt-like products.
For a scaled up application of bioactive peptides, the resistance to the
industrial conditions ofmanufacturing, packaging, and storage has to be
assessed. Contreras, Sevilla, et al. (2011) monitored the antihyperten-
sive peptidesαs1-CN f(90–94) and f(143–149), RYLGY and AYFYPEL, re-
spectively, for scaling up the production of an antihypertensive casein
hydrolysate. The identiﬁcation and quantiﬁcation of these two peptides
was performed by RP-HPLC–ESI-IT, and it was found that theywere sta-
ble during the processes of atomization, homogenization, and
pasteurization.
In cheese, the ripening time can have an important effect in the con-
centration of bioactive peptides. The concentration of the antihyperten-
sive peptides IPP and VPP has been monitored during ripening of
different Swiss cheese varieties by using RP-HPLC and linear ITwith triple
MS detection (Meyer, Bütikofer, Walther, Wechsler, & Sieber, 2009). In a
wider study, Sforza et al. (2012) provided a detailed peptidomic study on
the evolution of the oligopeptide fraction in Parmigiano–Reggiano cheese
from curd to 24 months aging, making possible to discriminate cheeses
according to their aging time. Packaging technology and storage time
have been considered in a recent study where the peptide proﬁle was
monitored during the shelf life at 4 °C of cheeses packaged using two dif-
ferent technologies, vacuum packaging and modiﬁed-atmosphere pack-
aging (Sánchez-Rivera, Recio, Ramos, & Gómez-Ruiz, 2013). Semi-
quantitative analysis of peptides (RP-HPLC–ESI-IT) revealed some differ-
ences between different packaging technologies but a common trend in
the evolution of the peptides during storage was observed: differences
weremore pronounced at longer storage times (90 d) and peptide evolu-
tion during storage was similar for both packaging techniques
Protein lactosylation is amodiﬁcation ofmilk proteins by theMaillard
reaction, a non-enzymatic glycation in which the carbonyl group of re-
ducing sugars, such as lactose, primarily reacts with the ε-amino group
of Lys residues leading to the formation of lactulosyl-lysine. Themodiﬁca-
tion leads to a decrease ofmilk nutritional value as it reduces the bioavail-
ability of the essential amino acid Lys. MALDI-TOF has been applied for
investigating protein lactosylation in heat treated milk samples
(Siciliano, Mazzeo, Arena, Renzone, & Scaloni, 2013). Likewise, peptide
lactosylation in milk powder stored for 4 weeks was analyzed by a
MRM method using a hybrid QqQ/Linear IT mass spectrometer (Le,
Deeth, Bhandari, Alewood, & Holland, 2013). The possibility to quantify
peptide lactosylation allows to follow peptide degradation during stor-
age, which is important when determining the shelf life of a functional
food based on bioactive peptides.
5. Future prospects
In theﬁeld of bioactive peptides, peptidomics is a discipline of choice
because peptides are the concerned molecules. Liquid chromatography
and capillary electrophoresiswill continue to progress through themin-
iaturization of the components to provide, besides the suitable MS in-
strumentation, increasingly better analytical tools for unequivocal
peptide determination. Meanwhile, bioinformatic tools still have to be
developed focused on this research area. For peptides absorbed that
can reach blood circulation, their course in the organism has to be
followed to determine their metabolism and kinetic in the organism.
The correlation studies between the observed effects and the concentra-
tions of the peptides in body ﬂuids and even in the target organs will be
progressively considered. Besides, the in vivo formation of derived
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active fragment merit attention. In the cases where peptide bioactivity
is mediated in the gut lumen or through receptors on the intestinal
cell wall, only peptide stability in the intestinal environment would be
necessary. To date, such data have been scarcely reported, and they
refer to ACE-inhibitory peptides, which are the most extensively stud-
ied. In the ﬁeld of food digestion, the analysis of digest peptidomes
will provide data about cleavage traits according to enzyme activities
which will help to understand this physiological path that every food
matrix has to undergo. Of special interest in this context is the correla-
tion between in vivo digestion data and those obtained in in vitro
models. In addition, the identiﬁcation of new biomarkers based on
peptidomics constitutes a novel research line that should be encour-
aged. Due to the possible interaction of peptides with other food com-
ponents or their degradation, a careful monitoring of bioactive peptide
stability during processing or storage is mandatory in view of possible
formation of toxic or allergenic substances and also to maintain the de-
sired dosage, for the optimal exploitation of this valuable resource.
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Abstract: 
The ability of dairy Debaryomyces hansenii, Kluyveromyces lactis and 
Kluyveromyces marxianus strains to release the casein-derived antihypertensive 
sequences RYLGY, AYFYPEL, LHLPLP, HLPLP, VPP and/or IPP was 
examined. Yeast strains were grown in medium with casein as sole nitrogen 
source and the yeast casein hydrolysates (CSHs) were analysed by HPLC-
MS/MS to search for the six antihypertensive sequences. Only LHLPLP and 
HLPLP were identified in CSHs and exclusively in D. hansenii Dh1 and Dh14 
hydrolysates in which both antihypertensive sequences represented 
approximately 6 (CSH Dh1) and 10% (CSH Dh14) of total peptide content. In 
addition, a complete analysis of selected CSHs by HPLC-MS/MS allowed the 
identification of 35 (Dh1) and 46 (Dh14) additional peptides, which could also 
contribute to the observed in vitro ACE inhibitory potency of both hydrolysates 
(Dh1, IC50 = 13.6 ± 1.8 µg/mL; Dh14, IC50 = 17.5 ± 2.1 µg/mL) and might confer 
them multifunctional properties. Finally casein zymography revealed the 
presence of at least one extracellular protease with a molecular mass of about 50 
kDa. In conclusion, the present study contributes to a better insight into bioactive 
compounds produced by dairy yeasts and shows the feasibility of D. hansenii 
strains to produce antihypertensive casein-derived peptides. 
 
Keywords: Dairy yeasts, Debaryomyces hansenii, Kluyveromyces lactis, 
Kluyveromyces marxianus, casein-derived antihypertensive peptides. 
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Abbreviations 
 
ACE: angiotensin I-converting enzyme; CSH: casein hydrolysate; GRAS: 
generally recognized as safe; LAB: lactic acid bacteria; RP-HPLC-MS/MS: 
reversed phase-high performance liquid chromatography tandem mass 
spectrometry; RP-HPLC-UV-MS: reversed-phase high performance liquid 
chromatography-UV and mass spectrometry; SHR: spontaneously hypertensive 
rat. 
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1. Introduction 
 
Casein is an excellent substrate to produce peptides with angiotensin I 
converting enzyme (ACE)-inhibitory and antihypertensive effects (Otte, Shalaby, 
Zakora, Pripp, & El-Shabrawy 2007; Martínez-Maqueda, Miralles, Recio, & 
Hernández-Ledesma, 2012). Basically, processing of milk proteins with food 
grade proteolytic preparations or fermentation of milk with lactic acid bacteria 
(LAB) proteolytic starters have been employed to release antihypertensive 
peptides. Both approaches have conducted to the development of commercial 
products based on milk proteins with antihypertensive effects in humans. In fact, 
one of the most popular functional foods contain the casein-derived ACE61 
inhibitory tripeptides VPP and IPP, which can be obtained by means of either 
milk fermentation (Nakamura, Yamamoto, Sakai & Takano, 1995) or enzymatic 
hydrolysis using microbial proteases (Mizuno, Nishimura, Matsuura, Gotou & 
Yamamoto, 2004). We have previously identified casein-derived sequences with 
antihypertensive activity using both methods. Two novel peptides of sequences 
RYLGY and AYFYPEL were identified from a peptic casein hydrolysate 
(Contreras, Carrón, Montero, Ramos, & Recio, 2009.). Both exerted in vitro 
inhibitory effects on ACE activity (IC50 values of 0.71 and 6.58 µM, respectively) 
and effectively decreased systolic blood pressure after oral administration to 
spontaneously hypertensive rats (SHRs) at 5 mg/kg of body weight. With respect 
to the fermentation strategy, the antihypertensive sequence LHLPLP was 
identified as one of the major peptides responsible for the ACE-inhibitory and 
antihypertensive effects of fermented milk produced by Enterococcus faecalis 
(Muguerza et al., 2006; Quirós et al., 2007). This sequence showed an IC50 value 
of 5.5 ± 0.4 µM against ACE activity and exhibited potent antihypertensive effect 
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at a dose of 2 mg/kg (Quirós et al., 2007). Further characterization suggested the 
pentapeptide HLPLP as the minimum active form responsible for the 
antihypertensive effect of LHLPLP (Quirós, Dávalos, Lasunción, Ramos, & Recio, 
2008.). Since the pathogenic potential of some Enterococcus strains (Franz, 
Holzapfel, & Stiles, 1999) may hamper their use in the food industry, production 
of HLPLP by enzymatic hydrolysis with food-grade enzymes was also optimized 
(Quirós, Hernández-Ledesma, Ramos, Martín Álvarez, & Recio, 2012). 
 
Recently, we have shown the ability of some proteolytic dairy yeast strains 
belonging to Debaryomyces hansenii, Kluyveromyces lactis and Kluyveromyces 
marxianus species to generate casein-derived antihypertensive hydrolysates 
(García-Tejedor, Padilla, Salom, Belloch, & Manzanares, 2013). With the aim of 
further characterize these non-conventional dairy yeasts as feasible GRAS 
(Generally Recognized As Safe) microorganisms for the production of 
antihypertensive peptides, here we screen up to thirty-three of these strains on 
the basis of their ability to release previously identified casein derived 
antihypertensive sequences (RYLGY, AYFYPEL, LHLPLP, HLPLP, VPP and 
IPP) obtained either by enzymatic hydrolysis or bacterial fermentation. In 
addition, the presence of extracellular caseinolytic activity in selected strains is 
evaluated. Finally, quantification of the aforementioned sequences and 
identification of new main casein-derived peptides in the selected yeast casein 
hydrolysates are carried out, and their potential bioactivities in terms of ACE 
inhibition and other functional effects are discussed. 
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2. Materials and Methods 
2.1. Materials 
Casein (Promilk 85) was obtained from Ingredia (Arrax Cedex, France). 
ACE from porcine kidney, bicinchoninic acid protein assay kit, Hammarsten 
casein and Triton X-100 were purchased from Sigma (St. Louis, MO, USA). 
Glucose was obtained from Panreac (Barcelona, Spain), bacteriological peptone 
was purchased from Cultimed (Barcelona, Spain) and yeast extract and agar 
were acquired from Pronadisa (Madrid, Spain). The fluorogenicsubstrate o-
aminobenzoyl-Gly-p-nitro-Phe-Pro was provided by Bachem Feinchemikalien 
(Bubendorf, Switzerland). Coomassie Brilliant Blue G-250, 30% acrylamide/bis 
solution 29:1 and Precision Plus Protein Dual Color standards were obtained 
from Bio-Rad Laboratories (Hercules, CA, USA). 
 
2.2. Yeast strains and growth conditions 
Thirty-three yeast strains belonging to D. hansenii (Dh1-Dh23), K. lactis  
(Kl1-Kl8) and K. marxianus (Km1-Km2) species isolated from artisanal ewes’ and 
goats’ milk cheeses (Padilla, Manzanares & Belloch, 2014) were used in this 
study. Yeast strains were maintained on GPYA medium (2% glucose, 0.5% 
peptone, 0.5% yeast extract and 2% agar, pH 5.5). 
 
2.3. Preparation of casein hydrolysates 
Stock solution of casein was sterilized by autoclaving at 121°C, 15 min. 
Casein medium (2% casein, 2% glucose) was inoculated with 106 cells/ml from 
pre-cultured strains on GPY (GPYA without agar) and incubated at 28°C and 100 
rpm in an orbital shaker for 6 days. At the end of the incubation period yeast cells 
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were sedimented by centrifugation (3220 x g, 10 min), and the supernatants 
ultrafiltered using Amicon Ultra 10K centrifugal filter devices (Millipore 
Corporation, Billerica, MA, USA). Supernatant ultrafiltrates enriched in peptides 
of molecular weight lower than 10 kDa were considered as casein hydrolysates 
(CSHs). Supernatant concentrates (> 10 kDa) were used for zymography 
experiments as specified further. 
Protein concentration was estimated by the bicinchoninic acid method using 
bovine serum albumin as standard (Ruiz-Giménez et al., 2012). 
 
2.4. In vitro assay of ACE-inhibitory activity 
In vitro ACE-inhibitory activity of CSHs was measured using the fluorescent 
method described by Sentandreu & Toldrá (2006) based on the hydrolysis of the 
internally quenched fluorescent substrate o-aminobenzoyl-Gly p-nitro-Phe-Pro by 
the action of ACE. The IC50 value of CSHs was defined as the protein 
concentration required to inhibit 50% of the ACE activity, and the value for each 
experiment was estimated by non-linear regression of the experimental data to a 
four parameter logistic curve using the software package SigmaPlot v 10.0 
(SPSS Inc., Chicago, IL, USA). 
 
2.5. Casein zymography 
Zymography was performed according to Folio, Ritt, Alexandre, & Remize 
(2008) with minor modifications. Briefly, samples (casein supernatant 
concentrates) in loading buffer without β-mercaptoethanol were loaded onto a 
10% (w/v) SDS/PAGE gel (Laemmli, 1970) co-polymerized with 0.12% (w/v) 
Hammarsten casein. After electrophoresis and brief washing in ultrapure water,  
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the gel was washed for 2 h on a rotary shaker with 2.5% (v/v) Triton X-152 100. 
Afterwards the gel was washed twice with reaction buffer (50 mM citrate 
phosphate buffer, pH 6) and then incubated overnight in reaction buffer at room 
temperature. The gel was stained with 0.1% (w/v) Coomassie Brilliant Blue G- 
250 for 1 h and then de-stained. Protease activity bands were visualized as white 
bands on a dark blue background. 
 
2.6. Synthesis and quantification of peptides HLPLP and LHLPLP 
The peptides HLPLP f(134-138) and LHLPLP f(133-138) from β-casein, 
were synthesized in-house using the fluorenyl-methoxy-carbonyl chloride (Fmoc) 
solid-phase method with a 431A peptide synthesizer (Applied Biosystems Inc. 
Überlingen, Germany). Peptide purity was calculated by reversed phase high 
performance liquid chromatography-UV and mass spectrometry (RP-HPLC-UV-
MS). Six-point calibration curves of the pure peptides HLPLP and LHLPLP (from 
1.95 to 62.5 µg/mL) were prepared in Milli-Q deionized water. Duplicate 
injections were done for each point on the calibration curve. The quantification of 
the peptides in each CSH was performed by the extraction of their characteristic 
ions. 
 
2.7. Peptide sequencing by reversed phase-high-performance liquid 
chromatography tandem mass spectrometry (RP-HPLC-MS/MS). 
The analyses of CSHs by RP-HPLC-MS/MS were performed on an Agilent 
HPLC (Agilent Technologies, Waldbronn, Germany) system followed by on-line 
MS/MS analysis on a quadrupole ion trap instrument (Esquire 3000, Bruker 
Daltonik GmbH, Bremen, Germany) as previously described (Sánchez-Rivera, 
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Diezhandino, Gómez-Ruiz, Fresno, Miralles, & Recio, 2014). Chromatographic 
separations were performed with a Mediterranea Sea18 150 mm × 2.1 mm 
column (Teknokroma, Barcelona, Spain). The flow rate was 0.2 mL/min and the 
injection volume 50 µL. Peptides were eluted with a linear gradient from 0% to 
45% of solvent B (acetonitrile:formic acid 0.1%) and 55% solvent A (water:formic 
acid 0.1%) in 120 min. The target mass was set at mass-to-charge ratio (m/z) 
750, and the mass acquisition ranged from 200 to 2000 m/z. 
 
2.8. Statistical data analysis 
IC50 values of CSHs were compared using Student’s t-test. Differences with 
P-values < 0.05 were considered significant. Data statistical analysis was 
performed using the GraphPad Prism 4 software (GraphPad Software Inc, La  
Jolla, CA, USA). 
 
3. Results and discussion 
In the present study, 33 CSHs generated by D. hansenii (CSH Dh1- Dh23) 
K. lactis (CSH Kl1-Kl8) and K. marxianus (CSH Km1-Km2) strains isolated from 
artisanal cheeses (Padilla et al., 2014) were analysed by HPLC MS/MS to search 
for the previously identified antihypertensive sequences RYLGY, AYFYPEL, 
LHLPLP, HLPLP, VPP and/or IPP. Peptides RYLGY, AYFYPEL, VPP and IPP 
were not identified in any of the CSHs. However, peptide HLPLP and its 
precursor sequence LHLPLP were released from casein after growth of D. 
hansenii strains Dh1 and Dh14. Figure 1 shows the UV chromatogram and the 
extracted ions corresponding to both peptides.  
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Figure 1. UV chromatogram of the casein hydrolysate Dh1 (A) and Dh14 (B). Extracted 
Ion chromatogram (EIC) of the peptides LHLPLP and HLPLP in Dh1 (C) and Dh14 (D). 
Fragmentation pattern of LHLPLP (E) and of HLPLP (F), with mass-to-charge ratios 
(m/z) of 689.5 and 576.3, respectively. 
 
 
Quantification of HLPLP and LHLPLP in CSH Dh1 and Dh14 was carried 
out using linear regressions obtained by HPLC-MS/MS. As shown in Table 1, 
highest total content was obtained in CSH Dh14. However both hydrolysates 
contained similar quantities of the pentapeptide. These antihypertensive peptides 
represented approximately 6 and 10% of total peptide content in Dh1 and Dh14 
hydrolysates, respectively. No significant differences were found between the 
ACE inhibitory potencies of both D. hansenii CSHs, which showed IC50 values of 
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13.6 ± 1.8 µg/mL (Dh1) and 17.5 ± 2.1 µg/mL (Dh14). ACE inhibition was slightly 
higher than the previously reported values of milk fermented by E. faecalis (34-59 
µg/mL; Muguerza et al., 2006) but lower than that showed by a pepsin casein 
hydrolysate (5.68 µg/mL; Contreras et al., 2009). 
 
Table 1. Content of peptides LHLPLP and HLPLP in casein hydrolysate (CSH) 
Dh1 and Dh14. 
 
CSH 
 
 
LHLPLP 
(µg/mg) 
 
 
HLPLP 
(µg/mg) 
 
Total 
(µg/mg) 
 
Dh1 
 
 
15.6 
 
43.5 
 
59.1 
Dh14 
 
52.7 46.4 99.1 
 
 
During milk fermentation, proteolysis by LAB has been studied in detail. The 
key enzyme in this process is a cell-envelope proteinase involved in the first step 
of casein degradation (Savijoki, Ingmer, & Varmanen, 2006). By contrast, 
although yeast caseinolytic activity is well documented few reports deal with the 
characterization of the extracellular proteolytic system. With regards to D. 
hansenii, Kumura, Takagaki, Sone, Tsukahara, Tanaka, & Shimazaki (2002) 
reported that a cell-wall associated protease acted on β-casein whereas αS-
casein degradation was attributed to an intracellular protease released by cell 
lysis. However, extracellular proteolytic activity on both αS- and β-casein for D. 
hansenii strains isolated from cheese has been described (Gardini et al., 2006). 
Here we conducted a casein zymography to detect extracellular proteases in the 
supernatants of the two selected D. hansenii strains. On casein substrate, 
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extracellular proteolytic activities were detected (Figure 2). Analysis of Dh14 
supernatant revealed the presence of one hydrolysis band which corresponded 
to a molecular mass of about 50 kDa. The same band was observed in Dh1 
supernatant, in which a second band of slightly higher molecular mass was also 
detected. Band intensities for both supenatants were not related to the amount of 
total protein loaded (Dh1, 4.8 µg; Dh14, 4.4 µg). Although increasing amounts of 
Dh14 total protein were loaded onto SDS/PAGE gels for protease detection no 
other clear activity bands were observed (data not shown). These results might 
suggest a different proteolytic profile for both strains in the conditions tested. 
Future work should include purification of the extracellular D. hansenii enzymes 
and determination of its biochemical properties. 
 
Figure 2. Casein zymography of D. hansenii Dh1 and Dh14 extracellular proteolytic 
activities. Lane M, molecular weight markers (Precision Plus Protein Dual Color 
standards, Bio-Rad); lane 1, Dh1 culture supernatant concentrate (4.8 µg); lane 2, Dh14 
culture supernatant concentrate (4.4 µg). 
 
Over the last two decades, a large number of casein-derived peptides 
obtained by fermentation and enzymatic hydrolysis with ACE-inhibitory potency 
and proven antihypertensive effects in SHRs have been identified (Martínez-
Maqueda et al., 2012). Although LHLPLP and HLPLP might contribute to the 
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inhibitory potency of D. hansenii CSHs, other sequences generated from casein 
hydrolysis might also be responsible for the observed inhibitory effects. This 
prompted us to carry out a complete analysis of CSH Dh1 and Dh14 by HPLC 
MS/MS, which allowed the identification of 35 and 46 additional peptides (Table 2 
and 3), respectively.  
 
Table 2. Identification of peptides contained in D.hansenii casein hydrolysate (CSH) 
Dh1. 
 
Ion for 
MS/MS (m/z)a 
Observed 
massb 
Theoretical 
mass 
Protein fragment Identified 
sequencec 
806,388 805,372 805,401 αS1-CN f(24-30) FVAPFPE  
530,179 529,172 529,29 αS1-CN f(25-29) VAPFP  
659,312 658,304 658,333 αS1-CN f(25-30) VAPFPE  
608,373 607,366  607,333 αS1-CN f(32-36) FGKEK  
618,394 617,387 617,302 αS1-CN f(35-39) EKVNE  
632,362 631,354 631,318 αS1-CN f(81-85) IQKED  
502,15 501,143 501,28 αS1-CN f(95-98) LEQL  
468,196 467,189 467,249 αS1-CN f(127-130) IHAQ  
602,321 601,313 601,307 αS1-CN f(138-142) VNQEL  
680,309 679,302 679,297 αS1-CN f(159-164) YPSGAW  
517,184 516,177 516,233 αS1-CN f(160-164) PSGAW  
777,435 776,428 776,407 αS1-CN f(167-173) VPLGTQY  
581,257 580,25 580,286 αS1-CN f(169-173) LGTQY  
555,344 554,337 554,27 αS1-CN f(181-185) DIPNP  
519,164 518,156 518,234 αS1-CN f(186-190) IGSEN  
602,321 601,313 601,253 αS2-CN f(4-8) MEHVS  
1000,532 999,525 999,539 αS2-CN f(100-108) YQGPIVLNP  
837,459 836,452 836,476 αS2-CN f(101-108) QGPIVLNP  
698,394 697,386 697,401 αS2-CN f(116-122) AVPITPT  
528,248 527,24 527,296 αS2-CN f(118-122) PITPT  
720,417 719,409 719,422 αS2-CN f(198-203) TKVIPY  
628,27 627,263 627,323 β-CN f(6-11) LNVPGE  
748,265 747,258 747,304 β-CN f(38-43) QQQTED  
622,309 621,302 621,316 β-CN f(59-63) VYPFP  
439,026 438,018 438,284 β-CN f(74-77) IPPL  
668,38 667,373 667,39 β-CN f(74-79) IPPLTQ  
732,347 731,34 731,385 β-CN f(113-118) KYPVEP  
690,282 689,275 689,323 β-CN f(127-132) LTDVEN  
577,164 576,157 576,239 β-CN f(128-132) TDVEN  
689,449 688,442 688,427 β-CN f(133-138) LHLPLP  
576,304 575,297 575,343 β-CN f(134-138) HLPLP 
649,265 648,258 648,28 β-CN f(144-148) MHQPH  
805,351 804,343 804,384 β-CN f(155-161) VMFPPQS  
780,457 779,45 779,491 β-CN f(170-176) VLPVPQK  
536,148 535,14 535,228 β-CN f(193-196) YQEP  
633,35 632,343 632,353 k-CN f(26-30) IPIQY  
663,318 662,311 662,339 k-CN f(43-47) YQQKP  
aCharge of precursor ion: 1; bCalculated monoisotopic mass; cMain peptides peptides are 
labeled in bold. Casein (CN) 
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Table 3. Identification of peptides contained in D.hansenii casein hydrolysate (CSH) 
Dh14. 
 
Ion for MS/MS 
(m/z)a 
 
Observed 
massb 
 
Theoretical 
mass 
 
Protein fragment 
 
Identified 
sequencec 
805.399 805,378 805,401 αS1-CN f(24-30) FVAPFPE  
676,407 675,400 675,359 αS1-CN f(29-34) PEVFGK  
707,446 706,439 706,401 αS1-CN f(31-36) VFGKEK  
763.321 762,322 762,358 αS1-CN f(54-59) MEDIKQ  
732.394 631,328 631,318 αS1-CN f(55-59) EDIKQ  
903,472 902,465 902,453 αS1-CN f(135-142) MIGVNQEL  
517,171 516,164 516,233 αS1-CN f(160-164) PSGAW  
789,371 788,634 788,370 αS1-CN f(179-185) FSDIPNP  
730.385 729,314 729,329 αS1-CN f(184-190) NPIGSEN  
675.257 674,322 674,324 β-CN f(1-5) RELEE  
649,284 627,306 627,323 β-CN f(6-11) LNVPGE  
633,295 632,288 632,277 β-CN f(38-42) QQQTE  
748,284 747,277 747,304 β-CN f(38-43) QQQTED  
875.371 876,305 876,346 β-CN f(38-44) QQQTEDE  
632.355 631,335 631,318 β-CN f(44-48) ELQDK  
681,303 680,296 680,313 β-CN f(52-57) FAQTQS  
622,309 621,302 621,316 β-CN f(59-63) VYPFP  
668,416 667,409 667,390 β-CN f(74-79) IPPLTQ  
769.342 768,386 768,438 β-CN f(74-80) IPPLTQT  
866,472 865,465 865,491 β-CN f(74-81) IPPLTQTP  
753,385 752,378 752,407 β-CN f(75-81) PPLTQTP  
689.313 688,395 688,412 β-CN f(95-100) VSKVKE  
760,456 759,449 759,449 β-CN f(95-101) VSKVKEA  
577,327 576,267 576,294 β-CN f(98-102) VKEAM  
651,384 650,376 650,343 β-CN f(111-115) FPKYP  
732.274 731,364 731,385 β-CN f(113-118) KYPVEP  
611.329 610,267 610,260 β-CN f(119-123) FTESQ  
698,269 697,262 697,292 β-CN f(119-124) FTESQS  
904,446 903,439 903,455 β-CN f(125-132) LTLTDVEN  
689.313 688,392 688,427 β-CN f(133-138) LHLPLP  
802,505 801,498 801,511 β-CN f(133-139) LHLPLPL  
1130,667 1129,660 1129,686 β-CN f(133-142) LHLPLPLLQS  
576,334 575,327 575,343 β-CN f(134-138) HLPLP  
793,521 792,514 792,511 β-CN f(135-141) LPLPLLQ  
880,515 879,508 879,543 β-CN f(135-142) LPLPLLQS  
670,420 669,413 669,406 β-CN f(137-142) LPLLQS  
533,184 532,177 532,265 β-CN f(140-143) LQSW  
649.329 648,277 648,280 β-CN f(144-148) MHQPH  
805.402 804,348 804,384 β-CN f(155-161) VMFPPQS  
649,327 648,320 648,344 β-CN f(164-169) SLSQSK  
543,270 542,262 542,343 β-CN f(168-172) SKVLP  
559,253 558,246 558,284 β-CN f(185-189) MPIQA  
762,385 761,378 761,396 β-CN f(191-196) LLYQEP  
649,318 648,310 648,312 β-CN f(192-196) LYQEP  
826,445 825,438 825,450 β-CN f(199-206) GPVRGPFP  
939,500 938,493 938,534 β-CN f(199-207) GPVRGPFPI  
658,370 657,363 657,370 k-CN f(119-124) IPTINT  
757,362 756,355 756,365 k-CN f(155-161) SPPEINT  
aCharge of precursor ion: 1; bCalculated monoisotopic mass; cMain peptides peptides are labeled 
in bold. Casein(CN)  
Results 
 
95 
 
The most abundant peptides in each hydrolysate are given in bold. As can 
be seen in Table 2, most of the peptides present in CSH Dh1, derived from 
hydrolysis of αS1-CN (15 fragments) and β-CN (14 fragments) whereas only 6 
and 2 peptides corresponded to αS2-CN and к-CN fragments, respectively. By 
contrast, in CSH Dh14 most of the peptides (37 fragments) derived from β-CN. In 
addition 9 fragments from αS1-CN and 2 from к-CN were also identified, while 
none of the fragments derived from αS2-CN. Finally, only 11 of the peptides 
identified, including the two antihypertensive sequences LHLPLP and HLPLP, 
were common for both D. hansenii strains, which indicates strain-specific 
proteolysis in accordance with the results obtained in the zymogram and also as 
described for the Streptococcus thermophilus cell envelope proteinase (Miclo et 
al., 2012). 
Sequences LHLPLP and HLPLP were also included in several longer 
fragments identified in CSH Dh14, such as LHLPLPL, HLPLPL and 
LHLPLPLLQS. The heptapeptide LHLPLPL, with an IC50 value of 425 ± 44 µM 
against ACE, was also identified in E. faecalis fermented milk (Quirós et al., 
2007). Another peptide (β-CN f(58-76), LVYPFPGPIPNSLPQNIPP; IC50 = 5.2 ± 
0.3 µM) identified in E. faecalis fermented milk caused also significant decrease 
of the systolic blood pressure in SHRs (Quirós et al., 2007). Part of thi sequence 
(VYPFP) was also identified in both D. hansenii CSHs. On the other hand, 
although neither VPP nor IPP were found in D. hansenii CSHs, sequences 
containing the latter at the N-terminal end were identified (IPPL, IPPLTQ, 
IPPLTQT and IPPLTQTP). Whether these newly identified sequences could also 
contribute to the ACE-inhibitory activity of CSH Dh1 and Dh14 deserves further 
characterization studies. Moreover, the role of gastrointestinal digestion to 
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generate active fragments from longer sequences should also be taken into 
account, although degradation of active fragments can also occur. More than 
60% of the identified sequences have at least one Pro residue. Particularly, Pro 
in the C-terminal and antepenultimate position has been recognised as one of the 
most favourable residues for peptide binding to the active site of ACE (Rohrbach, 
Willians, & Rolstad, 1981). Interestingly, in addition to the antihypertensive 
sequences LHLPLP and HLPLP, peptides VAPFP, DIPNP, VYPFP, FSDIPNP 
and GPVRPFP with a Pro residue in bothpositions might be promising 
candidates to inhibit ACE activity. Finally, some other sequences identified in 
CSH Dh1 and Dh14 were previously characterised as ACE-inhibitory and 
antioxidant peptides (sequence YQEP in Dh1; Silva, Pihlanto, & Malcata, 2006) 
or having lipoxygenase inhibitory properties (VLPVPQK in Dh1; Rival, Fornaroli, 
Boeriu, & Wichers, 2001). Also some sequences identified here share structure 
homology with fragments able to inhibit prolyl-peptidases of human colon cells 
(FVAPFPE, VAPPFP and VAPFPE in Dh1; Juillerat-Jeanneret, Robert, & 
Juillerat, 2011) or having immune-modulating and ACE-inhibitory properties 
(GPVRGPFPI and GPVRGPFP in Dh14; Hayes, Stanton, FitzGerald, & Ross, 
2007; Hernández-Ledesma, Amigo, Ramos, & Recio, 2004). The multifunctional 
properties and the resulting health benefits of dairy protein hydrolysates have 
been pointed out by several studies (reviewed in Hernández-Ledesma, García-
Nebot, Fernández-Tomé, Amigo, & Recio, 2014). To what extent D. hansenii 
CSHs might exert different functional effects requires further research. 
Our results point to D. hansenii strains Dh1 and Dh14 as feasible GRAS 
microorganisms with strain-specific caseinolytic systems for the production of  the 
antihypertensive sequences HLPLPL and HLPLP. These two peptides could at 
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least in part be responsible for the ACE-inhibitory properties of both D. hansenii 
CSHs, although data reported here suggest that other potential bioactive 
sequences are also produced. D. hansenii, one of the predominant yeast species 
in all type of cheeses, plays important roles in cheese making and further 
investigation is needed to exploit its biotechnological potential. 
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 ABSTRACT 
 Peptides released during the shelf life of cheeses pack-
aged using 2 different technologies, vacuum packaging 
(VP) and modified-atmosphere packaging (MAP), were 
identified by on-line reverse phase-HPLC-tandem mass 
spectrometry. A total of 22 peptides from the N-termi-
nal domain of αS1-casein (CN) and 26 from β-CN were 
identified, the latter more evenly distributed over the 
whole sequence. Peptides were monitored during the 
shelf life of these cheeses when stored at 4°C, revealing 
that the peptide profile changed significantly with the 
storage time. Qualitative differences between VP and 
MAP cheeses were only found for 3 αS1-CN peptides, 
which were absent in MAP cheeses. Semiquantitative 
analysis of peptides revealed some differences between 
cheeses packaged using different technologies. However, 
evolution of peptides during storage followed a com-
mon trend in both types of cheeses. In addition, the 
presence of certain peptides, which had been previously 
described because of their potential bioactivity, is illus-
trated. For instance, some of the identified peptides had 
been previously reported as antihypertensive peptides, 
such as peptide αS1-CN (1–9) or β-CN f(201–209). 
 Key words:   cheese ,  vacuum packaging ,  modified-
atmosphere packaging ,  cheese bioactive peptide 
 Short Communication 
 Proteolysis is a phenomena occurring during cheese 
ripening comprised of numerous biochemical reactions 
that contribute to the flavor and texture of the final 
product. In the primary proteolysis, indigenous milk 
enzymes and those present in the coagulant play an 
important role. During secondary proteolysis, a great 
variety of peptides are released from the milk CN frac-
tion by proteolytic enzymes which mainly belong to 
microorganisms that participate in cheese manufactur-
ing (primary and secondary starters, as well as adventi-
tious microflora; Fox, 1989). 
 In recent decades, food packaging has undergone 
major technological development, partly in response 
to consumer demand for preservative-free food and in 
control-packaging methods to preserve quality and food 
safety. Changes in consumer preferences have affected 
buying habits and a growing interest in sliced and 
ready-to-eat products has been observed. These types 
of goods have a high value of convenience, but are also 
susceptible to physical and chemical changes. Vacuum 
packaging (VP) of cheese retards molds growth; how-
ever, the product may undergo changes in color, flavor, 
and texture (Romani et al., 2002) or show excessive 
surface humidity due to the migration of water from 
the inside to the surface (Pantaleão et al., 2007). There-
fore, VP is not suitable for all kinds of cheeses, as it 
may lead to some structural and visual changes in the 
product. Consequently, alternative methods of packag-
ing have been proposed, such as modified-atmosphere 
packaging (MAP). This technique appears suitable for 
cheese packaging, taking into account physicochemical 
and microbiological criteria (Dermiki et al., 2008), es-
pecially when using a gas mixture combination of 30% 
CO2 to 70% N2, which is able to extend the shelf life in 
terms of microbiological stability, keeping the sensory 
characteristics of Provolone cheese (Favati et al., 2007) 
or Greek whey cheese (Papaioannou et al., 2007) intact. 
 When cheese is packed to extend its shelf life, the 
effect of packaging on the ripening process should be 
evaluated. Some studies focused on the evaluation of 
proteolysis of VP cheese during ripening have been car-
ried out using total nitrogen and ripening index (Tara-
kci and Kucukoner, 2006). The application of reverse 
phase-HPLC analysis (Sousa et al., 2001; Poveda et al., 
2003) or HPLC-tandem mass spectrometry (HPLC-
MS/MS; Piraino et al., 2007) has been proposed as a 
reliable tool to evaluate proteolysis in cheese. However, 
to our knowledge no comparative studies have been 
carried out on peptide profile changes occurring along 
the shelf life of cheese subjected to different packaging 
techniques. 
 In this study, HPLC-MS/MS detection has been 
used to identify the peptides released and evaluate the 
peptidic profile changes during the shelf life of cheeses 
packaged using 2 different technologies. Based on previ-
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ous studies, the presence, origin, and potential bioac-
tivities of these peptidic sequences are also discussed.
Semihard cheeses samples, provided by a national 
dairy manufacturer, were made out of mixed pas-
teurized sheep, cow, and goat milk with 2 different 
packaging systems (VP for cheese wedges and MAP 
for sliced cheeses). Prior to cheese packaging, the curd 
was processed using different molds, depending on the 
final format, and subsequently ripened for 20 d under 
controlled temperature and humidity conditions
Cheese samples were received immediately after 
manufacturing and stored at 4°C for the duration of 
the study: 0, 30, 60, and 90 d for the MAP samples, 
and 0, 30, 60, 90, and 150 d for the VP samples. In both 
cases the maximum number of storage days refers to 
the shelf-life of the respective cheese type.
Water-soluble extracts were obtained at each selected 
time according to the method described by Gómez-Ruiz 
et al. (2002). Supernatants were ultrafiltered on a 3,000 
Da cut-off ultrafiltration membrane (Pall Corporation, 
Ann Arbor, MI). The 3,000 Da permeates were freeze-
dried and kept at −20°C until their analysis.
Reverse phase-HPLC-MS/MS analyses of the perme-
ates <3,000 Da were carried out on an Agilent HPLC 
system (Agilent Technologies, Waldbronn, Germany) 
connected on line to an Esquire-LC quadrupole ion 
trap instrument (Bruker Daltonik GmbH, Bremen, 
Germany). A Mediterranea Sea18 15 × 0.21 cm column 
was used in the experiments (Teknokroma, Barcelona, 
Spain). Auto MS(n) analyses used a signal threshold 
of 10,000, a voltage ramp from 0.35 to 1.4 V for the 
fragmentation of precursor ions, and an isolation width 
of 4.0 m/z. The estimated amount of peptides (in arbi-
trary units) in each sample was calculated by extract-
ing their corresponding characteristic ions (molecular 
ion or doubly charged ion, when present); duplicate 
samples were prepared for each time and package con-
dition, and were individually analyzed.
The peptide profile of the different cheeses was stud-
ied by evaluating both the UV spectra and the mass 
spectra after analysis by liquid chromatography. Es-
sentially no differences in the UV spectra were found 
between the 2 types of packaging along the storage 
times (results not shown). A more detailed MS analy-
sis revealed some differences in the peptide profile of 
cheeses packaged with both systems. A total of 48 pep-
tides were identified, 22 sequences belonging to αS1-CN 
and 26 sequences to β-CN. No peptides were detected 
from αs2-CN or κ-CN. This can be linked to their lower 
content compared with αS1- or β-CN. In addition, the 
fragment incorporated to the curd derived from κ-CN, 
para-κ-CN, has been described to be rather resistant to 
proteolysis. As cheeses were manufactured with differ-
ent types of milk some of the sequences could belong to 
different species (cow, goat, or sheep). Figure 1 shows 
the αS1-CN-derived peptides identified in VP and MAP 
cheeses, their presence during the storage time, and 
their intensity obtained from the HPLC-MS analysis 
at 0 d of MAP cheese. Most of the identified peptides 
from αS1-CN were released from the N-terminal seg-
ment. The peptides that showed the highest intensities 
at 0 d corresponded to αS1-CN f(1–16), f(17–23), and 
f(24–32), although many other peptides that also belong 
to these 3 regions were identified. In cheese, chymosin 
rapidly cleaves at Phe23-Phe24 in cow milk and Phe23-
Val24 in sheep and goat milk, giving 2 major fragments 
as a result: αS1-CN f(1–23) and f(24–199) (McSweeney 
and Fox, 1993). Further hydrolysis by cell envelope-
associated proteinases and endopeptidases of starter 
and nonstarter bacteria release several peptides from 
the fragment αS1-CN f(1–23). As shown in Figure 1, the 
same sequences were identified regardless the packag-
ing method used; the only exceptions were the αS1-CN 
peptides RPKHPIK, LPQEVLN, and PFPEVF, which 
were absent in MAP cheeses. Additional differences be-
tween the 2 packaging methods were also notable at the 
quantitative level. For example, the evolution of some 
of the most abundant αS1-CN peptides during the stor-
age time in VP and MAP cheeses is shown in Figure 2. 
In some cases, higher peptide intensities during storage 
time were detected in VP cheeses compared with MAP 
cheeses, especially at longer storage times (90 d). This 
is the case of the peptides αS1-CN f(24–32) and αS1-CN 
f(25–32; Figure 2). However, some peptides reached 
higher concentration in MAP cheeses compared with 
VP cheeses, as can be observed for the peptide αS1-CN 
f(1–16). Concerning their evolution during the storage 
time, some peptides [αS1-CN f(17–23), αS1-CN f(24–32), 
and αS1-CN f(25–32)] behaved similarly regardless the 
packaging technology, whereas others followed different 
patterns [αS1-CN f(1–9) and αS1-CN f(17–22)].
In contrast to αS1-CN, peptides from β-CN were more 
evenly identified over the whole sequence. For β-CN 
peptides, no qualitative differences were found between 
VP and MAP cheeses (Figure 3). Those peptides that 
reached the highest concentrations in the water-soluble 
extract corresponded to β-CN f(1–6), f(44–52), f(45–52), 
and f(47–52; Figure 4). It is notable that, in general, 
for β-CN peptides differences were more pronounced at 
longer storage times (90 d) and peptide evolution during 
storage was similar for both packaging techniques. At 90 
d, peptides β-CN f(7–14) and f(44–52) reached higher 
levels in VP cheeses than MAP cheeses, but the opposite 
was found for β-CN f(46–52), f(47–52), and f(74–82).
Some of the peptides identified in the water-soluble 
extracts of these cheeses have been previously de-
scribed because of their potential to exert biological 
activities. For instance, αS1-CN f(1–9) with sequence 
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Figure 1. Peptides derived from αS1-CN identified in the water-soluble extract of semihard cheeses vacuum packaged (VP) and modified-atmosphere packaged (MAP). Peptides 
were identified by HPLC-tandem mass spectrometry analysis, and the intensity of the peptides of MAP cheeses at 0 d is represented on the right (value × 107 units). Protein 
fragments come from cow (c), sheep (s), and goat (g) milk. The first column of the table indicates calculated monoisotopic mass, and the numbers for VP and MAP indicate the 
presence of peptides at 0 (1), 30 (2), 60 (3), 90 (4), and 150 (5) d. 
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RPKHPIKHQ had been identified and isolated in other 
cheeses, such as 8 mo-ripened Gouda cheese (Saito et 
al., 2000), Festivo cheese (Ryhänen et al., 2001), and 
Scandinavian cheeses (Lund and Ardö, 2004). A potent 
angiotensin-converting enzyme (ACE)-inhibitory activ-
ity had been reported for this peptide (IC50 = 13.4 μM), 
although it showed weak antihypertensive activity in 
rats (Saito et al., 2000). Similarly, other peptides that 
possess ACE-inhibitory activity are αS1-CN f(18–23), 
ENLLRF, with IC50 = 82.4 ± 9 μM (Quirós et al., 2005), 
and αS1-CN f(25–32), VAPFPEVF, which shows mod-
erate ACE-inhibitory activity (Contreras et al., 2009). 
Another related identified fragment was the peptide 
αS1-CN f(24–32), FVAPFPEVEF, which had been re-
ported with both antimicrobial activity (Rizzello et al., 
2005) and ACE-inhibitory activity (Ong et al., 2007). A 
decapeptide derived from the αS1-CN N-terminal region, 
αS1-CN f(3–13), has demonstrated antioxidant activity 
and stimulatory activity of adiponectin secretion in adi-
pose cell culture (Higurashi et al., 2007). It has to be 
highlighted that this sequence is included in several of 
the most abundant peptides in Figure 1.
One of the most abundant peptides, β-CN f(1–6), 
RELEEL, had been previously identified in fermented 
milk produced by Lactobacillus helveticus CP790, show-
ing moderate ACE-inhibitory and antihypertensive 
Figure 2. Relative amount of αS1-CN-derived peptides found in the 3,000 Da permeate from the water-soluble extracts of vacuum-packaged 
(dark gray bars) and modified-atmosphere-packaged (light gray bars) cheeses stored at 4°C during their shelf life (150 and 90 d, respectively). 
Amount of peptide is expressed as intensity (arbitrary units) of the signal obtained from the HPLC-tandem mass spectrometry analysis. Each 
value corresponds to the average of a duplicate sample.
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Figure 3. Peptides derived from β-CN identified in the water-soluble extract of semi-hard cheeses vacuum packaged (VP) and modified-atmosphere packaged (MAP). Peptides 
were identified by HPLC-tandem mass spectrometry analysis, and the intensity of the peptides of MAP cheeses at 0 d is represented on the right (value × 107 units). Protein 
fragments come from cow (c), sheep (s), and goat (g) milk. The first column of the table indicates calculated monoisotopic mass, and the numbers for VP and MAP indicate the 
presence of peptides at 0 (1), 30 (2), 60 (3), 90 (4), and 150 (5) d. 
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activity (Maeno et al., 1996). Specifically important in 
terms of bioactivity is the presence of the β-CN peptide 
LHLPLPL [f(133–139)], a well-conserved sequence in 
many species. Although this peptide shows only moder-
ate ACE-inhibitory activity (IC50 = 432.7 μM; Miguel 
et al., 2006), it can be a precursor of the potent an-
tihypertensive peptide LHLPLP (Quirós et al., 2007). 
Likewise, the peptide with sequence YPFTGPIPN [β-
CN f(60–68)] showed a potent ACE-inhibitory activity 
(IC50 = 14.8 μM) (Saito et al., 2000), and was isolated 
in Manchego cheese (Gómez-Ruiz et al., 2004). Other 
identified peptides from β-CN reported as moderate 
ACE-inhibitors are β-CN f(69–75) with sequence KV-
LPVPQ (although with significant antihypertensive ac-
tivity in rats; Maeno et al., 1996) and peptide DKIHPF 
[f(47–52)], identified in several Spanish cheeses (Gómez-
Ruiz et al., 2004, 2006). Likewise, peptide VRGPFPIIV 
[β-CN f(201–209)] showed a significant effect on the 
reduction of blood pressure in rats despite possessing 
only moderate ACE-inhibitory activity (Miguel et al., 
2006).
In summary, 48 peptides were identified in the water-
soluble extracts of VP and MAP cheeses. It has been 
described that product composition, processing, stor-
age conditions (time and temperature), and packaging 
contribute to the residual cheese-ripening processes 
observed during storage. The influence of 2 factors, 
storage time and packaging, were evaluated in this 
Figure 4. Relative amount of β-CN-derived peptides found in the 3,000 Da permeate from the water-soluble extracts of vacuum-packaged 
(dark gray bars) and modified-atmosphere-packaged (light gray bars) cheeses stored at 4°C during their shelf life (150 and 90 d, respectively). 
Amount of peptide is expressed as intensity (arbitrary units) of the signal obtained from the HPLC-tandem mass spectrometry analysis. Each 
value corresponds to the average of a duplicate sample.
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study. During storage time at 4°C it was observed that 
the peptide profile changed under both packaging tech-
nologies. The variation mainly referred to the relative 
amount of the different peptides, as most of the pep-
tidic sequences identified were the same regardless of 
packaging technique and storage time. Some exceptions 
were the αS1-CN peptides f(1–7), f(11–17), and f(27–32) 
that were only identified in VP cheeses. In contrast, 
the same β-CN peptides were identified in VP and MP 
cheeses. Comparing both packaging systems, a non-
constant pattern was observed concerning the relative 
amounts of peptides during the storage time. Looking 
at the longest common storage time (90 d), peptides 
such as αS1-CN f(24–32), f(25–32), and β-CN (44–52) 
reached higher relative levels in VP cheeses compared 
with MAP cheeses, whereas the opposite was observed 
for other peptides [αS1-CN f(1–16), β-CN f(46–52–32), 
and β-CN (74–82)]. In addition, though all β-CN pep-
tides showed a similar trend during storage time in both 
types of cheeses, the behavior of αS1-CN peptides in VP 
and MP cheeses varied depending on their sequence. 
The identification of these minor differences between 
VP and MAP cheeses merits further research to bet-
ter understand their correlation with the organoleptic 
properties of cheeses packaged with different technolo-
gies. Among the identified peptides, several of them 
have been described as bioactive sequences showing dif-
ferent bioactivities. These bioactivities should be also 
further evaluated using in vivo studies to corroborate 
the potential of these cheeses.
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Peptidomic study of Spanish blue cheese
(Valdeo´n) and changes after simulated
gastrointestinal digestion
It is increasingly evident that digestion can affect the biological activity of cheese by
the release of new active peptides from their precursors or, on the contrary, giving rise to
fragmentswithout activity. The characterization of the peptidome of a Spanish blue cheese,
Valdeo´n, has been conducted before and after gastrointestinal digestion, and the digests
have been compared to those obtained from pasteurized skimmed milk powder (SMP)
using a bioinformatics platform. Peptidomic profiling of digests revealed several regions
that are especially resistant to digestion (among them -casein 60–93, 128–140, and 193–
209). Some of them correspond to well-conserved regions between species (human, cow,
sheep, and goat) and include peptide sequences with reported bioactivity. The great peptide
homology found between both digests, cheese and SMP, suggests that the gastrointestinal
digestion could bring closer the profile of productswith different proteolytic state. Although
most of the biologically active peptides found in cheese after digestion were also present
in SMP digest, there were some exceptions that can be attributed to the absence of the
relevant precursor peptide before digestion.
Keywords:
Active peptide / Gastrointestinal digestion / Peptidomics / MS/MS / Valdeo´n
cheese DOI 10.1002/elps.201300510
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Peptides in cheese are not only important for the organolep-
tic characteristics of this product but they might also con-
tribute to its high biological value. An important number of
medium and low molecular weight peptides resulting from
casein during cheese ripening have been identified. Many
of these peptides can interact with receptors at the gastroin-
testinal tract (opioid receptors), facilitate mineral absorption
as the caseinophosphopeptides (CPPs), or be absorbed and
reach the blood streamwhere they can exert a biological effect,
for instance, the antihypertensive activity [1,2]. These peptides
are released by residual coagulant, indigenousmilk enzymes,
starter, and nonstarter adventitious microflora; and, some-
times, enzymes from secondary flora (e.g. from Penicillium
Correspondence:Dr. BeatrizMiralles, Instituto de Investigacio´n en
Ciencias de la Alimentacio´n, CIAL (CSIC-UAM, CEI UAM+CSIC),
Nicola´s Cabrera, 9, 28049 Madrid, Spain
E-mail: beatriz.miralles@csic.es
Abbreviations: ACE, angiotensin I-converting enzyme; CPP,
caseinophosphopeptide; IC50, the half maximal inhibitory
concentration; SMP, skimmed milk powder; WSE, water-
soluble extract
sp. in mould-ripened cheeses) [3]. Upon human ingestion,
gastrointestinal enzymes come into play. There are several
studies on cheese digestion using human gastrointestinal
enzymes under physiological conditions [4–6]. These in vitro
simulations are intended to be consistent with the in vivo
digestion studies [7, 8]. It is increasingly evident that diges-
tion can affect the biological activity, by the release of new
active peptides from their precursors or, on the contrary, giv-
ing rise to fragments with less or no activity. This brings up
the question about the effect that this physiological process
could have on the peptide profile of food matrices containing
the same proteins but in a different proteolytic state. In or-
der to shed some light on this issue, we have characterized
the peptidome of the Spanish fat, blue-veined cheese. This
cheese is made out of cow`s milk or a mixture of cow, sheep,
and/or goat’s milk, in a region called Valdeo´n (Leo´n, Spain).
Its authenticity is guaranteed by a Protected Geographical In-
dication since 2003. The peptide profile of Valdeo´n cheese has
been checked before and after simulated gastrointestinal di-
gestion. The digestion products have been compared to those
obtained from pasteurized skimmed milk powder (SMP), a
∗These authors contributed equally to this work.
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
1628 L. Sa´nchez-Rivera et al. Electrophoresis 2014, 35, 1627–1636
matrix wheremilk proteins aremainly intact, subjected to the
same enzymatic digestion.
2 Materials and methods
2.1 Samples
Two samples of different batches of 60 days old cheese, made
out of pasteurized cow and goat’s milk, were analyzed. One
corresponded to the winter cheese production (batch D) and
the other to the summer production (batch A), according to
the standard methods established by the Regulation Council.
The protein in dry matter contents of cheese (Kjeldahl stan-
dard method, International Dairy Federation) were 36.2 and
35.7%, respectively. A sample of SMP (protein content was
40.0%) purchased at a local market was also used.
2.2 Preparation of samples
The water-soluble extracts (WSE) of Valdeon cheese were
obtained as described by Go´mez-Ruiz et al. [4]. Afterwards,
the WSEs were ultrafiltrated using membranes Centripore
Amino Ultra of 3000 Da (Millipore, MA, USA). TheWSE and
ultrafiltrates were frozen at –20°C until analysis.
In order to perform CPPs determination, an enrichment
step by selective precipitation was carried out, as previously
described [9]. Briefly, this was performed by adding CaCl2 at
1% w/v (40 mol CaCl2/mol casein) and ethanol, 99.8% v/v
to a final concentration of 50% v/v. The resulting precipitate
was collected by centrifugation at 12 000 × g for 10 min at
10°C, resolubilized in Milli-Q R© water, subsequently freeze-
dried and stored at –20°C until use.
2.3 Simulation of the in vitro static gastrointestinal
digestion
A representative sample of cheese (1 g) and water weremixed
(0.5%, p/v) and homogenized using an ULTRATURRAX T25
Basic S25N-18G (IKA R© Werke, Germany). The SMP was re-
constituted with water (10%) and homogenized. The simu-
lated gastrointestinal digestions were carried out in triplicate
by the method previously described [10]. The samples were
dissolved (13mg/mL of protein) in simulated gastric fluid (35
mM NaCl) at pH 2, preheated at 37°C. Porcine pepsin at an
enzyme/substrate ratio of 1:20 w/w (182 units/mg) at 37°C
during 1 h, in the presence of phosphatidylcholine (P3841;
Sigma) vesicles was used. The in vitro duodenal digestionwas
carried out on the resulting product from stomach digestion
adjusted to pH 7 by using 1M CaCl2, 0.25 M Bis-Tris pH 6.5,
and 0.125 M bile salts equimolar mixture of sodium tauro-
cholate (Sigma) and glicodeoxycholic acid (Sigma). Trypsin
(EC 232–650–8, Sigma; 40 units/mg protein), Chymotrypsin
(EC 232–671–2, Sigma; 0.5 units/mg protein), porcine pan-
creatic lipase (EC 232–619–9, Sigma; 28.9 units/mg protein),
and colipase (EC 259–490–12, Sigma; enzyme: substrate ratio
1:895 w/w) were diluted in 35mMNaCl adjusted to pH 7 and
added to the mixture. The reaction was stopped by adding
Pefabloc R© SC (Fluka 76307) at 1 mM final concentration.
2.4 SDS-page
Samples were diluted at a concentration of 2 mg/mL of pro-
tein in a buffer containing 2% w/v SDS, 62.5 mM Tris HCl
pH 6.8, 10% v/v glycerol, 5% v/v -mercaptoethanol were
heated for 5 min at 95°C and loaded on 12% Bis-tris poly-
acrylamide gels (Criterion_XT, Bio-Rad, CA, USA). Elec-
trophoretic separations were run at 150 V in a Criterion
cell using XT-MES running buffer. Gels were stained with
Coomassie Blue (BioSafe Coomassie G-250 Stain, Bio-Rad).
2.5 Analysis by reversed phase-HPLC-MS/MS
Reversed phase-HPLC-MS/MS analyses of WSE and digests
from cheese and SMP samples were carried out as described
by Sa´nchez-Rivera et al. [11]. The column used was Waters
(XBridgeTM BEH 300 C18 5 m, 4.6 × 250 mm; Waters,
MA, USA), the injection volume 50 L, and the flow set at
0.8 mL/min. The peptides were eluted with a linear gradi-
ent from 0 to 45% of solvent B (acetonitrile/trifluoroacetic
acid 0.027%) and 55% of solvent A (water/trifluoroacetic acid
0.037%) in 60 min. Two runs were performed per diges-
tion triplicate in order to set up the method for different
target mass: 600m/z (permeate3 kDa, WSE and SMP) and
1200 m/z (WSE and SMP). Spectra were recorded over the
mass/charge m/z range 100–3000.
In the case of samples enriched in CPPs, the analyses
were carried out using a Mediterranea Sea18 150 mm ×
2.1 mm column (Teknokroma, Barcelona, Spain). The in-
jection volume was 50 L and the flow rate 0.2 mL/min. A
linear gradient from0 to 45%of solvent B (acetonitrile/formic
acid 0.1%) and 55% of solvent A (water/formic acid 0.1%) in
120 min was used. In these analyses, the target mass was set
at 750 m/z and 1500 m/z.
Data processing was done by using Data AnalysisTM (ver-
sion 4.0; Bruker Daltoniks, Germany). The peptide sequenc-
ingwas performed byMASCOT, using a homemade database
that includes the cow’s and goat’s milk proteins and main
genetic variants thereof. The matched MS/MS spectra were
interpreted by using BioTools version 3.2 and the compara-
tive peptidome analysis by means of the bioinformatics plat-
formProtein Scape 3.0, both fromBrukerDaltoniks. Peptides
present in at least one replicate have been included in data
sets.
3 Results and discussion
3.1 Electrophoretic profile of WSE of the cheeses
and SMP
Figure 1A shows theSDS-PAGEseparation ofValdeo´n cheese
(batches D and A) and their gastrointestinal simulations in
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Figure 1. (A) Bis-Tris SDS-PAGE electrophoretic run of commer-
cial casein (lane 1), WSE of Valdeo´n cheese batch D (lane 2), batch
A (lane 3) and digests of cheese in triplicate from batch D (lanes 4–
6) and batch A (lanes 7–9). (B) Bis-Tris SDS-PAGE electrophoretic
run of SMP control sample before digestion (lane 1), digests of
SMP in triplicate (lanes 2–4). MM = molecular marker.
triplicate. Figure 1B corresponds to PAGE-SDS of SMPdigest
in triplicate. Despite the extensive proteolysis that naturally
occurs in Valdeo´n cheese, as a blue-mould cheese, there were
still bands corresponding to caseins in the cheese before di-
gestion (WSE). Similar protein patterns could be observed
for both batches. After gastrointestinal digestion these bands
were barely visible. The bands that remained detectable with
MWs of approximately 24, 14, and 12 kDa were also found af-
ter the electrophoretic separation of the gastrointestinal fluid
in a blank (i.e. digestion without sample, data not shown) and
therefore, they could correspond to the enzymes employed or
fragments thereof, since theMWof trypsin and chymotrypsin
are 23.3 and 24 kDa, respectively.
3.2 Peptide profile of Valdeo´n cheese
The identified peptides (121) in the total WSE and the 3 kDa
fraction of the two different cheese batches before digestion
are listed in Supporting Information Table 1. Peptides identi-
fied in at least one batch have been included, since 75% of the
peptides were found in both. Those peptides originating from
the most abundant casein fractions (- and s1-casein, from
cow, and/or goat) dominated the cheese peptidome although
a few peptides derived from s2-casein and -casein were
also detected. The analysis of the 3 kDa permeate fraction
allowed to narrow the identification of 64 peptides between
500–1000 Da, that contained less than 7 residues. The blue
cheese undergoes extensive proteolysis due to the action of
enzymes from different origins as mentioned before, with
the main contribution from the mould culture, Penicillium
roqueforti. This leads to the larger number of different pep-
tides produced in blue cheese compared to semihard cheeses
[12].
Figure 2 shows the peptides released from - and s1-
casein, where bovine and/or caprine origin is indicated. A
distributed pattern of peptides was found within the -casein
sequence, covering most of its sequence (78% protein cov-
erage) (Fig. 2A). The N-terminal part of the protein, where
the phosphorylated serines are located, was source of a high
amount of peptides, whose detection was enhanced by the se-
lective precipitation employed. A total of 19 CPPs were identi-
fied from -casein. Among these, 5 contained more than one
phosphorylated serine and the other 13 were identified in the
region comprised between the residues 30–46 of the -casein
sequence, and were monophosphorylated. From these, four
arose from the 29–30 cleavage site (f30–36/37/39/42), which
is characteristic of aspartyl-proteinases action, secreted by P.
roquefortii [13, 14]. In accordance to our results, numerous
phosphorylated peptides from the N-terminal region of -
casein had been also reported in Parmiggiano cheese [15].
Similarly, various peptides from the C-terminal region of this
protein have been found in Manchego [4], Parmiggiano [15],
and Cheddar cheeses [16], among others. Some other re-
gions that gave rise to a notable number of peptides were
the ones containing residues 60–70, 80–90, 110–120, 130–
140, and the C-terminal part of the -casein sequence. Some
of the identified regions include previously reported bio-
logically active sequences like opioid peptides: fragment (f)
60–66 (-casomorphin 7) and f114–119 (neocasomorphin)
[17] or angiotensin I-converting enzyme (ACE) inhibitors,
like f47–52 (DKIHPF), which had been previously found in
Manchego cheese [4, 18]. Other identified peptides, like -
casein f169–175 had been previously reported to show low in
vitro ACE-inhibitory activity, whose half maximal inhibitory
concentration (IC50  1000) was high, but it exerted a high
antihypertensive activity in spontaneously hypertensive rats
after oral administration [19].
The sequence coverage of s1-casein reached 52%
(Fig. 2B). Among others, 17 CPPs were identified of which
four of them arose from region 109–118 andweremonophos-
phorylated. CPPs containing two or more phosphorylated
residues were also found, as it is the case of f62–73. Like-
wise, 12 of the CPPs from s1-casein were diphosphorylated
and belonged to the domain comprised between residues
39 and 55. In complex peptide mixtures the detection of
phosphorylated forms is impaired, since the nonphospho-
rylated peptides are more easily ionized. To overcome this
difficulty, instead of a selective precipitation, other authors
have conducted a selective isolation on TiO2 micro-columns
when analyzing complex samples from milk proteins diges-
tion [20]. On the other hand, the region comprising the
residues from 83 to 91 was also source of a noteworthy
number of peptides, 8 identified sequences. Similarly, in
Manchego cheese, numerous peptides between residues 83
and 95 were found [4], while in Parmiggiano cheese, peptides
s1-casein f80–114, f83–114, and f85–114 were identified [15].
Among the identified peptides from s1-casein, the sequence
f157–164, withACE-inhibitory activity (IC50 98M), had been
previously found in fermented casein with different lactic
acid starters, and after hydrolysis with pepsin and trypsin
[21].
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Table 1. Identified peptides with reported bioactivity found before and/or after simulated digestion of Valdeo´n cheese
Fragment Before digestion After digestion Activity
s1-Casein f(143–149)a) AYFYPEL Antihypertensive [34]/Mucin production [35]
s1-Casein f(144–149)a) YFYPELc) Antioxidant [31, 33]/Mucin production [35]
s1-Casein f(157–164)a) b) DAYPSGAW DAYPSGAWc) IACE [21]
-Casein f(47–52)a) b) DKIHPF DKIHPF IACE [4, 18]
-Casein f(60–68)a) YPFPGPIPN IACE/Antihypertensive [48]
-Casein f(98–105)a) VKEAMAPKc) IACE [32]
-Casein f(108–113)a) b) EMPFPKc) IACE [21]
-Casein f(114–119)a) b) YPVEPF YPVEPFc) Opioid [17]
-Casein f(133–138)a) b) LHLPLP Antihypertensive [29]
-Casein f(133–139)a) b) LHLPLPLc) IACE [29]
-Casein f(132–140)a) NLHLPLPLL IACE [30]
-Casein f(130–140)a) VENLHLPLPLL IACE [30]
-Casein f(169–175)a) b) KVLPVPQ Antihypertensive [19]
-Casein f(193–198)a)/f(191–196)b) YQEPVL IACE [48]
-Casein f(18–24)a) FSDKIAK Antibacterial, IACE [37]
a) Peptide sequence is present only in cow’s milk.
b) Peptide sequence is present in goat’s milk.
c) Found also in skim milk powder digests.
3.3 Identification of peptides after simulation of
gastrointestinal digestion of Valdeo´n cheese
A total of 139 peptides were found after Valdeo´n cheese di-
gestion (Supporting Information Table 2). There was not a
great difference in the number of peptides found before di-
gestion (121 peptides), due to the proteolysis naturally occur-
ring in this cheese [22–24]. However, a careful analysis, us-
ing a bioinformatics platform (ProteinScape), revealed some
differences in the peptide profile before and after gastroin-
testinal digestion. A total of 28 peptides found in the di-
gested cheese samples were already present before digestion
that demonstrates their resistance to the gastrointestinal en-
zymes, and resulted in a total peptide homology of 12.1%.
Indicative examples of resistant peptides to digestion from -
casein are GPFPIIV [f203–209 (cow’s milk)/f201–207 (goat’s
milk)], YPVEPF f114–119, and DKIHPF f47–52. The last se-
quence has been often found after simulated digestion of
different dairy products, including in vivo studies [8]. How-
ever, the two first peptides have been found only in cheese
and not in simulated digests of other dairy products, which
could indicate that they are generated by the fermentation
process [4, 25, 26]. Regarding the s1-casein resistant pep-
tides, the sequences f83–89 (KEDVPSE), f84–90 (EDVPSER),
and f83–90 (KEDVPSER) survived digestion. These results
are in agreement with previous reports that found several
peptides comprised between residues 80–91 in casein sub-
jected to simulated gastrointestinal digestion [20]. Moreover,
s1-casein f80–88 (HIQKEDVPS), f80–89 (HIQKEDVPSE),
f80–90 (HIQKEDVPSER), f80–91 (HIQKEDVPSERY), and
f81–89 (IQKEDVPSE) have been identified in the jejunum of
healthy humans who ingested casein [8]. Another resistant
sequence corresponded to an ACE-inhibitory peptide, f157–
164 DAYPSGAW, which had been also detected in an in vivo
study of the evacuation of casein peptides in calf stomach [27].
In addition, new peptides formed during digestion were
identified. An example of new sequences generated during
digestion is the -casein f133–138 (LHLPLP), a potent anti-
hypertensive peptide [28], whose precursor peptide f128–138,
was present in cheese before digestion (Table 1). Therefore,
it is important to highlight that the active form of the anti-
hypertensive peptide, which produced a decrease in the sys-
tolic blood pressure of spontaneously hypertensive rats of
25.3 mm of Hg [29], was released during cheese-simulated
digestion but not during SMP digestion. Another new pep-
tide arose from digestion, -casein f132–140, NLHLPLPLL,
had been previously identified in sodium caseinate hy-
drolysates produced by Lb. helveticusNCC2765, and described
as ACE-inhibitor, showing an IC50 value of 15 M [30]. Both
peptides belong to a highly conserved -casein region in
different mammals, which has led to numerous and dif-
ferent combination of peptides that have been found in di-
gests from human milk [31] and cows’ milk proteins both
in vitro [20, 26] and in vivo [8], by using different MS com-
binations: nanoLC-QTOF, HPLC-ion trap, or MALDI-TOF.
Another new released sequence from -casein was f98–105,
EAMAPK, previously described as antioxidant [32]. Similarly,
the -casein f108–113, EMPFPK, to whom ACE-inhibitory
activity has been attributed [21], was only identified after di-
gestion (Table 1). Furthermore, this peptide has been also
found in human effluents after ingestion of casein [8]. From
the s1-casein sequence, peptides f144–149 (AYFYPEL) and
f143–149 (YFYPEL) were generated during digestion. Both
peptides have been previously found to exert antioxidant
activity [31, 33], and mucin secretory activity in HT29-MTX
cells [35]. In addition, the second one has demonstrated po-
tent antihypertensive activity [34] (Table 1). Both peptides
are known to be released after hydrolysis of casein with
pepsin [36]. The sequence f143–149 (AYFYPEL) has been
also found in human [7] and calf stomach [27] during in vivo
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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digestion studies. Although before simulated digestion, no
peptides were found beyond position 164, after digestion at
least 10 fragments from the C-terminal part of the protein
were identified. The formation of these peptides might be
produced by the action of gastric pepsin, since s1-casein
f165–169 has been found in calf stomach after casein inges-
tion [27]. -Casein gave rise to newly released peptides during
in vitro digestion, as for instance, f18–24. This peptide shows
ACE-inhibitory activity (IC50 113.6 M) and antibacterial ac-
tivity [37].
A total of 39 CPPs could be identified in cheese digests.
The majority of these peptides (30) were monophosphory-
lated. Similar results were reported in digestion studies of
Beaufort cheese [6] and casein [20]. From these identified
CPPs, 16 arose from -casein, 14 of which were monophos-
phorylated and belonged to the region corresponding to
residues 30–46. Moreover, eight of these peptides survived
digestion, since they were already present before digestion
(f30–37/42, f32–37/42/43, and f33–37/42/43). Interestingly,
the common trait of these eight peptides after digestion is the
presence of 30Ile 32Lys, and 33Phe at the N-terminal ending
but the absence of 31Glu. Moreover, the digestion process led
to the formation of four additional peptides from this domain
containingN-terminal Phe33 (f33–39/44/45/46), which canbe
generated by pepsin [38]. Some identified CPPs showed two
or more phosphorylated residues. Among them, the peptides
-casein f7–25 and alsos2-casein f5–15, displayed the cluster
sequence SpSpSpEE, which could provide mineral-binding
properties [39]. s1-Casein gave rise to 14 CPPs after diges-
tion, seven of them being diphosphorylated, while the other
seven were monophosphorylated, and belonged to the do-
mains 40–55 and 108–119, respectively. No CPPs were found
froms1-casein 60–70, where the phosphorylated cluster is lo-
cated. Despite the sequence C- or N-terminal changes caused
by the digestive enzymes activity, no change in the phospho-
rylated residues was observed for the identified CPPs upon
cheese digestion.
3.4 Comparison of peptides released after
simulation of gastrointestinal digestion of
Valdeo´n cheese and skimmed milk powder
In order to assess if the same peptides can be generated with
the ingestion of foods with a very different proteolytic state,
the peptide profile of the digested cheese was compared with
that found after gastrointestinal digestion of SMP (Support-
ing Information Table 3). The analysis revealed a difference
in the number of peptides found in SMP (84 peptides) and
cheese (122 peptides, leaving out those fromgoat origin). Tak-
ing into account that no undigested casein was found neither
in Valdeo´n cheese nor SMP (Fig. 1), this difference was at-
tributed to the high grade of proteolysis of Valdeo´n cheese.
The proteolysis in cheese creates a large number of cleavage
sites exposed to enzymes leading to the generation of a higher
number of different peptides. Despite of this, good sequence
coverage was reached in the peptide analysis of both, Valdeo´n
cheese and SMP digests. In the case of -casein, protein cov-
eragewas slightly higher in cheese (87%) than inmilk powder
(80.4%).
The exhaustive comparative analysis revealed differences
in peptide identity between the SMPand cheese digests. From
the casein fraction, 36 peptides were found to be common
for both matrices, and a total peptide homology of 19% was
achieved. -Casein contributed the most to this issue, since
25 of the common peptides were generated from this pro-
tein. In contrast, as described above, the percentage of ho-
mology in cheese (before and after digestion) was 12.1%. The
higher peptide homology between digested cheese and the
SMP digest suggests that the digestion process reduces the
differences in the peptidome of both matrices. Figures 3 and
4 show the peptides that have arisen from -casein and s1-
casein, respectively, after digestion of Valdeo´n cheese and
SMP. In -casein, various peptides belonging to the region
128–140 displayed C-terminal Leu residues, which could be
due to the chymotrypsin activity in accordance to previous
studies [40]. This domain seemed to be particularly resis-
tant to hydrolysis during cheese ripening or digestion. For
instance, the nonactive fragments f133–139 (LHLPLPL) and
f134–139 (HLPLPL) were found in both digested matrices.
Dupont et al. [41] also reported the resistance of this region
and the presence of those two peptides after in vitro diges-
tion of -casein. Although the high number of peptides from
this highly conserved region is remarkable, the potent anti-
hypertensive peptide, LHLPLP f133–138 could not be found
in milk digests. It seems that the presence of a certain pre-
cursor peptide is needed for the release of the active pep-
tide during digestion [42]. However, recently this peptide
was identified in the jejunum of humans who consumed
casein [8]. It remains to be investigated if this peptide could
be released in vivo in a sufficient amount to exert an anti-
hypertensive effect, since in most clinical studies where milk
or fermented milk is used as control, no antihypertensive
effects were observed [43–45]. Similarly, bovine s1-casein
f144–149 (YFYPEL), whose antioxidant activity has been cited
above, was identified in SMP together with the related frag-
ment 145–149 (FYPEL), but the antihypertensive sequence
f143–149 (AYFYPEL) was not found. Nevertheless, the last
sequence was found in human gastric samples after inges-
tion of milk or yogurt [7]. It would be of great interest to
know the amount of these peptides after human digestion to
correlate their activity with their presence in gastrointestinal
effluents.
Other peptides that were found in both digests are the -
casein sequences VKEAMAPK f98–105, EMPFPK f108–113,
reported as ACE-inhibitors [21, 33] and YPVEPF f114–119,
reported as opioid [17]. The -casein region 106–119, that
gave rise to the latter peptides, together with the domains
60–93 and 133–140 seem to be very resistant to gastrointesti-
nal digestion in both SMP and cheese, probably due to the
presence of Pro in their sequences [46]. These results are in
agreement with those found in casein fractions and -casein
digests [20, 41]. Moreover, the resistance of the phosphory-
lated regions of caseins to digestion has been proved in these
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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samples. In Valdeo´n cheese, the -casein region 30–46 ap-
peared to be highly resistant, leading to the formation of 14
CPPs in digests. Picariello et al. [20] also reported the presence
of numerousCPPs from this region and specifically found the
sequences f33–42 and f33–43 after in vitro digestion of casein.
In SMP, a total of 18 CPPs were identified. Ten of them were
found in -casein, only three of those beingmonophosphory-
lated. However, the phosphorylated region 5–25 appeared to
be more resistant to digestion, giving rise to seven peptides,
among them, two sequences containing the phosphoseryl
cluster, i.e. f12–25 and f6–25. The phosphoseryl cluster was
conserved in both SMP f12–25, f6–25, and cheese f7–25, as
a common trait resulting from digestion. This is consistent
with the presence of -casein f7–25, f2–25, and f1–24 in lu-
men contents of rats perfused with -casein f1–25 [47]. This
behavior could help to elucidate and better understand the
cleavage patterns and breakdown of milk proteins and pep-
tide release during the gastrointestinal process in the small
intestine.
4 Concluding remarks
The peptide profile of Valdeo´n cheese showed the presence of
some ACE inhibitory and opioid peptides. After gastrointesti-
nal simulation, a higher number of bioactive peptides, includ-
ing antihypertensive, antioxidant, intestinal mucin-secretor,
and antibacterial were found. However, not all these se-
quences could be detected after digestion of SMP. The ex-
ceptions could be due to peptide precursor differences that
result in a distinct peptide profile after digestion. On the other
hand, the peptidomic profiling of digests reveals several re-
gions that are especially resistant to gastrointestinal digestion
in SMP and cheese, mainly in -casein 60–93, 128–140, and
193–209 but also in -casein 30–46, and s1-casein 40–55 and
109–118, where the phosphoserines are located. Indeed, no
changes in the phorphorylated residues were observed after
simulated digestion of cheese. Some of these resistant re-
gions are well conserved between species in dairy proteins.
Interestingly, numerous sequences with reported biological
activity belong to them. The higher peptide homology be-
tween digested cheese and the SMP digest compared to that
found in cheese before and after digestion, confirms that the
digestion process could bring closer the profile of certain re-
gions, even if they have different grade of proteolysis before
digestion. The remaining differences in the cleavage pattern
during digestion could also have other health implications,
like metabolic or toxicological ones (exposure of potential
epitopes). Kinetics of peptide release could provide further
information in this sense.
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ABSTRACT 
This study aims at the evaluation of the impact of heat treatment on the 
hydrolysis kinetics of milk proteins and on the peptide release during dynamic 
gastric digestion. SDS-PAGE and ELISA techniques were employed to assess 
the hydrolysis of proteins over time of digestion. The evolution of the peptidome 
generated through dynamic digestion of heated and non-heated milk, was 
studied at different times, by using MS-based techniques (ion trap and MALDI-
TOF/TOF) preceded by liquid chromatography. The homology values between 
samples, point out the importance of the exposure time to enzyme on the identity 
of peptides, causing an increase of 14% in peptide homology from 50 min to the 
end of digestion. Peptide homology at the end of digestion (48%), confirmed the 
impact of heat treatment on the identity of peptides generated from the two milk 
samples during digestion, despite their identical initial protein content and being 
the same matrix in both cases. Heat treatment produced an increase of the 
resistance in the casein fraction. However, β-Lg was found to be more 
susceptible to hydrolysis. Although differences on the pattern of peptide release 
were found between both samples, also some common traits after digestion were 
found. Resistant regions could be confirmed through the analyses, such as the 
region comprised between the residues 76-93 of β-casein, where several binding 
epitopes are included. Also, β-casein regions 126-140 and 190-209 were found 
to be resistant. 
Keywords: dynamic digestion / Peptidomics/ mass spectrometry/ heat treatment 
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1.  Introduction 
The study of digestion process has gained importance in the last years, since the 
release of products through this physiological event may have subsequent health 
implications. The evaluation of the peptides generated during digestion may be 
relevant to understand this process itself, in respect of protein behavior upon 
digestion, but also for nutritional, pharmacological and toxicological concerns. 
The formation of peptides derived from milk proteins digestion has been recently 
reviewed (Sanchez-Rivera, Martínez-Maqueda, Cruz-Huerta, Miralles, & Recio, 
2014a), pointing out the importance of MS-based techniques on the study of 
digestion process, applied to either targeted or untargeted products. Several in 
vitro static digestion models have been developed and widely used over the 
years (Guerra et al., 2012; Hur, Lim, Decker, & McClemens, 2011; Kopf-Bolanz 
et al., 2012). These models intended to mimic physiological conditions, however, 
they lack of mechanisms to control the sequential secretion of enzymes, the 
removal of digestion products, the appropriate mixing and the continuous 
changes in pH. Therefore, dynamic digestion models, either monocompartmental 
or bi- and multicompartmental ones, have been proposed to be more realistic 
with respect to physiological parameters (Guerra et al., 2012; Ménard et al., 
2014; Wickham, Faulks, & Mills, 2009). Gastric phase plays an important role in 
digestion, since the peptides produced by pepsin are delivered to small intestine, 
where they can either interact in situ with gastrointestinal receptors or be 
absorbed, mainly in duodenum and upper jejunum (Shimizu et al., 2010; 
Langerholc, Maragkoudakis, Wollgast, Gradisnik, & Cencic, 2011).  
However, it is increasingly evident that food processing can influence the 
behavior of proteins towards digestion, and therefore it may affect the release of 
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peptides. Milk products are often thermally-treated in food industry in order to 
enlarge their shelf-life, or to modify their functional properties (Guo, Fox, Flynn, & 
Kindstedt, 1996). Food processing has an impact on structural and nutritional 
characteristics of proteins that could result in a loss of amino acid bioavailability 
(Guo, Flynn, & fox, 1999; Finot, Deutsch, & Bujard, 1981). The modifications that 
proteins usually undergo through these technological processes include unfolding 
and protein aggregation. The formation of heat-induced aggregates of casein and 
whey protein has been reported (Patel, Singh, Anema, Creamer, 2006; Jean, 
Renan, Famelart, Guyomarc’h, 2006). Likewise, modifications on β-Lactoglobulin 
(β-Lg) structure upon heat treatment have been evaluated under different 
conditions, for instance pH, ionic strength, protein concentration (Loveday, Wang, 
Rao, Anema & Singh, 2012; Aymard, Durand & Nicolai, 1996; Iametti, Cairoli, 
Gragory & Bonomi, 1995). Nevertheless the extent to which proteins are altered 
during food processing depends on the type of process (Mills, Sancho, Rigby, 
Jenkins, & Mackie, 2009). These changes may have further health implications, 
for instance, a distinct effect on the allergenic response (Shandilya, Kapila, Haq, 
Kapila & Kansal, 2013), and also on the formation of bioactive peptides through 
digestion (Meisel et al., 1998). The heat-induced changes that food proteins 
undergo have been reported to influence their stability to in vitro static digestion 
of bovine and caprine milk (Almaas et al., 2006), of infant formula (Dupont, 
Boutrou, Ménard, Jardin, Tanguy, et al., 2010a), or even influence the kinetics of 
protein digestion in mini-pigs (Barbé et al., 2013). Although it is reported that β-
Lg is resistant to pepsin digestion (Miranda, & Pelissier, 1983), the increase of β-
Lg susceptibility to hydrolysis by this enzyme has been studied under different 
conditions, such as heat treatment at low pH, presence of alcohols, esterification 
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and heating under high pressure (Bateman, Ye, & Singh, 2010; Dalgalarrondo, 
Dufour, Chobert, Bertrand-Harb, & Haertlé, 1995; Chobert, Briand, Grinberg, & 
Haertle, 1995; Zeece, Huppert, & Kelly, 2008).  In this regard, the study of the 
peptidomic profile generated through dynamic digestion of milk products 
subjected to different heat treatments can help to understand the protein 
behavior under gastric digestion. Therefore, the aim of this work is to evaluate 
the impact of heat treatment on the hydrolysis kinetics of milk proteins and the 
distinct effect of this process on the evolution of the resulting peptidome 
generated at different times of gastric dynamic digestion, using a combination of 
two mass spectrometry analyzers (Ion trap and MALDI TOF/TOF). 
 
3.  Materials y methods 
3.1 Samples 
Two milk samples (unheated and heat treated skim milk) were used for the 
experiments. They were prepared using a skimmed milk powder as described by 
Barbé et al. (2013). The powder was reconstituted in distilled water to reach a 
final concentration of 50 g/L of protein.  Heat treatment (90ºC, 10 min) was 
applied to the reconstituted liquid to obtain the heat treated milk sample. The 
unheated milk did not undergo any treatment after reconstitution of the powder. 
For digestion process, 200 mL of each sample (unheated and heated milk) were 
used.  
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3.2 Dynamic digestion 
A dynamic digester available at STLO (INRA Rennes, France) was used to 
perform digestions on the two samples (unheated and heated milk) in triplicate. 
The digester was previously described by Ménard et al. (2014). The half–time of 
gastric emptying used in the present study was set at 191 and 283 min for 
unheated and heated milk, respectively, as estimated by Barbé et al. (2013) 
during a digestion study conducted in mini-pigs fed these milks. The beta (β) 
parameter for the Elashoff equation that controlled the gastric emptying was set 
at 0.8. The pH curve followed during digestions was controlled by the software 
(Ménard et al., 2014) using the pH data previously reported (Minekus, Marteau, 
Havenaar, & Huis in Veld, 1995). The enzyme used to perform digestions was 
porcine pepsin (P-6887, Sigma), at 1000 Units/mL (Chiang, Croom, Chuang, 
Chiou, & Yu, 2008) of simulated gastric fluid (SGF) (NaCl 150mM). The flow of 
SGF into the gastric compartment was set at 0.5 mL/min as previously described 
(Minekus et al., 1995). The sampling was done at 4, 10, 20, 50, 105, 165, 225, 
315 and 405 min.   
 
3.3 SDS-PAGE: 
SDS-PAGE analyses were performed using 4-12% Bis-Tris polyacrilamide 
precast gels (1.5 mm x 15 wells; NuPAGE Novex, Invitrogen). The triplicates of 
digestion at different times, mentioned above, were included in electrophoretic 
analyses. In addition, each milk sample before digestion was also analyzed in 
each SDS-PAGE run. These analyses were carried out as described by 
Bouzerzour et al. (2012). The molecular marker used for the experiments was 
Mark 12 Unstained Standard NuPAGE 4-12% (Invitrogen). The image analyses 
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of the gels were performed using Image scanner III (GE Health-care Europe 
GbmH, Velizy-Villacoublay, France). Densitometry analyses of the gel images 
were carried out using. The relative quantification of the β-lactoglobulin (β-Lg) 
through digestion process was performed by measuring the colored area volume 
of the band on the SDS-PAGE gel image. Both milk samples before digestion, 
included in each SDS-PAGE experiment, were used to establish the initial 
amount of protein. The volume of their colored area was measured and 
considered as 100%. The hydrolysis of this protein through digestion was 
estimated by referring the colored areas at different digestion times to that of the 
initial amount. 
3.4 ELISA 
Inhibition ELISA was performed on the triplicates of digestion from each sample 
(unheated and heat treated milk) at different times of digestion (0, 4, 10, 20, 50, 
105, 165, 205, 315 and 405 min). ELISA was carried out as previously described 
(Dupont, Mandalari, Molle, Jardin, Role-Répécaud, et al., 2010b) using caseins-
specific polyclonal antibodies to estimate the residual immunoreactivity of this 
protein during digestion process. Samples were first homogenized with a thurrax 
(Ultra Thurrax T8 IKA, Fischer Scientific, 20,000 tr/min-5 min). Each digestion 
time, mentioned above, was analyzed in triplicate.  
 
3.5 LC-MS/MS-based analysis by ion trap and MALDI TOF/TOF 
The triplicates of digestion from unheated and heated milk were individually 
analyzed by the two MS-based techniques: RP-HPLC-ion trap and nanoLC-
MALDI-TOF/TOF at three digestion times (4, 50 and 405 min).  
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The RP-HPLC-MS/MS analyses of samples were carried out on a HPLC-ion trap 
described by Sanchez-Rivera Recio, Ramos, and Gómez-Ruiz (2013). The 
column used for the experiments was a Mediterranea Sea18 15 cm × 0.21 cm 
(Teknocroma, Barcelona, Spain). The voltage ramp went from 0.35 V up to 1.4 V 
for the fragmentation of precursor ions and an isolation width of 4.0 m/z. The 
samples were eluted at 0.2 mL/min. A linear gradient was used from 0 to 45% of 
solvent B (trifluoroacetic acid-TFA 0.027% in acetonitrile) and 55% of solvent A 
(TFA 0.037% in water) in 120 min.  
 
The samples were also analyzed by a nano-LC (Easy-nLC II; Bruker Daltonik, 
GmbH Bremen, Germany) coupled to a fraction collector (Proteineer fc II; Bruker 
Daltonik) and finally by MALDI-TOF/TOF (Autoflex speed; Bruker Daltonik). The 
column used was a pepMap 100 column, C18 3µm of particle size, 75 µm x 15 
cm (Dionex Acclaim pepMap 100; Thermo Scientific). The elution of peptides was 
carried out with a linear gradient from 0 to 40% of solvent A (water/formic acid 
0.1%) and 60% of solvent B (acetonitrile/formic acid 0.1%) in 90 min. The flow 
was set at 300 nL/min and the injection volume was 18 µL. The fraction collector 
gathered the sample from the nano-LC and deposed a drop every 15 sec on a 
prespotted Anchorchip α-Cyano-4-hydroxycinnamic acid (HCCA) plate (set for 
proteomics II; PAC-II 384 well plate; Bruker Daltonics). Later on, the plate was 
washed with 10 mM monohydrated ammonium phosphate in aqueous solution at 
0.1% of TFA, to perform the MS/MS analyses off-line using MALDI-TOF-TOF. 
The mass range was set from 500-3500 m/z using an exclusion list containing 
the peaks from the matrix to avoid interferences.  
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Data processing was performed by using Data AnalysisTM (version 4.0; Bruker 
Daltoniks). The peptide sequencing was done by MASCOT, using a homemade 
database; and also by BioTools (version 3.2), using both, complete homemade 
database and individual homemade databases including all the milk proteins with 
the main genetic variants, by multiple protein search. The matched MS/MS 
spectra were interpreted by using BioTools (3.2). The comparison of the 
peptidomes between the samples and the evolution of the peptide profile over 
time was carried out by the bioinformatic platform ProteinScape (version 3.0), 
both from Bruker Daltoniks. 
 
3.6 Statistical analyses 
Two-way analysis of variance (ANOVA) was applied to ELISA and densitometry 
data using Graphpad Prism 5.0 software. The effect of time and the heat 
treatment on the hydrolysis of proteins were evaluated. The mean values are 
presented with the standard error of mean (SEM), and the effects were found 
significant at p≤0.001. Data were expressed as the percentage (%) of remaining 
protein over time of digestion with regard to the initial value (before digestion). 
 
4.  Results and discussion 
4.1 Hydrolysis of milk proteins by the action of pepsin 
Figure 1 shows the electrophoretic profile of unheated and heat treated milk 
at different times of digestion (0, 4, 10, 20, 50, 105, 165, 205, 315 and 405 min). 
In the case of the unheated milk (Figure 1A), it is observed that the casein 
fraction (32 kDa) is rapidly hydrolyzed compared to the heated one. At 4 min, the 
electrophoretic bands that corresponded to casein showed a drastic decrease in 
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the non-heated sample compared to the heated one, and at 10 min of digestion 
the casein bands are barely visible in unheated milk. This rapid degradation of 
casein by the action of pepsin is also in accordance with other results reported 
after gastric digestion of caseins (Picariello et al., 2010), or β-casein using adult 
and infant in vitro digestion models (Dupont, Mandalari, Molle, Jardin, Léonil, et 
al., 2010c) and of raw milk (Dupont et al., 2010b). However, in heated milk, the 
bands corresponding to the casein fraction still remained visible up to 50 min of 
digestion time. This suggests that food processing, such as heat treatment, has 
an influence on the kinetics of protein hydrolysis, in accordance to other studies 
(Almaas et al., 2006). 
As it can be observed in Figure 1A, the bands corresponding to β-Lg (18 
kDa) were visible until the end point of gastric digestion in unheated milk, 
although a slight decrease of the intact protein was observed at 315 and 405 min. 
Similar results were found by other authors after the gastric digestion of whey 
proteins (Picariello et al., 2010) or β-Lg (Dupont et al., 2010b). However, in the 
heated milk, at 50 min, the action of pepsin caused a pronounced decrease in the 
band corresponding to β-Lg (Figure 1B). This protein was completely degraded 
during gastric digestion. Although this protein has been reported to be resistant to 
the action of pepsin under gastric conditions (Miranda & Pelissier, 1983), it has 
also been shown that certain conditions such as heat treatment and the 
application of heat either at low pH or under high pressure can make the protein 
more susceptible to digestion (Peram, Loveday Ye, & Singh, 2013; Bateman et 
al., 2010; Zeece et al., 2008). It has to be taken into account, that under our 
conditions, a faster gastric emptying was established for unheated versus heated 
milk and therefore, the protein was exposed to the action of the enzyme shorter 
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time in the case of the non-heated milk. The remaining amount of β-Lg was 
estimated by using densitometry (figure 2A). At 105 min of digestion 70 % β-Lg 
remained in unheated milk while in heat treated milk only 35% of β-Lg was 
detected at the same time. 
 
 
Figure 1. SDS-PAGE electrophoretic run of unheated (1A) and heat treated milk (1B). 
Lane numbers represent the time of digestion (min). MM= molecular marker.   
 
Hydrolysis of milk proteins was also followed by ELISA using caseins-specific 
polyclonal antibodies (figure 2B). Again, it was confirmed the difference on 
caseins hydrolysis kinetics between heated and non-heated milk. These 
differences were more evident at early digestion times. After 4 min digestion, the 
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gastric digestion had caused an 80% decrease of the signal for casein in 
unheated milk while the decrease was just of 8% in heat treated milk. The 
resistance of casein to the action of pepsin in heated milk may be explained by 
the formation of aggregates of caseins with whey proteins during heat treatment 
of milk (Patel et al., 2006; Jean et al., 2006; Guyomarc'h, Law, & Dalgleish, 
2003). 
 
 
Figure 2.Evolution of β-Lg (2A) and caseins (2B) over time of dynamic 
gastric digestion. Mean values ± SEM (n=3) are expressed as the 
percentage (%) of the remaining protein in respect of the initial value 
(before digestion). Significant differences between UH (unheated milk) 
and HT (heat treated milk) at the same time of digestion were found at 
p≤0.001 (*). 
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4.2 Evolution of peptidomic profile of digests 
Overall, sequence coverage was found to increase over time of digestion, 
as more peptides could be identified, since they are gradually smaller and fit 
better to the selected target mass during the analyses. At the end point of 
digestion the sequence coverage reached for the major proteins was 80% and 
76% for β-casein and αS1-casein, respectively, in the case of heated milk; and 
83% and 83% for β-casein and αS1-casein, respectively, in the case of unheated 
milk. In general, more peptides were identified from the casein fraction in 
unheated milk compared to the heat treated one, and also a better sequence 
coverage was reached in the first case, suggesting that the heat treatment could 
influence the release and/or peptide identification under the same analyses 
conditions. Partly, this could be due to different phenomena that occur during the 
heat treatment, i.e., lactosylation, glycosylation, as well as protein-protein 
interaction, that represent an additional difficulty for peptide sequencing by MS. 
A study of peptide homology was carried out in digestion samples from 
heated and non-heated milk. These results show that the peptide homology 
between samples increased with time of digestion. The total peptide homology in 
samples at 4 and 50 min was found to be 34%. However, at 405 min this value 
increased up to 48%. These results point out the difference in the peptide release 
in both samples at early times of digestion (4 min and 50 min); and suggest that 
digestion process could bring closer the peptidome of the resulting products in 
both samples after 50 min, since at this point, the pattern of peptide release 
started to be similar in heated and non-heated milk. Nevertheless, the peptide 
homology of the two samples only reached 48% at the end of the gastric 
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digestion, in spite of being the same matrices, with the same initial protein 
content and composition. 
Figure 3 shows the peptides from β-casein identified in non-heated milk 
(3A) and heated milk (3B) at 4, 50 and 405 min of digestion. At 4 min, in both 
samples, most of the peptides belonged to the C-terminal region comprised 
between residues 190-209, suggesting that the hydrolysis starts at this part of the 
protein. Peptides from this region were more abundant in unheated milk (14 
peptides) compared to the heated sample (seven peptides), although some of 
these were common in both samples. Among them, f193-209 
(YQEPVLGPVRGPFPIIV), was also found in the stomach contents of calves 
(Yvon & Pelissier, 1987). In addition, f191-209, which was found only heated 
milk, was recently reported to show moderate IgE binding (Benedé et al., 2014). 
On the contrary, sequence f1-11 (RELEELNVPGE) was only found in unheated 
milk. Interestingly, the same sequence with Ile at C-terminal end, f1-12 
(RELEELNVPGEI) was found in the stomach of humans after milk ingestion 
(Chabance et al., 1998). Moreover, three large fragments were identified in 
heated milk containing 20, 21 and 22 residues (f143-163, f91-112, f141-163, 
respectively), whereas in the unheated one, smaller peptides were found from 
these regions, i.e., f143-156 and f94-105. The latter sequence 
(GVSKVKEAMAPK) was also identified in stomach of humans after 20 min of 
yogurt ingestion (Chabance et al., 1998). Moreover, the region 125-142 gave rise 
to several peptides in non-heated milk (five peptides), while in the heated treated 
sample only one was detected. No peptides from N-terminal phosphorylated 
region of the protein were identified. It is known that in complex samples 
detection of phosphorylated peptides detection is impaired by the presence of the 
Results 
 
141 
 
non-phosphorylated ones (Picariello et al., 2010). At 50 min, the C-terminal part 
of the protein still dominated the peptidome. Among them, f193-209 could still be 
found in both samples, accordingly to other studies (Yvon & Pelissier, 1987), and 
also the IgE binding peptide f191-209. Picariello et al. (2010) reported high signal 
in peptides generated from this region after gastrointestinal digestion of caseins. 
However, also other regions containing residues 1-14, 45-58 and 75-107 gave 
rise to several peptides in unheated milk digests (with 3, 6, 12 peptides, 
respectively). Among these sequences, f1-11 remained intact (present before 
digestion). In addition, 11 peptides from region 128-140 were identified i.e 
DVENLHLPLPLL, VENLHLPLPLL, NLHLPLPLL, LHLPLPLL among others. With 
respect to these domains (45-58, 75-107 and 128-140), similar patterns were 
observed in heated milk, although it was noteworthy the absence of peptides 
from region comprised between residues 1-14. Also, another exception was 
found, the f59-80 (VYPFPGPIHNSLPQNIPPLTQT) was only present in the heat 
treated sample, suggesting that this region in unheated milk might not have been 
released or, more likely, it could have been already digested into smaller 
sequences. At the end of digestion (405 min) a total of 68 peptides were 
identified in unheated and 60 in heated milk. The C-terminal part of the protein 
was not the main source of peptides. Although the pattern of peptide release at 
this point was similar in both samples, some differences were found. The N-
terminal part of the protein, gave rise to several new peptides in heated milk 
samples which had not been found at earlier times of digestion (f1-5, f1-6, f1-11, 
f6-11). Among them, f1-6 (RELEEL) was found in humans effluents after 
ingestion of caseins (Boutrou et al., 2013). By the contrary, in unheated milk, this 
part of the protein was hydrolyzed into several peptides, and, at 405 min, only f1-
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5 (RELEE) and f6-11 (LNVPGE) could be identified, noting the absence of f1-11. 
This suggests that the N-terminal part of the protein could be faster hydrolyzed in 
non-heated compared to heated milk. Moreover, numerous peptides from C-
terminal part of the protein could be still identified in both, non-heated (16 
peptides) and heated milk (17 peptides), among them f193-209, which was 
identified at all digestion times.  
 
Figure 3. Peptidomic profile from β-casein after dynamic digestion of unheated (3A) and heat 
treated milk (3B). The lines in light gray indicate 4 min of digestion, dark gray lines 50 min, and 
black lines the end point of digestion (405 min). 
KYPVEPFTESQSLTLTDVENLHLPLPLLQSWMHQPHQPLPPTVMFPPQSVL
RELEELNVPGEIVESLSSSEESITRINKKIEKFQSEEQQQTEDELQDKIHPFAQTQS
SLSQSKVLPVPQKAVPYPQRDMPIQAFLLYQEPVLGPVRGPFPIIV
B
SLSQSKVLPVPQKAVPYPQRDMPIQAFLLYQEPVLGPVRGPFPIIV
RELEELNVPGEIVESLSSSEESITRINKKIEKFQSEEQQQTEDELQDKIHPFAQTQS
LVYPFPGPIHNSLPQNIPPLTQTPVVVPPFLQPEVMGVSKVKEAMAPKHKEMPFP
KYPVEPFTESQSLTLTDVENLHLPLPLLQSWMHQPHQPLPPTVMFPPQSVL
A
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Nevertheless, other regions also seemed to be resistant. As an example of 
this, two sequences f164-189, SLSQSKVLPVPQKAVPYPQRDMPIQA (2876 Da) 
and f164-188, SLSQSKVLPVPQKAVPYPQRDMPIQ (2805 Da), containing 34 
and 33 residues, respectively, remained undigested in heated samples. This is 
also the case of region 76-93, whose hydrophobicity at pH 3 may have influenced 
the resistance of this area to pepsinolysis (Dupont et al., 2010c). Interestingly, 
this was also reported as a resistant region after digestion of raw, pasteurized, 
sterilized milks and yogurt using infant digestion model (Dupont et al., 2010b). 
Likewise, many peptides from this domain were identified in piglets after 
ingestion of infant formula (Bouzerzour et al., 2012). Moreover, similar results 
were reported after gastrointestinal digestion of other dairy products, such as 
blue cheese (Sánchez-Rivera, Diezhandino, Gómez-Ruiz, Fresno, Miralles, et al., 
2014b). Similarly, peptides from region 128-140 were highly abundant in both 
unheated and heated milk, showing a common trait in both cases. All of these 
sequences except one displayed Leu140 at C-terminal position. Recently, 
NLHLPLPLL f132-140, was identified in effluents of humans after casein 
ingestion (Boutrou et al., 2013). Probably, the resistance of these regions (76-93 
and 128-140) was also determined by the high content of proline residues in both 
cases (Vanhoof, Goossens, De Meester, Hendriks, & Scharpe, 1995; Hausch, 
Shan, Santiago, Gray, & Khosla, 2002). 
Figure 4 shows the identified peptides from αS1-casein in unheated (4A) and 
heat treated milk (4B) at different times of digestion (4, 50 and 405 min). The 
hydrolysis of this protein started from the N-terminal part of the protein (region 1-
39), and therefore determined the peptide release at early times of digestion. 
Large fragments from this part of the protein were abundant at 4 min of digestion 
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in both samples. Nevertheless, the sequences present in heated milk (i.e f1-
14/16/18/20/21/23, f3-20, f12/17/19-23) were larger than those found in the 
unheated one (i.e f1-9/12/14/16/18/20, 15/16/17/19-23). The antibacterial peptide 
Isracidin, f1-23 (RPKHPIKHQGLPQEVLNENLLRF) (table 1), was also found in 
the stomach of calves after ingestion of casein and skimmed milk (Yvon & 
Pelissier, 1987). Several sequences containing N-terminal Phe24 (five peptides) 
were found in both digests from heated and non-heated milk, among them, f24-
34 (FVAPFPEVFGK), being already present before digestion in both samples 
(data not shown). The presence of this peptide before digestion could be 
attributed to plasmin, since αS1-casein is susceptible to its action (McSweeney, 
Olson, Fox, Healy, & Hojurp, 1993), and concretely peptide bond Lys34-Glu35 was 
one of its specific sites of cleavage (LeBars, & Gripon, 1993). In both milk 
samples, the release of N-terminal peptides during digestion occurred from 
regions 1-23 and 24-39. This confirms the high susceptibility of the bond Phe23-
Phe24. No peptides were found from region 114-164, which is the phosphorylated 
domain of this protein. At the end point of digestion (405 min), the identification of 
peptides through the whole protein sequence was more homogeneous. Peptides 
from region 56-62, were identified for the first time in 405 min in unheated and 
heat treated milk. Likewise, new peptides were identified from domain 121-143 
only at the end point of digestion. In addition, the number of peptides identified in 
non-heated samples from regions 80-190 and 180-199 was twice those found in 
heated milk. Among them, f180-191 only found in unheated milk, and was also 
detected in the stomach of humans after the ingestion of yogurt (Chabance et al., 
1998). 
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Figure 4. Peptidomic profile from αs1-casein after dynamic digestion of unheated (3A) 
and heat treated milk (3B). The lines in light gray indicate 4 min of digestion, dark gray 
lines 50 min, and black lines the end point of digestion (405 min).  
 
Peptides from αS2-casein and κ-casein were identified in heat treated and 
non-heated milk digests at different times of digestion. The sequences identified 
from this protein represented a 14% and a 16%, respectively, of the total 
peptides, since these proteins are less abundant than β-casein and αS1-casein. It 
has been also proposed a higher resistance of αS2-casein and κ-casein to in vitro 
digestion compared to other caseins (Dupont et al., 2010a). Main differences 
between heated and non-heated samples at the end of the digestion were found. 
For instance, in heat treated milk, αS2-casein gave rise to five sequences from 
region 99-123, two of them had 23 (2718 Da) and 24 residues (2831 Da) but no 
RPKHPIKHQGLPQEVLNENLLRFFVAPFPEVFGKEKVNELSKDIGSESTEDQAME
DIKQMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLKKYKVPQLEI
VPNSAEERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAW
YYVPLGTQYTDAPSFSDIPNPIGSENSEKTTMPLW
A
RPKHPIKHQGLPQEVLNENLLRFFVAPFPEVFGKEKVNELSKDIGSESTEDQAME
DIKQMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLKKYKVPQLEI
VPNSAEERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAW
YYVPLGTQYTDAPSFSDIPNPIGSENSEKTTMPLW
B
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peptides from this region were detectable in the non-heated samples. This 
suggests that in unheated milk this region could have been hydrolyzed into 
smaller sequences, since peptides from that region had been identified at 50 min. 
Moreover, in unheated milk, two peptides from region 151-163 
(TKLTEEEKNRLNF and EEKNRLNF) were found. Interestingly, only one peptide 
was found from C-terminal part of the protein in non-heated milk, whereas four 
sequences were detected in heat treated samples, two of them f183-206 and 
f183-207 contained 23 and 24 residues, respectively. Both peptides showed 
antibacterial activity (Table 1) (Recio, & visser, 1999). 
Among the κ-casein sequences identified at the end point (405 min), six 
peptides from C-terminal region (139-169) could be found in heat treated milk 
and five in the unheated one. These results and the presence of f106-169 at 4 
and 50 min, point out the resistance of this area to digestion, in agreement with 
other reported results after casein digestion (Dupont et al., 2010a).  
No peptides from β-Lg were found at 4 min of digestion nor in heated 
neither in unheated milk. In the present work, this protein was found to be rapidly 
hydrolyzed in heated milk, and be resistant in the unheated one. After 405 min, 
several peptides from region 75-82 were found in heated, but also in non-heated 
milk, in agreement with the slight decrease of the intact protein observed at 315 
min (Figure 1A). In addition, peptides from the domain comprised between 
residues 95-149 were highly abundant at this point in both samples (seven and 
nine peptides in heat treated and unheated milk, respectively). Among these 
sequences identified in unheated milk, it is worthy to highlight that 4 of them 
(f123-130/131/132/133), were included in the region 125-135, which was 
reported to be especially resistant to digestion (Picariello et al., 2010). 
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To summarize, Table 1 shows the identified peptides physiologically 
relevant either concerning their potential bioactivity, their previous in vivo 
detection after dairy products ingestion or with allergenic implications as 
previously reported IgE epitopes. Different and common peptides could be 
observed in the two samples after digestion. Nevertheless, despite their 
similarities found in the sequence identity, Table 1 also shows their differences in 
regard to their time of release. In addition, the MS-based techniques, besides the 
identification of the peptides, allowed the observation of their behavior in terms of 
intensity (relative abundance) during digestion. Some differences in this sense 
were noticed between the two samples. For instance, several biologically active 
sequences from αs1-casein as DAYPSGAW (f157-164), YFYPEL (f144-149), and 
AYFYPEL (f143-149), among others, were found to be common for both 
samples, however, they showed differences in intensity between unheated and 
heated milk (data not shown).  
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Table 1. Identified peptides after gastric digestion of heated and unheat treated milk with previously reported bioactivity, and the time at which they were 
identified in each sample. Their presence in vivo in the gastrointestinal track within effluents gathered from humans or animals has been indicated.  
Sequence Protein fragment Sample In vivo Described activity Reference 
AYFYPEL αs1-CN f143-149 HT (50, 405); UH (50, 405) Human1; Calf3 Antihypertensive Contreras, Carrón, Montero, Ramos, & Recio, 2009 
DAYPSGAW αs1-CN f157-164 HT (50, 405); UH (50, 405) Calf3 ACE- inhibitor  Pihlanto-Leppälä, Rokka, & Korhonen, 1998 
NLHLPLPLL β-CN f132-140 HT (50, 405); UH (50, 405) Human2 ACE- inhibitor  Robert, Razaname, Mutter & Juillerat, 2004 
RPKHPIKHQGLPQEVLNENLLRF αs1-CN f1-23 HT (4, 50) Calf3 Antibacterial  Lahov, & Regelson, 1996 
YFYPEL αs1-CN f144-149 HT (50, 405); UH(50, 405) Human1 Antioxidant ; MSE Suetsuna, Ukeda, & Och, 2000;  Martínez-Maqueda, Miralles, Ramos, & Recio, 2013. 
RYLGY αs1-CN f90-94 HT (405); UH (50, 405)  Antihypertensive Contreras et al., 2009 
RYLGYL αs1-CN f90-95 HT (405)  Opioid  Loukas, Varoucha, Zioidrou, Streaty, & Klee, 1983 
VAPFPEVF αs1-CN f25-32 HT (405);  UH (50, 405) Human1 ; 2 ACE- inhibitor  Contreras et al., 2009 
FVAPFPEVF αS1-CN f24-32 HT (50, 405); UH (50, 405) Human2 ACE- inhibitor; antimicrobial  Ong, Henriksson, & Shah, 2007; Rizzelo et al., 2005 
LLYQEPVLGPVRGPFPIIV β-CN f191-209 HT (4, 50); UH (50)  ACE- inhibitor; IgE binding Yamamoto, Akino, &Takano, 1994; Benedé et al., 2014 
VVVPPFLQPEVM β-CN f82 - 93 UH (405)  IgE binding Benedé et al., 2014 
YAKPVA k-CN f61-66 HT (405)  Antihypertensive Miguel, Gómez-Ruiz, Recio, & Aleixandre, 2010 
HPHPHLSF k-CN f98-105 HT (4)  Antihypertensive Miguel et al., 2010 
VYQHQKAMKPWIQPKTKVIPYVRYL αS2-CN f183-207 HT (405) Mini-pig4 Antibacterial  Recio, & Visser, 1999 
VYQHQKAMKPWIQPKTKVIPYVRY αS2-CN f183-206 HT (405) Mini-pig4 Antibacterial  Recio, & Visser, 1999 
YQEPVLGPVRGPFPIIV β-CN f193-209 HT (4, 50, 405); UH (4, 50, 405) Calf
3; Mini-pig4; 
Calves5 
ACE- inhibitor; 
Immunomodulator Ong et al., 2007; Coste et al., 1992 
LYQEPVLGPVRGPFPIIV β-CN f192-209 HT (4, 50); UH (4, 50) Mini-pig4 Immunomodulator Coste et al., 1992 
PYVRYL αS2-CN f202-207 HT (4, 50, 405); UH (50)  Antihypertensive Recio et al., 2006 
SRYPSY k-CN f33-38 HT (50, 405); UH (405)  Opioid Yoshikawa, Tani, Yoshimura, & Chiba, 1986 
    
 
 
    
 
 
1
 Chabance et al., 1998 ;  2 Boutrou et al., 2013 ; 3 Yvon & Pelissier, 1987; 4Barbé et al., 2014 ; 5Scanff et al., 1992  
 
ACE : Angiotensin I-converting enzyme ; HT : Heat treated milk ; UH : Unheated milk ; MSE : Mucin secretion and expression. 
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4.  Conclusions 
The impact of the heat treatment on the peptidome released from milk 
proteins during gastric dynamic digestion was evaluated. The homology values 
between samples, point out the importance of the exposure time to enzyme on 
the identity of peptides, causing an increase of 14% in peptide homology from 50 
min to the end of digestion. Nevertheless, the peptide homology at the end of 
digestion only reached 48%. That confirms the impact of heat treatment on the 
identity of peptides generated from the two milk samples during digestion, 
despite their identical initial protein content and composition, and being the same 
matrix in both cases. Heat treatment produced an increase of the resistance in 
casein fraction. However, β-Lg showed to be more susceptible to hydrolysis.  
The MS analyses revealed differences between the heat and unheated milk 
in the pattern of peptide release and in the identity of the sequences, which may 
have been induced by the heat treatment. These differences could have 
implications in health, in regard to bioactivity or formation/resistance of potential 
epitopes. Nevertheless, also some common traits after digestion could be found. 
Resistant regions could be confirmed through the analyses, such as the region 
comprised between the residues 76-93 of β-casein, where several binding 
epitopes are included. Also, β-casein regions 126-140 and 190-209 were found 
to be resistant. The differences found on the peptide release could have distinct 
further nutritional and physiological implications, since the gastric emptying could 
deliver to the duodenum the peptides that have faster hydrolysis rate, i.e. αs1-
casein f25-32 (VAPFPEVF), αs1-casein f90-94 (RYLGY) or β-casein f 94-105 
(GVSKVKEAMAPK), β-casein f132-140 (NLHLPLPLL), αs1-casein f144-149 
(YFYPEL) among others. 
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ABSTRACT: The aim of this study was to investigate the oral bioavailability and 
kinetics of the milk casein-derived peptide HLPLP, which had previously demonstrated 
antihypertensive effect in spontaneously hypertensive rats. HLPLP disposition after 
single intravenous (4 mg/kg body weight) and oral (40 mg/kg body weight) doses was 
studied in rats. Plasma concentrations of HLPLP [β-casein fragment f(134-138)], and two 
derived fragments found after HLPLP administration, LPLP [β-casein fragment f(135-
138)] and HLPL [β-casein fragment f(134-137)] were determined by Ultrahigh 
Performance Liquid Chromatography (UPLC) coupled on line to a Q-TOF instrument. 
For HLPLP, the elimination half-lives (T1/2β) were 7.95 min after intravenous and 11.7 
min after oral administration. The volume of distribution at steady state (Vss = 30.8 L/kg) 
suggests a considerable uptake of HLPLP into tissues. HPLPL was converted to the 
peptides, LPLP and HLPL. After HLPLP intravenous administration, the elimination 
half-lives (T1/2β) for these biotransformed peptides, LPLP and HLPL, were 8.38 and 10.9 
min, respectively. After oral administration, HLPLP was rapidly absorbed with an 
absorption half-life (T1/2a) of 2.79 min. The oral bioavailability of HLPLP was found to 
be 5.18%. Our study suggested that HLPLP was rapidly absorbed and eliminated after 
oral administration, biotransformed into smaller fragments LPLP and HLPL, and 
distributed throughout the body by the circulation blood. The present pharmacokinetic 
information from a pre-clinical kinetic study in rats can also play an important role in 
designing future kinetic studies in humans for assessing HLPLP dose-response 
relationship 
 
Keywords: Antihypertensive peptide HLPLP, Oral bioavailability, Plasma disposition, 
Rats,  
Tandem MS.  
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INTRODUCTION 
Research on bioactive peptides has led to the discovery of particular protein sequences 
that modulate physiological functions with hormone- or drug-like activity.1 There are 
several peptides derived from food proteins that interact with the renin-angiotensin 
system and reduce arterial blood pressure. Much work has been done to assess the in vitro 
activity of food peptides on the angiotensin-I-converting enzyme (ACE). However, only 
in some cases the correspondence between in vitro and in vivo effects has been 
demonstrated.2  Discrepancy between ACE-inhibitory and antihypertensive activity of 
peptides can be due to their degradation during gastrointestinal digestion, the impaired 
access to the target organ in a sufficient amount or because other mechanism different 
than ACE inhibition may be involved.3  
 Milk fermentation represents one of the strategies most commonly employed to 
produce peptides with biological activity. For instance, recently Kluyveromyces 
marxianus has been demonstrated to produce antihypertensive lactoferrin-derived 
peptides, with ACE-inhibitory activity in vivo4. Milk fermented using selected strains of 
Enterococcus faecalis showed acute antihypertensive effect in spontaneously 
hypertensive rats (SHR) after a single oral administration.5 In following experiments, the 
decrease of the arterial blood pressure was demonstrated after long-term intake of 
fermented milk.6 The β-casein fragment (f) (133-138), with the sequence LHLPLP, was 
identified as one of the major peptides responsible for the biological activity of the 
fermented product. In fact, it is a potent in vitro ACE-inhibitor (IC50 of 5.5 µM) and 
antihypertensive peptide which causes a decrease in the systolic blood pressure in SHR of 
25.3 mm Hg at a dose of 2 mg/kg when orally administered.7 Simulated gastrointestinal 
digestion has shown that the sequence LHLPLP is resistant to digestive enzymes,8 but 
upon incubation using Caco-2 cells, it was partly hydrolysed by brush border peptidases 
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that cleaved the peptide bond between Leu and His, releasing the pentapeptide HLPLP. 
The peptide HLPLP is also resistant to in vitro gastrointestinal digestion and brush border 
peptidases of Caco-2 cells, being rapidly transported through the cell monolayer.9 This 
peptide HLPLP has been also demonstrated to exert antihypertensive activity in SHR.10 
Later on, the production of the active pentapeptide HLPLP by enzymatic hydrolysis from 
caseinate was also optimized11 as an alternative to the fermentation with E. faecalis 
strains since its use in the food industry is controversial due to their pathogenic 
potential.12 Since the peptide HLPLP might be commercially attractive as an active 
compound, it is important to investigate its capacity  to reach blood circulation.  
 Previous studies on oral bioavailability of selected food-derived peptides have 
reported their presence in plasma at pico- and nanomolar concentrations using very 
selective and sensitive analytical techniques.13 van Platerink et al.14 developed a sensitive 
method to detect peptides in human plasma samples with detection limits from 0.01 to 
0.001 ng/mL. Although the research on the absorption of antihypertensive peptides has 
revealed that certain short peptides, di- and tripeptides such as VY and IPP can reach 
blood stream undegraded after oral administration, either in fasted or fed states, very low 
absorption extents were reported15-17. To the best of our knowledge, kinetic studies with 
longer peptides than tri-peptides from dietary sources have not been reported. 
 Because the information regarding the kinetic profile is needed in order to 
establish a scientific basis for efficacy in the use of any food supplement, the objective of 
this study was to investigate the oral bioavailability and the kinetic behaviour of the 
antihypertensive peptide HLPLP after its administration to rats determining HLPLP 
plasma concentrations using a sensitive and specific analytical method. In addition, this 
technique allowed us to monitor the plasma concentrations of two derived peptide 
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fragments, LPLP [β-casein fragment f(135-138)] and HLPL [β-casein fragment f(134-
137)].  
 
MATERIALS AND METHODS 
Chemicals. The peptides HLPLP, β-casein f(134-138), HLPL, β-casein f(134-
137), HLP, β-casein f(134-136), LPLP, β-casein f(135-138), LPL, β-casein f(135-137) 
and PLP, β-casein f(136-138) were used in this study. These peptides were prepared in-
house following the solid-phase synthesis method with fluorenyl-methoxy-carbonyl 
(FMOC), using a 431A peptide synthesizer (Applied Biosystems Inc. Überlingen, 
Germany). Their purities, verified by reversed phase-high performance liquid 
chromatography-ultraviolet-mass spectrometry (RP-HPLC-UV-MS) as previously 
described,18 were 98.0%, 97.68%, 96.20%, 93.43% and 99.36%, respectively. Peptide 
PLP, with a purity of 92.94%, was purchased from SynPeptide CO, LDT (Shanghai, 
China). All other chemicals were of the highest quality grade and obtained from 
commercial sources. 
Animals and experimental design. The study was undertaken in 
accordance with the ethics requirements and authorized by the official ethical committee 
of University Complutense of Madrid. Adult male Wistar rats (Charles River Inc., 
Margate, Kent, UK) each weighing 220-230 g  of 9 weeeks of age were used. The 
animals were individually housed in polycarbonate cages with sawdust bedding and 
maintained in environmentally controlled rooms (22 ± 2ºC and 50 ± 10% relative 
humidity) with a 12 h light/dark cycle (light from 08.00 to 20.00 h). Food (A04 rodent 
diet, Panlab SL, Barcelona, Spain) and water were available ad libitum. The rats were 
divided into two groups, one group of 60 animals (Group 1) received the synthetic 
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peptide HLPLP intravenously and the other group of 84 animals (Group 2) orally. Group 
2 rats were deprived of food for 12 h before the single oral administration of 40 mg/kg 
body weight but they had ad libitum access to water. The peptide was dissolved in 
distilled water (10 mg/mL) and was administered by oral gavage in a volume of 1 mL 
peptide solution/rat of 250 g of body weight. Group 1 rats were given a single i.v. 
injection of 4 mg/kg body weight into the lateral tail vein (in this case a peptide solution 
of 4 mg/mL was prepared, and 0.25 mL peptide solution/rat of 250 g of body weight was 
injected). The i.v. 4 mg/kg and oral 40 mg/kg doses of peptide HLPLP were selected on 
the basis of preliminary experiments where both doses and routes of administration did 
not show any adverse effects, abnormal clinical signs, behavioral changes, body weight 
changes, or change in food and water consumption in the animals treated (data not 
shown). The oral HLPLP dose was higher than the i.v. dose due to the low absolute oral 
bioavailability described for other food-derived peptides in pigs, approximately 0.1%.17 
The administered oral dose is higher than that reported to cause a significant decrease in 
the systolic blood pressure in spontaneously hypertensive rats (SHR).10 Five additional 
animals were used as control to collect blank blood samples and to prepare calibration 
curves from plasma control fortified with the synthetic peptides HLPLP, LPLP and 
HLPL. 
Animals in groups 1 and 2 were killed by cervical dislocation (six animals at each 
time) and then exsanguination at 0, 1.5, 2, 3, 5, 8, 10, 15, 20 and 30 min after i.v.  and at 
0, 3, 5, 10, 15, 20, 30, 40, 45, 50, 55, 60, 65 and 70 min after oral administration of 
peptide HLPLP, respectively. Time points were selected based on preliminary 
experiments and taken into account the limit of quantification (LOQ) of the analytical 
method. Blood samples (1 ml) were withdrawn from jugular vein and collected in 
heparinized tubes. Plasma was separated by centrifugation and stored frozen at -80ºC 
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until analysed. Blood samples at time greater than 70 or 30 min after oral or i.v. HLPLP 
doses, respectively, were not collected, because preliminary experiments (data not 
shown) showed that at these times no levels of the synthetic peptides HLPLP, LPLP and 
HLPL were detected. 
Analysis of plasma samples. Plasma sample preparation. Plasma 
samples from rats were prepared by adding 40 µL of an aqueous solution of 10 % of 
trifluoroacetic acid (TFA) to 1 mL of plasma, homogenized in a vortex and the mixture 
was heated at 99ºC  for 2 min to precipitate proteins, as previously described.14 Then, the 
samples were centrifuged (MiniSpin, Eppendorf, Hamburg, Germany) at 8500 g for 30 
min. The supernatant was purified using mixed mode cation exchange cartridges (Bond 
Elut Plexa PCX, 60mg, 1mL, Agilent, Santa Clara, CA, USA). Cartridges were 
preconditioned with 1500 µL of methanol, and 2500 µL of Milli-Q water (Millipore, 
Bedford, MA, USA). The plasma sample, previously mixed (1:3 v/v) with an aqueous 
solution containing 2% orthophosphoric acid was loaded. The cleaning step consisted in 
the addition of 1500 µL of 2 % formic acid in Milli-Q water, and 2500 µL of a mixture 
comprised by 50% methanol and 50% acetonitrile (v/v). The elution step was carried out 
by adding 1 mL of ammonia at 5% (35% purity) in methanol:acetonitrile (50:50, v/v). 
The elution volume was afterwards totally dried by vacuum centrifugation (SpeedVac SC 
200 Savant, Irving, TX, USA). For the injection, the dried samples were reconstituted 
with 50 µL of 0.1% formic acid. 
To prepare the standard curves, the synthetic peptides HLPLP, LPLP and HLPL were 
diluted in Milli-Q water to final concentrations that ranged from 0.08 to 300 ng/mL, 
corresponding to 0.13 to 521 nmol/L, 0.18 to 682.9 nmol/L and 0.17 to 625.9 nmol/L 
respectively, in rat control plasma. Immediately after adding the peptide solution to the plasma, 
they were treated as described before for the preparation of plasma samples from rat assays. The 
calibration curves were injected the same day as the rat samples. 
Results 
 
168 
 
Peptide analysis by UPLC-Q-TOF. The analyses of samples were 
performed on an Acquity Ultrahigh Performance Liquid Chromatography (UPLC) from 
Waters (Milford, MA, USA), coupled to a Microtof-QII (Bruker Daltonik, Bremen, 
Germany). The LC-MS system was controlled by the HyStar 3.2 software (Bruker). The 
column employed for the analyses was an Acquity UPLC BEH 130 C18 of 2.1 mm × 100 
mm (Waters), with a particle size of 1.7 µm. The analyses were run at 30ºC, the flow rate 
was 0.2 mL/min and the injection volume was 25 µL. A linear gradient was set from 0 to 
45% of solvent B (acetonitrile/formic acid 0.1%) and 55% of solvent A (water/ formic 
acid 0.1%) in 16 min. The nebulizer pressure was set at 3 bar, the temperature of the 
source at 180ºC and the capillary voltage at 4.5 kV. MS full-scan acquisitions were first 
performed during UPLC runs, using a 50-1200 m/z range. The method developed was a 
pseudo-selected reaction monitoring (SRM) in which the parent ion with mass-to-charge 
(m/z): 576.343 was selected for fragmentation. The peptide HLPLP was identified by its 
retention time and also by its fragmentation profile. The identification of the possible 
derived peptide fragments, i.e., LPLP and HLPL, HLP, LPL, and PLP was done by the 
retention time and the extraction of the characteristic molecular ions m/z: 439.284, 
479.290, 366.206, 342.231 and 326.200, respectively. The Q-TOF analyzer was 
calibrated on a daily basis in MS mode, using the m/z ratios of adduct ions arising from 
sodium formiate as reference. 
Data analysis. The mean plasma concentration versus time after i.v. and oral 
administration were sequentially fitted to 1-, 2- and multiple-compartment models, using the 
computer program WinNonlin (Version 6.3; Pharsight Corporation, Mountain View, CA, 
USA). The model was determined for best fit on the basis of a smaller value for the 
Akaike’s Information Criterion (AIC).19 The  two-compartment model was the best fit for 
the two animal groups. This model was used to establish pharmacokinetic characteristics. 
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Mean plasma concentration curves of peptide HLPLP after a single i.v. and oral 
administration and those of the peptides LPLP and HLPL (metabolites in plasma) after a 
single i.v. administration of HLPLP were fitted to the following exponential equations: 
C = A1 × e -αt + A2 × e -βt  (i.v.) 
C = A1 × e -αt + A2  × e -βt  – A3  × e –Kat  (oral) 
where C is the plasma concentration of the compound; A1 and A2 and A3 are mathematical 
coefficients (i.e. A1 and A2 are the plasma concentrations extrapolated to time zero of the 
first and second elimination phases of the compound and A3 for the absorption phase); α is 
the hybrid rate constant for the distribution phase; β is the hybrid rate constant for the 
elimination terminal phase (i.e. α and β are the slopes of the first and second elimination 
phases of the compound disposition) and t is the time. Absorption half-life (T1/2a), half-life 
of α phase (T1/2α), the half-life of β phase (T1/2β), distribution rate constants for transfer of 
the compound from the central to the peripheral compartment (K12) and from the 
peripheral to the central compartment (K21), and the elimination rate constant (K10) were 
calculated using standard equations as described.20,21 After i.v. and oral administration, 
the area under the concentration-time curves (AUC) was calculated as follows: 
 AUC = (A1/α) + (A2/β); or  
AUC = (A1/α) + (A2/β) – (A3/Ka) 
where bioavailability (F) is (doseiv × AUCoral)/(doseoral × AUCiv). 
 Total plasma clearance (CL) was calculated, using the following formula: 
 CL = [dose (mg/kg)]/AUC; or  
CL = [dose (mg/kg)] (F)/AUC  
Mean residence time (MRT) (only for HLPLP i.v. administration) was calculated 
as follows: 
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MRT = [(A1/α2) + (A2/β2)] × (1/AUC) 
 Volume of distribution in the central compartment (V1) (only for HLPLP i.v. 
administration) was determined as follows: 
  V1 = [dose (mg/kg)]/ A1 + A2 
 Apparent volume of distribution in the second compartment (V2) (only for HLPLP i.v. 
administration) was determined as follows:  
 V2 = (V1) × (K12/K21) 
 Volume of distribution at steady state (Vss) (only for HLPLP i.v. administration) was 
determined as follows: 
 Vss = MRT × CL  
 Maximum drug plasma concentration (Cmax) after oral administration and the time at 
which Cmax was achieved (Tmax) was determined directly from the concentration versus time 
curve.  
RESULTS 
Quantitative determination of peptides by UPLC-Q-TOF. In 
preliminary experiments, the quantification of the HLPLP peptide was attempted with a 
sample preparation protocol consisting in the addition of 10% TFA to 1 mL of plasma 
followed by heating at 99ºC for 2 min to precipitate the proteins and further 
centrifugation. However, this protocol did not allow determining plasma peptide 
concentrations below 12.5 ng/mL. Therefore, peptide purification and concentration was 
investigated by using different solid phase extraction (SPE) cartridges, such as, reversed 
phase C18 cartridges, mixed-mode cation, anion, and weak cation exchangers and several 
solvent mixtures for the elution step. The best recovery values were obtained with a 
cation exchanger with mixed sorbent characteristics suitable for polar and non-polar 
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bases. The elution solvent selected was ammonia at 5% (35% purity) in 
methanol:acetonitrile (50:50, v/v).  
The calibration curves provided linear results over the HLPLP concentration 
values from 0.13 to 521 nmol/L in plasma (R2= 0.99). Figure 1a shows the extracted ion 
chromatogram of a blank plasma sample considering the masses of the pentapeptide 
HLPLP and both tetrapeptides, HLPL and LPLP, where it can be shown that there are no 
interferences with endogenous compounds are expected. The extracted ion chromatogram 
of the pentapeptide after oral and i.v. administration and its fragmentation pattern are 
shown in Figure 1b, 1c and 1d, respectively. One of the most intense fragment ions was 
observed at m/z 326.207, corresponding to y-type ion y3. Other major fragment ions were 
detected at m/z 251.149 and 461.290, which corresponded to b-type ions b2 and b4, 
respectively.  
 
Figure 1. a) Extracted ion chromatogram (EIC) of HLPLP (m/z 576.343; RT 9.4), LPLP (m/z 439.284; RT 
10.5) and HLPL (m/z 479.290; RT 8.4) in blank plasma. EIC of the peptide HLPLP (m/z: 576.343; RT 9.4 
min) b) at 15 after oral administration and c) at 20 min after intravenous administration. d) Fragmentation 
pattern of HLPLP at 15 min after oral administration. 
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These fragments (y3, b2, and b4) resulted from the cleavage at N-terminal proline, 
which often generates highly intense b and y-type fragment ions.22The recovery was 
calculated as the ratio between the concentration determined in a blank plasma sample 
spiked with HLPLP and further submitted to SPE purification and the concentration 
determined in a spiked sample after SPE purification. This was performed in triplicate 
using two concentrations of the peptide. The recovery values ranged from 96.9% to 
98.7%. The reproducibility was estimated by the analyses of five spiked plasma extracts 
purified by SPE in three different days separated by 10 days, and repeatability by 
performing these determinations in consecutive analyses. Relative standard deviations 
(RSD) of the peak areas were 6% and 5% for reproducibility and repeatability, 
respectively. These values reflect the high performance achieved in the present study in 
terms of accuracy and precision. The limit of detection (LOD) was estimated to be 0.03 
nmol/L, equivalent to 0.02 ng/mL, and was calculated as the concentration of peptide that 
gave a signal equal to 3 times the standard deviation of the blank. The LOQ was 
estimated at 0.17 nmol/L, equivalent to 0.10 ng/mL, by using 10 times the standard 
deviation of blank signal. With respect to the peptides LPLP and HLPL, the calibration 
curves provided linear results from 0.18 to 682.9 nmol/L (R2= 0.98) and 0.17 to 625.9 
nmol/L (R2= 0.99), respectively. The LOD values for LPLP and HLPL were estimated at 
1.13 ng/mL (0.50 nmol/L) and 0.11 ng/mL (0.22 nmol/L), respectively. The LOQ values 
for these peptides resulted in 1.67 ng/mL (3.71 nmol/L) and 0.36 ng/mL (0.75 nmol/L), 
respectively. 
 Pharmacokinetics of peptide HLPLP and its biotransformed 
peptides LPLP and HLPL.  
In the plasma samples collected at time 0, i.e. before HLPLP i.v. and oral 
administration, no peptides HLPLP, HLPL and LPLP were detected.  The two peptide 
  
fragments (m/z 479.290, 439.284) corresponding to HLPL and LPLP respectively, were 
found in plasma from 1.5 min until 30 min after 
after oral administration, peptide fragments were detected between 5 and 60 min although 
they could not be quantified at all time points.  
chromatogram of the derived peptides, LPLP and HLPL, at different times after oral and 
i.v. administration, and their corresponding fragmentation patterns.
Figure 2. a) Extracted ion chromatogram (EIC) of LPLP (RT 10.5 min) at 2 min after intravenous 
administration and b) at 40 min after oral administration of the peptide HLPLP; 
at 2 min after intravenous administration and 
pattern of e) LPLP and f) HLPL. 
 
Mean plasma concentrations of peptide HLPLP and its biotransformed peptides 
LPLP and HLPL after single HLPLP 
of peptide HLPLP after single oral administration are shown in 
plasma concentration-versus
173 
i.v. administration of HLPLP. However, 
Figure 2 shows the extracted ion 
 
c) EIC of HLPL (RT 8.4 min) 
d) at 60 min after oral administration of HLPLP; fragmentation 
i.v. administration, and mean plasma concentrations 
Figure 3.
-time curves indicated a biphasic decrease after 
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administration. Good fit of the observed data for a two
obtained.   
Figure 3.  (A) Mean plasma concentrations of the peptides HLPLP 
single HLPLP intravenous dose of 4 mg/kg of body weight, and 
peptide HLPLP () after single oral dose of 40 mg/kg of body weight. 
for six rats (i.e. six rats/time) (one
symbols. 
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-compartment open model was 
(), LPLP (▲), and HLPL (
(B) mean plasma concentrations of the 
Data represent mean ± S.D. values 
-way ANOVA). Symbols without bars indicate that S.D. is within the 
 
 
A 
 
) after 
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The values of the kinetic parameters of HLPLP and its derived peptides LPLP and 
HLPL after i.v. administration of HLPLP are presented in Table 1. Values of the relevant 
kinetic variables that described absorption and disposition kinetics of HLPLP after oral 
administration are presented in Table 2.  
 
Table 1. Kinetic parameters for peptide HLPLP and its biotransformed peptides LPLP and 
HLPL after a single HLPLP i.v. dose of 4 mg/kg body weight in rats 
      
    
Parametersa    HLPLP  LPLP   HLPL  
   
 
A1 (ng/mL)     189   537   91.8  
A2 (ng/mL)    75.7   141   9.60  
α (1/min)    0.64   0.77   0.90  
β (1/min)    0.09   0.08   0.06  
T1/2α (min)    1.08   0.90   0.77  
T1/2β (min)    7.95   8.38   10.9  
V1 (L/kg )    15.1     -     -  
V2 (L/kg)    15.7     -     -  
Vss (L/kg)    30.8     -     - 
K12 (1/min)    0.25   0.35   0.42  
K21 (1/min)    0.24   0.23   0.14  
K10 (1/min)    0.23   0.28   0.40 
AUC (µg min/L)   1163   2404   253 
MRT (min)    8.95   8.97   9.87  
CL (L/min/kg)               3.41      -     -  
    
 
a Kinetic parameters were calculated from the mean plasma concentration-time curves 
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Table 2. Kinetic parameters for peptide HLPLP after oral administration in rats 
         
Parametersa      Oral dose                                                  
                                  (40 mg/kg body weight) 
B1 (ng/mL)      242     
B2 (ng/mL)     56.9      
B3 (ng/mL)     299 
α (1/min)     0.29   
β (1/min)     0.06 
Ka (1/min)     0.25     
T1/2α (min)     2.38  
T1/2β (min)     11.7 
T1/2a (min)     2.79 
AUC (µg min/L)     603    
F (%)      5.18     
CL (L/min/kg)                  3.41   
Cmax (ng/mL)     20.1 
Tmax (min)     11.8  
 
a Kinetic parameters were calculated from the mean plasma concentration-time curve 
 
DISCUSSION 
The limited information available on the absorption of antihypertensive peptides derived 
from food proteins makes difficult to interpret the functional properties of these bioactive 
peptides and to make an efficacy assessment as a new food supplement. These topics are 
commonly under debate for most functional ingredients. 
Efficacy and safety assessment of many substances are normally extrapolated 
from animal data to humans. Laboratory animals, particularly rodents, are widely used for 
these evaluations. When several factors like differences in species sensitivity are 
considered, kinetic variables are of major importance and should be taken into account in 
extrapolation of laboratory data to humans, since changes in various kinetic parameters 
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are either easily determined experimentally or can be predicted with a reasonable 
accuracy. It is apparent that the principles of pharmacokinetics are indispensable in the 
overall assessment of human health risk.  
 Kinetic characteristics combined with dynamic patterns should be considered in 
the efficacy evaluation of peptide HLPLP. Pre-clinical pharmacokinetic information in 
experimental animals, such as the rat, is essential in designing further pharmacokinetic 
studies in humans which should be applied to the safe and effective use of this bioactive 
peptide.23  
To the best of our knowledge, the present paper is the first report of plasma 
disposition of HLPLP peptide in rats using a selective analytical method in order to 
evaluate its pharmacokinetic profile. The LC-MS determination of the peptide was 
carefully optimized by selecting the parameters and analysis mode providing the highest 
signal-to-noise ratio. The validation parameters used show that the method is reliable and 
sensitive and allow an adequate characterization of the disposition of peptide HLPLP in 
rat plasma. In addition, this analytical method also allowed the identification and the 
quantification of two derived fragments, LPLP and HLPL, from the hydrolysis of HLPLP 
by the action of plasma peptidases. However, the presence of shorter fragments derived 
from the action of plasma peptidases on HLPLP cannot be excluded. The inherent 
limitations of the mass spectrometry techniques to identify small peptides and the 
complexity of the matrix may have impaired detection of shorter fragments.  
 This study reports the kinetics of the peptide HLPLP after a single i.v. (4 mg/kg 
body weight) and oral (40 mg/kg body weight) administration in rats. Plasma disposition 
of HLPLP after i.v. and oral administration in rats as well as the appearance of the 
peptide fragments,  LPLP and HLPL after i.v. administration of HLPLP were best 
described by use of a two-compartment open model. Disappearance of the peptide from 
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plasma was characterized by an initial rapid distribution phase followed by a rapid 
elimination phase. van der Pijl et al.17 reported in pigs that elimination from plasma of the 
proline-rich tripeptides IPP, VPP and LPP, followed a two-compartment decay process 
only for 18 of the 30 observations. Therefore, it was concluded that the pharmacokinetic 
behavior of these peptides in pig can be described with both 1- and 2- compartment 
model, although values for AIC for fitted peptide plasma concentrations after i.v. 
administration were lower using a two-compartment model.17  
 In the present study, after i.v. administration of HLPLP  at 4 mg/kg, the 
distribution phase was rapid (T1/2α = 1.08 min) and with a high value of Vss (30.79 L/kg) 
which suggests that the peptide HLPLP is distributed into extravascular tissues. The 
elimination half-life (T1/2β) calculated after i.v. administration was 7.95 min, much longer 
than that reported in pigs for peptides IPP, LPP or VPP (range T1/2el = 2.5 - 3.1 min).16 
The T1/2β of peptide HLPLP increased from 7.95 min after i.v. to 11.7 min after oral 
administration. This may indicate that the plasma disposition of HLPLP after oral 
administration could be conditioned by the absorption process. 
Peptide HLPLP was extensively biotransformed to peptides LPLP and HLPL in 
rats and, after i.v. administration, represented 206% and 21.8% of the HLPLP plasma 
concentrations, respectively, as calculated by the ratio between the AUC for LPLP or 
HLPL and AUC for HLPLP.  This suggests that these biotransformed peptides might 
contribute to the physiological activity of the peptide. At this respect, further experiments 
aiming the evaluation of the activity of these derived peptides are already in progress.  
When orally administered, HLPLP was rapidly absorbed through the 
gastrointestinal tract in rats, as reflects a T1/2a of 2.79 min. This T1/2a is comparable to that 
previously obtained in pigs for the tripeptides IPP, LPP and VPP, where after a single 
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oral dose of 4 mg/kg body weight, the absorption half-life ranged from 2.0 to 4.6 min.17 
The absorption rate of the peptide HLPLP was low with a Cmax of 20.1 ng/mL at 11.8 min 
(Tmax) after oral dose of 40 mg/kg body weight. However, it has to be highlighted that, as 
shown after i.v. administration, HLPLP is rapidly hydrolysed by plasma peptidases into 
smaller fragments but they were not considered to calculate the absorption rate. In 
addition, it is hypothesized that other smaller fragments, tri-and di-peptides, might be 
released by the action of the peptidases, and due to the rapid degradation of the peptide, 
the effective absorption is underestimated. Nevertheless, the oral bioavailability found for 
HLPLP (5.18%) in rats was higher than that estimated for peptides IPP, LPP and VPP in 
pigs, for which approximately 0.059 - 0.077% of the dose was absorbed.17 Probably, the 
low bioavailability of HLPLP observed in the present study could be due to first-pass 
effect (metabolism in gastrointestinal tract or liver before reaching systemic 
circulation.24,25 However, the absolute bioavailability of 5.18% after oral administration 
of the peptide HLPLP which is not high for a small organic molecule, it is a valuable data 
for a peptide, given that they are subjected to extensive metabolism by peptidases before, 
during and after the absorption process. The bioavailability of a chemical compound is a 
prime consideration in formulation approaches, especially when attempting to increase 
bioavailability through physicochemical and technical manipulations in regard of the 
dosage form. Further studies in this concern should be conducted.  
 In summary, the present study indicates that when orally given, peptide HLPLP is 
absorbed and distributed throughout the body by the blood stream. The kinetic 
characteristics of peptide HLPLP identified in this study warrant further research on 
possible new ways of supplementation in food to increase its absorption and time of 
exposure. The present pharmacokinetic information in rats can play an important role 
designing future kinetic studies in humans for assessing HLPLP dose-response 
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relationship. In addition, this work reports an accurate analytical method for the 
determination of HLPLP, which also allowed the identification and quantification of 
some derived peptide-fragments. Although the peptapeptide reaches the blood stream, its 
rapid degradation in plasma affects the estimation of the kinetic parameters. This study 
raises as well the question about the final active form of dietary compounds, and 
specifically of dietary peptides, in the organism. 
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ABSTRACT 
Recently, the intact absorption of β-casein f(133-138), HLPLP, into rat blood 
circulation after oral administration has been demonstrated and several derived 
fragments were detected after both, intravenous and oral administration. In this 
study, an incubation of the penta-peptide in rat plasma was performed and the 
peptide fragments generated by plasmatic peptidases (HLPL, LPLP and HLP) 
were detected and quantified by using ultra-high performance liquid 
chromatography (UPLC) coupled on line to a Quadrupole-time-of-flight (Q-TOF). 
The tetra peptides (HLPL and LPLP) and the tri-peptide HLP were generated 
within seconds of incubation and were detected up to 60 min (HLPL), 120 min 
(LPLP) and 240 min (HLP). These peptide fragments and other two possible 
fragments (LPL and PLP) were chemically synthesized and administered to SHR 
to assess their antihypertensive activity. The ability to inhibit the angiotensin-
converting-enzyme (ACE) was assessed on aortic rings by measuring the 
response to angiotensin I in presence of each peptide. All peptides showed 
potent antihypertensive activity and inhibition of vascular contraction elicited by 
angiotensin I. 
 
Keywords: antihypertensive peptides, in vitro incubation, plasma metabolism, 
peptide fragments, tandem mass spectrometry, SHR.  
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1.  Introduction 
In recent years, the evaluation of changes that bioactive peptides undergo 
in the organism after ingestion has gained importance, since these modifications 
determine their fate and further health effect. Among these changes, 
gastrointestinal digestion and subsequent phenomena such absorption, 
distribution, metabolism and elimination (ADME) play a key role in the evaluation 
of bioactivity of peptides. During gastrointestinal digestion, food peptides can 
resist or can undergo hydrolysis, and this may cause a loss of their activity or, on 
the contrary, the release of the active sequence. For instance, the active form of 
the peptide β-casein f(169-175) is generated after losing the C-terminal 
glutamine residue during digestion (Maeno et al., 1996). Several antihypertensive 
peptides from an egg white peptic hydrolysate, such as RADHPFL and 
YAEERYPIL are degraded when subjected to simulated gastrointestinal 
digestion, giving rise to smaller active peptides, such as, RADHP and YPI 
(Miguel et al., 2006). Once the stability of peptides to digestion is ensured, 
bioavailability studies need to be conducted, in order to determine the 
accessibility of potential biologically active peptides in the organism (Sánchez-
Rivera et al., 2014). In this regard, mass spectrometry (MS)-based techniques 
have permitted the development of sensitive methods to detect and quantify 
small changes of peptides in plasma samples, reaching detection limits in the 
picogram range (van Platerink et al., 2006). These sensitive MS-based methods 
have been employed to detect bioactive peptides, such as casein-derived peptide 
IPP, in plasma of humans who ingested a peptide-enriched beverage containing 
this peptide (Foltz, et al., 2007). Likewise, Matsui et al. (2002) reported the 
presence of the bioactive dipeptide VY, from sardine muscle, in blood circulation 
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of humans after ingestion of a drink that contained VY. Van der Pijl et al. (2008) 
conducted a pharmacokinetic study to determine the peptides IPP, LPP and VPP 
in plasma of pigs after intravenous or intragastric administration thereof. 
Moreover, having evaluated the changes through digestion and the 
absorption of peptides, the assessment of the peptide stability to plasma 
peptidases plays an important role on the exhibition of its antihypertensive effect. 
In this regard, some peptides, such as IVY, have been incubated in plasma with 
the aim of studying their metabolism, being hydrolysed by plasma peptidases to 
give rise to the active di-peptide VY (Matsui et al., 2000). Other authors studied 
the metabolism and distribution of tri-peptides (VPP and IPP) in aorta, lung, 
kidney, heart and brain of rats fed sour milk containing these peptides. They 
reported the presence of the intact tri-peptides in abdominal aorta (Masuda et al., 
1996). 
Previous studies of our group demonstrated that certain strains of 
Enterococcus faecalis were able to produce fermented milk that caused a 
decrease in systolic blood pressure (SBP) after its single oral administration to 
SHR (Muguerza et al., 2006), and after long-term intake (Miguel et al., 2005). 
The peptide LHLPLP, f(133-138) from β-casein, was one of the sequences that 
most contributed to the biological effect caused by the fermented milk, and its 
isolated form exerted ACE-inhibitory and antihypertensive activity (Quirós et al., 
2007). This sequence was reported to be resistant to gastrointestinal digestion 
(Quirós et al., 2009). However, it was partly degraded by brush border enzymes 
when incubated with Caco-2 cells, releasing the peptide HLPLP, f(134-138), 
which underwent epithelial transport across the Caco-2 cell monolayer (Quirós et 
al., 2008). Recently, the intact absorption of β-casein f(133-138), HLPLP, into rat 
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blood circulation after oral administration thereof at a single dose of 40 mg/kg 
body weight has been demonstrated (Sánchez-Rivera et al., 2015). In this study, 
several derived fragments were detected after both, intravenous and oral 
administration of the penta-peptide HLPLP. However, whether the derived 
fragments released in plasma could retain any biological activity remains to be 
demonstrated. 
The aim of this study is to identify if the peptide fragments derived from the 
action of plasmatic peptidases on HLPLP can exert in vivo antihypertensive 
activity. For this purpose, the peptide fragments generated during peptide 
incubation of the peptide in rat plasma were identified by ultra-high performance 
liquid chromatography (UPLC) coupled on line to a quadrupole-time-of-flight (Q-
TOF) analyser. Identified fragments were chemically synthesized and their 
antihypertensive effect was evaluated on spontaneously hypertensive rats (SHR) 
after single oral administration. The ability to inhibit ECA, as a possible 
mechanism of action, was also assessed in isolated aortic rings. 
2.  Materials and methods 
2.1 Peptide synthesis and standard solution preparation 
Peptides were synthesized in-house by conventional fluorenyl-methoxy-
carbonyl chloride (fmoc) solid-phase method, using a 431A peptide synthesizer 
(Applied Biosystems Inc. Überlingen, Germany). The synthesized peptides 
corresponded to β-casein sequences: HLPLP f(134-138), HLPL, f(134-137), 
HLP, f(134-136), LPLP, f(135-138), and LPL, f(135-137). Peptide PLP, β-casein 
f(136-138), was purchased from SynPeptide CO, LDT (Shanghai, China). Their 
purities were above 93%, calculated by RP-HPLC-UV-MS. All other chemicals 
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were of the highest quality grade. To prepare the standard curve of HLPLP, 
HLPL, LPLP and HLP in plasma, the synthetic peptide diluted in Milli-Q water 
was added to plasma to reach peptide concentration from 2.5 ng mL-1 to 20 µg 
mL-1 and treated as described by Sánchez-Rivera et al. (2015).  
2.2 Incubation of peptide β-casein f(134-138) in rat plasma 
The peptide HLPLP, β-casein f(134-138) was incubated in rat control 
plasma obtained from female Wistar rats (250-300 g). The rats were 
anaesthetized using pentobarbital at intraperitoneal dose of 60 mg kg-1 body 
weight and the blood was extracted by cardiac puncture (5 mL per rat), with 5 mL 
23G syringe. The blood was introduced in a lithium-heparin 9 mL tube, and 
centrifuged at 3600 rpm for 20 min at 4 ºC. The supernatant was collected and 
freezed at -20 ºC until use. Plasma was mixed 5:1 with the peptide aqueous 
solution to reach a final concentration of 0.06 mg mL-1. This mixture was kept at 
37 ºC during the experiment in a thermally controlled water bath (AQUAline 
AL25, LAUDA WOBSER, GmbH & Co., Postfach, Germany). Sampling was done 
at 5, 30, 60, 120 and 240 min after peptide addition to the plasma, and also an 
aliquot was taken just after the peptide was spiked in plasma and vortexed for 10 
seconds (T0). The incubation was stopped using TFA (10%, v/v) and the plasma 
samples were treated as described by Sánchez-Rivera et al. (2015).    
 
 
 
2.3 UPLC-Q-TOF analyses 
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The analyses of the plasma samples were performed on an UPLC from 
Waters (Milford, MA, USA), coupled to a MicroTOF-QII instrument (Bruker 
Daltonik, Germany). These analyses were carried out as described by Sánchez-
Rivera et al. (2015) with some modifications. The pseudo-selected ion monitoring 
(SRM) method was set up to fragment the following parent ions, with mass-to-
charge ratio (m/z) of 576.343, 439.284, 479.290, 366.206, 342.231, and 326.200, 
which corresponded to the sequences HLPLP, LPLP, HLPL, HLP, LPL and PLP, 
respectively. The amount of peptide fragments at different incubation times was 
estimated by the extraction of the corresponding molecular ions (m/z). Blank 
plasma was previously analyzed to confirm that there were no such fragments 
naturally present in plasma before these experiments. 
2.4 Pharmacological activity assays. 
All the animal trials were carried out according to the European Union 
guidelines for the ethical care and use of laboratory animals (European Directive 
2010/63/EU). 12 to15- week old SHR were purchased from Elevage Janvier (Le 
Genest, Saint Isle, France). The animals were housed in groups of three rats and 
kept at 23 ºC with 12 h light/dark cycles in the Animal Experimentation Service of 
Salamanca University (NPAE SA001). Standard food (Global Diet 2014, Harlan, 
France) and water were available ad libitum. The synthesized peptides dissolved 
in ultrapure water were orally administered using an esophageal cannula, at a 
single dose of 7 mg kg-1 body weight and the control group received the same 
volume of water. The animals were deprived of solid food diet 12 h before 
experiments, only having access to sucrose (80 g L-1) and NaCl (2 g L-1) solution. 
The systolic blood pressure (SBP) were measured as previously described 
(Sánchez et al., 2011), using the CODA tail-cuff blood pressure system (Kent 
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Scientific, Torrington, CT, USA). The measurement of SBP was performed before 
peptide administration to estimate the basal blood pressure, and after 
administration thereof at 2, 4, 6, 8 and 24 h. 
On the other hand, isolated thoracic aorta rings were mounted in organ bath with 
Krebs solution at 37 ºC aerated with carbogen as described elsewhere (Sánchez 
et al. 2011). After an equilibration period for 1 h at a resting tension of 2 g, the 
functionality of the rings was tested with a 120 mM solution of KCl. After that, 
rings were incubated with different peptides (HLPLP, LPLP, HLPL or HLP) at a 
dose of 10-4 M, for 30 min, and the contractile response to Ang I (10-7 M) was 
evaluated. Captopril (10-6 M) was used as positive control. 
2.5 Statistical analysis 
The mean values are expressed with the standard error of mean (SEM). The 
effect of each administered peptide over time and versus the control (water) was 
recorded. Two-way analysis of variance (ANOVA), using GraphPad Prism 5.0 
(GraphPad software Inc., San Diego, USA) was performed. Bonferroni post-test 
was applied to establish the significant differences between the peptides and the 
control. Responses to Ang I were expressed as mg of contraction and statistical 
analysis was made using one way ANOVA comparing responses to Ang I in 
absence and presence of the peptides during the incubation period. Differences 
were considered significant at p≤0.05. 
 
3. Results 
3.1 Hydrolysis of β-casein f(133-138), HLPLP, by plasma peptidases 
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To evaluate the resistance of β-casein f(133-138) HLPLP to plasma 
peptidases over time and to identify the formation of derived fragments, the 
penta-peptide was incubated in plasma for 4 h. A slight disappearance was 
observed from time zero to 5 min (Figure 1a); although from this point to 30 min, 
6-fold decrease was observed. Then, plasma peptidases caused a pronounced 
depletion on its concentration from 30 to 60 min of incubation (10 fold decrease, 
from 0.9 to 0.09 µM). Nevertheless, the peptide was detected until 240 min. The 
formation of all possible tetra- and tri-peptides was monitored by pseudo-SRM 
and three derived fragments could be identified and quantified during incubation 
in plasma, i.e., LPLP, HLPL and HLP. The release of the peptide fragments 
occurred rapidly and the two tetra-peptides, HLPL (Figure 1b) and LPLP (Figure 
1c) were detected at the first sample withdrawn from the incubation (time zero). 
These tetra-peptides suffered a decrease from 5 to 30 min. The first one, only 
resisted during 60 min of incubation, however the latter one, could be identified 
up to 120 min. The tri-peptide HLP (figure 1 d) was also detected at time zero, 
and increased significantly during the first 5 min of incubation in plasma, keeping 
a rising trend until 60 min; to finally suffer a pronounced decrease, but this 
fragment was detected until 240 min. 
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Figure 1. Concentrations (µM) of the peptides HLPLP (a), HLPL (b), LPLP (c) and HLP (d) 
identified during the incubation of the penta-peptide in plasma. Mean values ± SEM (n=3).  
 
3.2 Evaluation of the antihypertensive activity 
In order to assess the antihypertensive activity of the fragments released 
during plasma incubation of HLPLP, these chemically synthesized peptides were 
orally administered to SHR. Despite the tri-peptides LPL and PLP were not found 
during the in vitro incubation in plasma, their antihypertensive effect was also 
tested in SHR because their in vivo release cannot be excluded. Figure 2 shows 
the antihypertensive effect of the different β-casein peptides, orally administered 
to SHR at a single dose of 7 mg Kg-1 body weight. The administration of HLPLP 
and its derived peptide fragments led to different behaviours in regard to the 
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trend of SBP decrease. The parent peptide, HLPLP, (Figure 2a), showed a 
maximum decrease on SPB at 2 h post-administration (21.1 ± 3.4 mmHg). 
Subsequent recovery occurred from this point. However, the two tetra–peptides, 
HLPL and LPLP (Figures 2b and 2c) caused reduction on SBP that reached its 
maximum 4 h after administration (19.4 ± 3.8, and 16.2 ± 3.8 mmHg, 
respectively). The administration of the tri-peptides HLP, LPL and PLP to SHR 
led to a delay on the decrease of SBP compared to the previous ones. In the 
case of the tri-peptides HLP and LPL, 6 h were needed to reach a maximum 
peak of SBP reduction (15.2 ± 1.4 and 22.0 ± 2.5 mmHg, respectively). Finally, 
the administration of PLP induced the most effective SBP decrease in terms of 
endurance. This peptide caused a gradual drop of SBP values that reached its 
maximum at 8 h post-administration (21.2 ± 3.4 mmHg). The long-lasting effect of 
this peptide, led to a slow rate of recovery. At 24 h, significant differences on the 
reduction of SBP could be still observed.  
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Figure 2. SBP decrease (∆) caused in SHR after administration of water (*), HLPLP (a), HLPL 
(b), LPLP (c), HLP (d), LPL (e) and PLP (f). Mean values ± SEM (n=5-6) are represented. 
Statistical differences were found at p≤0.05 (*), p≤0.01 (**) and p≤ 0.001(***). 
 
To investigate whether the antihypertensive activity of these peptide could 
be due to ACE inhibition, the response of angiotensin I in isolated aortic rings 
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to Angiotensin-I (780 +/- 100 mg) was significantly reduced in the 
presence of the peptides tested at 10-4 M dose. The highest reduction (44%) was 
achieved with HLPLP, but no significant differences were observed among all 
tested peptides. This reduction was much more efficient with the ACE inhibitor 
captopril (82%, at 10-6 M dose). 
 
 
 
 
 
 
 
 
4. Discussion 
Most studies on food-derived antihypertensive peptides associate the orally 
administered sequence with a given effect, although it is known that peptides are 
going to suffer further hydrolysis during digestion, absorption and, if they reach 
circulation, they could be further degraded by plasmatic peptidases. The region 
from β-casein f(133-138) has been shown to be especially resistant to digestion 
and related fragments have been found by us and others after simulated 
gastrointestinal digestion of dairy products (Dupont et al., 2010; Gómez-Ruiz et 
al., 2004; Hernández-Ledesma et al., 2004; Sánchez-Rivera et al., 2014b) or 
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even in human jejunal aspirates (Boutrou et al., 2013). This hexa-peptide was 
hydrolyzed, by the action of the brush-border peptidases, into the penta-peptide 
HLPLP, and in this form was rapidly transported across a Caco-2 cell monolayer 
(Quirós et al., 2008). Recently, the absorption of this penta-peptide in rats and 
the kinetic parameters of absorption and elimination have revealed that HLPLP is 
rapidly absorbed although the oral bioavailability (5.18%), calculated on the basis 
of HLPLP concentration in plasma, was found to be low. Interestingly, it was 
observed that this penta-peptide was further hydrolyzed into smaller fragments in 
vivo but it remained to ascertain if these derived fragments could retain 
antihypertensive activity. 
In this work, the in vitro incubation of the penta-peptide in rat plasma 
resulted in the identification of two tetra-peptides and one tri-peptide, LPLP, 
HLPL and HLP. The increase in concentration undergone by the latter peptide 
from 5 to 60 min coincides with the decrease monitored for HLPL and HLPLP. 
These results could indicate the formation of the tri-peptide from both the penta- 
and tetra-peptide, by the action of plasma peptidases. In addition, the 
concentration calculated for HLPL is much lower than that of LPLP and HLP, 
suggesting that HLPL could be extensively hydrolyzed into HLP. The initial 
concentration of HLPLP detected in plasma was under the expected value, 
probably due to its fast degradation in favour of its derived fragments. A similar 
case was the rapid degradation by plasma peptidases undergone by Lactokinin 
[β-lactoglobulin f(142-148)] during its in vitro incubation in human serum (Walsh 
et al., 2004). The concentrations of LPLP and HLP were higher than that of the 
precursor peptide (6 and 5-fold, respectively), showing the rapid and extensive 
hydrolysis of the penta-peptide into smaller peptide fragments even a few 
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seconds after incubation (time zero). This is consistent with the degradation of 
Angiotensin II within seconds in plasma (Moskowitz, 2003). Thus, the formation 
of other peptide fragments cannot be excluded during the incubation of HLPLP in 
plasma. Undoubtedly, there is an inherent limitation of mass spectrometry 
techniques to identify short peptides, which could have impaired the identification 
of other derived fragments. Two of the peptide fragments (LPLP and HLPL) 
identified in this study during in vitro incubation of the penta-peptide are 
coincident with those recently reported after the oral and intravenous 
administration of HLPLP in rats (Sánchez-Rivera et al., 2015). Although these 
results are obtained in rat plasma, similar degradation could be expected in 
humans. In this regard, Matsui et al. (2000) reported the same degradation 
products of the peptide IVY, the smaller peptide fragments VY and Y, during its 
incubation in rat and human plasma although the parent peptide disappeared 
faster in human plasma.  
Despite the tri-peptides LPL and PLP were not found during HLPLP 
incubation in plasma, the antihypertensive activity was also tested in SHR since 
their presence cannot be excluded. Probably, as demonstrated for the peptide 
LHLPLP (Quirós et al., 2009), the tested peptides survive gastrointestinal 
digestion due to the presence of Pro residues, which confer resistance to 
digestive enzymes (Haush et al., 2002; Vanhoof et al., 1995). This resistance 
could guarantee the arrival of the undegraded peptide to small intestine, 
concretely duodenum and upper jejunum, where the absorption mainly takes 
place (Langerholc et al., 2011); or where they might interact with receptors at the 
gut.  From our results, it was surprising that, after oral administration, the shorter 
the peptide, the longer it took to reach the maximum SBP decrease. Likewise, 
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other tri-peptides, such as, IPP showed its maximum decrease on SBP at 8 h 
post-administration to SHR (Nakamura et al., 1995). The delay found on the 
antihypertensive effect after the administration of the tri-peptides (LPL, PLP and 
HLP) was also similar to that observed for other short peptide fragments from αs1-
casein, RYLG f(90-93) and RY f(90-91) with regard to the parent peptide 
(Contreras et al., 2013).  In our previous report, it was found that HLPLP is 
rapidly absorbed, with absorption half-time (T1/2a) of 2.79 min and time to reach 
the maximum concentration (Tmax) of 11.8 min (Sánchez-Rivera et al., 2015). In 
the present work the time of maximum SBP decrease was found at 2 h. Likely, 
these parameters have been described for the tri-peptides VPP and IPP in a pig 
model (T1/2a 4.6 min; Tmax 8.9 min and T1/2a 3.3 min; Tmax 8.6 min, respectively), 
and the absorption time was similar to that of HLPLP, although the Tmax was 
shorter for these two tri-peptides (van der Pijl et al., 2008). In spite of achieving 
the maximum concentration in plasma faster than HLPLP, these tri-peptides 
caused a maximum decrease on SBP in SHR at 4 and 8 h post-administration, 
respectively (Nakamura et al., 1995). These results suggest that there is a 
discrepancy between the parameters calculated for the absorption of peptides 
and the subsequent biological effect observed after administration. Activity of 
peptides may be affected by their further metabolism, once they reach circulation, 
as it could be the case of HLPLP. Hence, these results point out the importance 
of the pharmacokinetic studies focused on absorption and further metabolism of 
peptides.  
In view of the results obtained on aortic rings, we can say that the 
antihypertensive effect of peptide HLPLP and those produced by the action of 
plasma peptidases is due, at least in part, to its ability to inhibit ACE. These 
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results are consistent with previous works published by our group where the 
precursor peptide of HLPLP i.e LHLPLP, β-casein f(133-138), showed 
antihypertensive activity and inhibited ACE activity in vitro (IC50 5.4 uM) (Quirós 
et al., 2007). Similarly, IPP and VPP have been reported as ACE inhibitors in 
vitro with an IC50 value at micromolar level (Nakamura et al., 1995). In addition, 
these tri-peptides have also shown ACE-inhibitoty activity in mesenteric rings 
after 24h of incubation with the tri-peptides (Jäkala et al., 2009). Furthermore, 
other peptide fragments (LPLP) identified after incubation of the penta-peptide 
possess favourable structural features for ACE binding, such as the proline 
residue at C-terminal end and at the antepenultimate position of the sequence 
(Cheung et al., 1980; Rohrbach et al., 1981). 
In addition, our results after oral administration, and especially the finding of 
the potent tri-peptide PLP, have allowed the identification of novel active β-casein 
tri-peptides, which could be produced by fermentation or hydrolysis with food-
grade enzymes. The structure of PLP is favourable to bind and inhibit ACE, due 
to the presence of two proline residues, although further assays are needed to 
confirm this fact (Cheung et al., 1980; Rohrbach et al., 1981). 
 
4.  Conclusions 
The incubation of the antihypertensive peptide β-casein f(134-138) HLPLP 
in rat plasma permitted the identification of several derived fragments (HLPL, 
LPLP and HLP), which are physiologically relevant in regard to the 
antihypertensive effect. Some of them, such f(134-136) HLP could be detected 
until 240 min of incubation time. All possible peptide-fragments derived from 
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HLPLP retained antihypertensive activity when orally administered to SHR. From 
all the peptide fragments, the tri-peptide PLP showed the longest lasting 
antihypertensive effect which was significant up to 24 h after administration. The 
incubation in plasma of HLPLP, which was known to be absorbed intact into 
circulation, was a good in vitro approach of its further degradation by plasmatic 
peptidases. Indeed, the in vitro incubation was in accordance to the peptide 
fragments found after intravenous and oral administration of HLPLP to rats. 
These results could play an important role in the overall physiological effect of the 
penta-peptide HLPLP. Inhibition of ACE is involved in the mechanism of 
antihypertensive action of these peptides, although further studies should be 
conducted to explore other possible mechanisms involved. 
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ABSTRACT 
The antihypertensive activity of three αs1-casein-derived peptides and a casein 
hydrolysate containing these sequences was evaluated in the presence of 
naloxone. The activity of the casein hydrolysate was reverted by this opioid 
antagonist at 2, 4 and 6 h post-administration. Similarly, the antihypertensive 
effect of peptides RYLGY and AYFYPEL, [αs1-casein f(90-94) and f(143-149), 
respectively] was antagonized by the co-administration of naloxone. However, 
the decrease of the systolic blood pressure caused by YFYPEL αs1-casein f(91-
94) was not significantly modified by naloxone. Peptidomic analysis of the active 
hydrolysate and a simulated gastrointestinal digest of the precursor casein 
revealed some differences that may explain the different in vivo effect on systolic 
blood pressure. Altogether, these results revealed that the activity of peptides 
from αs1-casein, f(90-94) and f(143-149), and the effect of the casein hydrolysate 
is mediated by interaction with opioid receptors. 
 
Keywords: naloxone, antihypertensive peptides, opioid receptors, casein 
hydrolysate, SHR 
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1.  Introduction 
Among bioactive peptides derived from food, antihypertensive peptides are 
undoubtedly the group from which more information is available (Jäkala & 
Vapaatalo, 2010; Hernández-Ledesma, Contreras, & Recio, 2011). Much work 
has been done to evaluate the in vitro activity of peptides on the angiotensin-I-
converting enzyme (ACE), an enzyme which plays an important role in the 
regulation of blood pressure. However, for many peptides, an important lack of 
correlation has been found between the in vitro ACE-inhibitory activity and the in 
vivo antihypertensive activity. It has been postulated that this discrepancy can be 
due to the further degradation of peptides during gastrointestinal digestion, or 
because other mechanisms different than ACE inhibition may be involved 
(Martínez-Maqueda, Miralles, Recio, & Hernánadez-Ledesma, 2012). There are 
several examples where gastrointestinal digestion leads to an inactive form of the 
peptide (Walsh et al., 2004). On the contrary, several active sequences have 
been found to be resistant to digestion, especially those rich in proline residues 
(Quirós, Contreras, Ramos, Amigo, & Recio, 2009), and in other cases, the 
active form of the peptide is released during digestion (Maeno, Yamamoto, & 
Takano, 1996). 
Regarding the mechanism of action, ACE-inhibition is the mechanism most 
widely studied for food derived peptides. For instance, it has been proved that 
spontaneously hypertensive rats (SHRs) fed a fermented milk containing the tri-
peptides IPP and VPP showed a notable decrease of serum ACE activity (Jäkälä, 
Jauhiainen, Korpela, & Vapaatalo, 2009a; Jäkälä et al., 2009b). Microarray 
analysis showed a significant increase in the endothelial nitric oxide synthase 
(eNOS) gene expression in addition to other genes involved in blood pressure 
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regulation after the administration of these two tri-peptides to SHR for five days 
(Yamaguchi, Kawaguchi, & Yamamoto, 2009). The involvement of opioid 
receptors has been also demonstrated for some antihypertensive food-derived 
peptides, such as, α-lactorphin, [α-La f(50-53)], with sequence YGLF (Nurminen 
et al., 2000). This peptide has been found to lower blood pressure in SHR and 
produce and endothelium-dependent relaxation in mesenteric arteries which was 
reverted by an eNOS inhibitor (Sipola et al., 2002). 
Our group has reported the antihypertensive activity of a peptic casein 
hydrolysate in SHR. Two αs1-casein-derived peptides, f(90-94), RYLGY and 
f(143-149), AYFYPEL, with antihypertensive activity in addition to in vitro 
antioxidant and ACE-inhibitory activity, were identified as the main sequences 
responsible for the antihypertensive effect (Contreras, Carrón, Montero, Ramos, 
& Recio, 2009). These two peptides were partly resistant to gastrointestinal 
enzymes (Contreras et al., 2012) and were transported through intestinal cell 
monolayers, such as, a co-culture of 75/25 Caco-2 and HT29-MTX cells 
(Contreras, Sancho, Recio, & Mills, 2012). The administration of this casein 
hydrolysate for 6 weeks to SHR revealed that not only the development of 
hypertension was attenuated in the treated group of animals, but they showed 
improved aorta and mesenteric acetylcholine relaxations and increased eNOS 
expression in aorta. Treated animals also displayed a decreased left ventricular 
hypertrophy, compared with the control group, which was accompanied by a 
significant decrease in interstitial fibrosis (Sánchez et al., 2011). One of the 
proposed active peptides found in this casein hydrolysate is similar to a 
previously reported opioid peptide, αs1-casein f(90-95), RYLGYL (Loukas, 
Varoucha, Zioudrou, Streaty, & Klee, 1983), and others, such as, AYFYPEL or 
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YFYPEL with two Tyr residues separated by Phe, resemble the proposed 
structural characteristics proposed for exogenous opioid peptides (Meisel, 1997). 
The aim of this work was to evaluate, by the use of an opioid antagonist, if 
the activity of these αs1-casein peptides, and the casein hydrolysate containing 
these, was mediated through the interaction with opioid receptors. In addition, the 
antihypertensive activity of the casein used as substrate for the peptic hydrolysis 
process was evaluated. A peptidomic study was performed to identify main 
differences in the profile of the active hydrolysate and the peptides released 
during casein simulated gastrointestinal digestion. 
 
2. Materials and methods 
2.1 Peptide synthesis and casein hydrolysate preparation 
Peptides from αs1-casein, fragment (f) (90-94), RYLGY, f(143-149), 
AYFYPEL and YFYPEL f(144-419) were synthesized in-house by using the 
method fluorenyl-methoxy-carbonyl chloride (Fmoc) solid-phase. A 431A peptide 
synthesizer (Applied Biosystems Inc. Überlingen, Germany) was employed. Their 
purities were calculated by reversed phase liquid chromatography-UV and mass 
spectrometry. The casein used was a commercial casein product (Promilk-85B 
Casein, Arras Cedex, France). The preparation of the casein hydrolysate 
(Lowpept®) was carried out with food-grade pepsin as previously described by 
Contreras et al. (2009). All other chemicals were obtained from commercial 
sources and of high quality grade.  
2.2. Simulated gastrointestinal digestion 
Results 
 
218 
 
The simulation of gastrointestinal digestion was based on the method 
reported by Martos, Contreras, Molina, and López-Fandiño (2010), with some 
modifications. The gastric step in this work included 2.5 mM of CaCl2, and to stop 
the reaction at the end of the duodenal step, Pefabloc SC (Fluka 76307) was 
used at a final concentration of 1 mM. The casein powder was dissolved in milliQ 
water at 5% (w/v) to start the digestion process at gastric phase. 
 
2.3 Analysis by RP-HPLC-MS/MS 
The casein hydrolysate and the casein subjected to simulated 
gastrointestinal digestion were analyzed by HPLC (Agilent Technologies, 
Waldbronn, Germany) coupled to an ion trap instrument (Esquire 3000, Bruker 
Daltonik GmbH, Bremen, Germany). The analyses and data processing were 
performed as previously described by Sánchez-Rivera et al. (2014). The column 
used was a Mediterranea Sea 18 150 mm × 2.1 mm column (Teknokroma, 
Barcelona, Spain). Solvent A (water/trifluoroacetic acid, 1000:0.37 v/v), and 
solvent B (acetonitrile/trifluoroacetic acid, 1000: 0.27 v/v). A linear gradient was 
used from 0 to 55% of solvent A and 45% of solvent B in 120 min. Spectra were 
acquired at mass/charge (m/z) range of 100-3000. The samples were run at two 
different target mass: m/z of 750 and 1500.  
2.3 Animal assays and experimental design 
All the animal trials were carried out in agreement with the European Union 
guidelines for the ethical care and use of laboratory animals (European Directive 
86/609/CE). SHR aged from the 14th to the 16th-week were purchased from 
Elevage Janvier (Le Genest, Saint Isle, France). The animals were housed in 
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groups of three rats with 12h light/dark cycles and kept at a controlled 
temperature of 23°C. Standard food (Global Diet 201 4, Harlan, France) and 
water were available ad libitum. The synthetic peptides and the casein 
hydrolysate dissolved in pure water, were orally administered to rats by a cannula 
from mouth to stomach, at a single dose of 5 and 300 mg kg-1 body weight, 
respectively. The opioid antagonist, naloxone, was administered by 
subcutaneous injection, just after the administration of the peptide or the 
hydrolysate, at a dose of 10 mg kg-1 body weight. Control trials were performed 
by oral administration of water or casein (same dose as the hydrolysate, on 
protein basis); and by subcutaneous injection of naloxone (10 mg kg-1 body 
weight). The animals were deprived of solid food diet 12 h before experiments. 
During this period they only had access to NaCl (2 g L-1) and sucrose (80 g L-1) 
solution. The systolic blood pressure (SBP) were measured using the CODA tail-
cuff blood pressure system (Kent Scientific, Torrington, CT, USA), as previously 
described by Sánchez et al. (2011). The SBP was measured before each 
experiment to estimate the basal blood pressure. After administration of the 
peptides, hydrolysate, casein or water, the SBP was measured at 2, 4, 6, 8 and 
24 h. However, after the administration of the peptide with naloxone or only 
naloxone (control), the first 6 h post-administration were recorded. 
2.4 Statistical analysis 
The effects of casein hydrolysate, peptides, casein, water or naloxone were 
calculated as changes in SBP (increase or decrease) from the baseline values. 
Data were expressed as the mean values ± standard error of mean (SEM). Two-
way analysis of variance (ANOVA), using GraphPad Prism 5.0 (GraphPad 
software Inc., San Diego, USA) was carried out. A post-test (Bonferroni) was 
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applied to establish the significant differences between the effect of the peptides 
or the hydrolysate vs the controls. Significant differences were considered at 
p≤0.05, p≤0.01 and p≤0.001. 
 
3. Results 
3.1. Antihypertensive activity of the peptic casein hydrolysate, its precursor 
casein and the synthetic peptides. Reversion by naloxone. 
The effect on blood pressure of the casein hydrolysate and the casein used 
as substrate in its production was followed during 24 h after oral administration at 
300 mg kg-1 body weight (Figure 1). Non-hydrolysed casein did not produce a 
significant decrease of the SBP in the animals (p<0.05). The peptic casein 
hydrolysate produced significant SBP decreases vs water at 2, 4, 6 and 8 h post-
administration, with maximum decrease post-administration at 6 h (-14.3 ± 4.6 
mm Hg). The subsequent recovery occurred from 6 to 8 h.  
 
 
 
Results 
 
221 
 
 
Figure 1. Changes in SBP after oral administration of the casein hydrolysate (300mg kg-
1
 body weight) vs administration of water or casein (300mg kg-1 body weight). Data are 
expressed as mean values ± SEM (n=4-6). Significant differences after administration of 
the casein hydrolysate vs water are indicated at P≤ 0.05(*) and P≤ 0.01 (**). Significant 
differences after administration of casein hydrolysate vs the control of casein were found 
at P≤ 0.01 (##).  
 
The casein hydrolysate was also administered together with naloxone, a 
competitive antagonist of opioid receptors, and the antihypertensive effect was 
reverted at 2, 4 and 6 h post-administration (Figure 2A).  
Three peptides, RYLGY, AYFYPEL and YFYPEL, contained in the active 
casein hydrolysate with sequences compatible with that described for 
casomorphins, were synthetized and orally administered to SHR. The three 
synthetic peptides produced a significant decrease in the SBP of the animals at 
all times recorded, i.e., 2, 4, 6 and 8 h (Figure 2 B, C and D). The decrease on 
SBP recorded after the administration of RYLGY and AYFYPEL was similar to 
that previously obtained by Contreras et al. (2009) for these peptides at same 
oral dose. The maximum decrease after the administration of RYLGY (Figure 2A) 
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was at 6 h (-23.8 ± 2.5 mm Hg), for AYFYPEL the maximum was reached at 4 h 
(-21.1 ± 3.2 mm Hg) (Figure 2B), and for YFYPEL the maximum was recorded at 
6 h (-18.8 ± 3.5 mm Hg) (Figure 2D). When naloxone was subcutaneously co-
administered, the antihypertensive effect of RYLGY and AYFYPEL was 
completely reverted at 2, 4 and 6 h post-administration. In the case of RYLGY, at 
8 h, significant differences were still found when co-administered with naloxone. 
However, in the case of YFYPEL, the opioid antagonist did not significantly affect 
the blood depressor effect caused by this peptide at 4 and 6 h. Naloxone alone 
did not exert any effect of the blood pressure of SHRs (Figure 2).  
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Figure 2. Changes in SBP after oral administration of (A) casein hydrolysate (300mg kg-1 body weight), and (B) peptide RYLGY, (C) peptide AYFYPEL and 
(D) peptide YFYPEL (5mg kg-1 body weight), vs co-administration thereof with naloxone or control of naloxone (10mg kg-1 body weight, subcutaneous). Data 
are expressed as mean values ± SEM (n=4-6). Significant differences after administration of the peptide vs the peptide with naloxone at P≤ 0.05(*), P≤ 0.01 
(**) and P≤ 0.001(***). Significant differences after administration of the peptide with naloxone vs the control of naloxone at P≤ 0.05(#), P≤ 0.01 (##) and P≤ 
0.001(###). Significant differences between the administration of the synthetic peptides and water control were at P≤ 0.05(a), P≤ 0.01 (b) and P≤0.001(c). 
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3.2. Peptidome of the casein hydrolysate and the casein gastrointestinal digest. 
The analysis of the peptidomic profile derived from the peptic hydrolysate is 
shown in Table 1. The comparison of the hydrolysate peptide profile with the 
precursor-casein gastrointestinal digest is shown for αs1-casein (Figure 3), since 
the three active peptides belong to this protein. As it can be observed, most 
sequences are not coincident. Among others, the active peptide αs1-casein f(90-
94), RYLGY, could not be found after simulated digestion of casein. On the 
contrary, some common peptides could be identified in both samples i.e. f(25-
31), VAPFPEV,  f(143-149), AYFYPEL, f(144-149), YFYPEL f(165-172), 
YYVPLGTQ, and f(173-179), YTDAPSF (Figure 3).  
 
 
Figure 3. Identified peptides from αs1-casein present in the casein hydrolysate and in the 
precursor-casein digest.  
 
DIKQMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLKKYKVPQLEI
VPNSAEERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAW
YYVPLGTQYTDAPSFSDIPNPIGSENSEKTTMPLW
RPKHPIKHQGLPQEVLNENLLRFFVAPFPEVFGKEKVNELSKDIGSESTEDQAME
Hydrolysate
Casein digest
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Table 1. Identified peptides from casein (CN) hydrolysate. Peptides with favorable 
structural features for opioid receptor binding are highlighted in bold. 
Observed Mass Calculated Mass Range Sequence 
    
β-CN 
   675.300 674.293 1-5 RELEE  
1284.700 1283.693 1-11 RELEELNVPGE  
1300.700 1299.693 59 - 70 VYPFPGPIPNSL  
1320.800 1319.793 81 - 92 PVVVPPFLQPEV  
1451.900 1450.893 81 - 93 PVVVPPFLQPEVM  
1057.600 1056.593 85 - 93 PPFLQPEVM  
746.500 745.493 94 - 100 GVSKVKE  
1244.700 1243.693 94 - 105 GVSKVKEAMAPK  
1473.900 1472.893 128 - 140 TDVENLHLPLPLL  
1587.000 1585.993 127 - 140 LTDVENLHLPLPLL  
1689.000 1687.993 128 - 142 TDVENLHLPLPLLQS  
1472.900 1471.893 130 - 142 VENLHLPLPLLQS  
1372.800 1371.793 129 - 140 DVENLHLPLPLL  
1257.800 1256.793 130 - 140 VENLHLPLPLL  
1698.900 1697.893 143 - 156 WMHQPHQPLPPTVM  
787.400 786.393 157 - 163 FPPQSVL  
748.400 747.393 193 - 198 YQEPVL  
1782.200 1781.193 193 - 208 YQEPVLGPVRGPFPII  
 
 
αs1-CN 
 939.000 1875.985 1-16 RPKHPIKHQGLPQEVL  
662.400 661.393 19 - 23 NLLRF  
1837.100 1836.093 24 - 39 FVAPFPEVFGKEKVNE  
 758.400 757.393 25 - 31 VAPFPEV  
1219.700 1218.693 25 - 35 VAPFPEVFGKE  
1690.000 1688.993 25 - 39 VAPFPEVFGKEKVNE  
671.400 670.393 90 - 94 RYLGY  
 693.500 1384.985 99 - 109 LRLKKYKVPQL  
1003.700 1002.693 102 - 109 KKYKVPQL  
902.400 901.393 143 - 149 AYFYPEL  
 831.400 830.393 144 - 149 YFYPEL  
 710.500 709493,0 149 - 153 LFRQF  
854.500 853.493 151 - 156 RQFYQL  
866.400 865.393 157 - 164 DAYPSGAW  
 517.300 516.293 160 - 164 PSGAW  
940.500 939.493 165 - 172 YYVPLGTQ  
1721.900 1720.893 165 - 179 YYVPLGTQYTDAPSF  
 800.300 799.293 173 - 179 YTDAPSF  
κ-CN 
1422.900 1421.893 18 - 29 FSDKIAKYIPIQ  
1585.900 1584.893 18 - 30 FSDKIAKYIPIQY  
833.400 832.393 43 - 49 YQQKPVA  
946.600 945.593 43 - 50 YQQKPVAL  
1253.700 1252.693 56 - 66 LPYPYYAKPAA  
804.400 803.393 162 - 169 VQVTSTAV  
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Table 1 continue 
 
αs2-CN    
973.500 972.493 89 - 95 YQKFPQY  
888.400 887.393 187 - 193 QKAMKPW  
 
 
4.  Discussion 
The three αs1-casein-derived peptides studied caused a significant 
decrease in SBP of SHR at 2, 4 and 6 h post-administration. To the best of our 
knowledge, this is the first report on the antihypertensive activity of YFYPEL. The 
blood pressure reduction caused by RYLGY, AYFYPEL and the casein 
hydrolysate was antagonized by the co-administration of the opioid antagonist, 
naloxone at all the times studied (Figure 2). The opioid activity of homologous, 
but slightly longer peptides than RYLGY, had been previously reported. 
Concretely, αs1-casein f(90-96), RYLGYLE, showed the most potent opioid 
activity in different bioassays, followed by αs1-casein f(90-95), RYLGYL (Loukas 
et al., 1983). These αs1-casein-derived peptides have been described as, 
moderate in strength, δ-opioid agonists. Some food-derived peptides, for 
instance, α-lactorphin, which is described as a µ-opioid receptor ligand with low 
potency, could produce a decrease in SBP after administration to SHR by 
interaction with opioid receptors (Nurminen et al., 2000). The implication of 
central opioid receptors would be undesirable in these types of food products, 
and in fact, the effect produced by α-lactorphin was not related to central opioid 
receptors (Ijäs et al., 2004). This opioid peptide was also demonstrated to 
improve endothelial function associated to an increase of nitric oxide (Sipola et 
al., 2002). Opioid receptors have been reported to play a role in the heart and 
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cardiovascular system and it has been proposed that a deficiency of the κ-opioid 
receptor may cause hypertension, since this receptor may be a component in the 
central nervous system involved in the regulation of blood pressure (for a review, 
see Pugsley, 2002). Several studies have also indicated the contribution of 
endogenous opioid peptides in the regulation of blood pressure. After i.v. 
administration of µ- and δ- and κ-opioid agonists to stressed rats, the 
involvement of µ- and δ-opioid receptors was demonstrated and they were able 
to reduce blood pressure and heart rate (Sun, Liu, Li, & Ingenito, 1996). 
Endomorphin 2 and its homologous (D[Ala2]-endomorphin 2) endogenous ligands 
for the µ-opioid receptor, decrease heart rate, cardiac output, and total peripheral 
resistance when administered i.v., and these responses were reverted by 
naloxone and were mediated by the release of nitric oxide from the vascular 
endothelium (Champion & Kadowitz, 1998). Similarly, the active casein 
hydrolysate tested in this study had previously demonstrated an improvement of 
endothelial function in aortic and mesenteric rings accompanied by an increase 
of eNOS expression in aorta (Sánchez et al., 2011). In the same study, the 
animals fed with the hydrolysate had a significant reduction of left ventricle weight 
(compared with the control group) and a significant decrease in collagen 
deposition measured in left ventricle. Receptor binding studies in the heart, have 
confirmed the existence of the δ-opioid receptor (Krumins, Faden, & Feuerstein, 
1985; Ventura, Bastagli, Bernardi, Caldarera, & Guarnieri, 1989), although the 
distribution of the δ-opioid receptor in the rat heart favors atrial tissue and the 
right side of the heart more than the left side of the heart (Barron, 1999).  
In the case of peptide AYFYPEL, naloxone antagonized the effect of this 
peptide on SBP. Naloxone is a non-selective opioid antagonist with slightly higher 
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affinity for µ-opioid receptors and with lower affinity for κ- and δ-opioid receptors. 
The common structural features between endogenous and exogenous opioid 
peptides are the presence of Tyr at N-terminal end and Phe or Tyr at third or 
fourth position, except for α-casein opioids, which contain an Arg as N-terminal 
residue (Meisel, 1997). In spite of the structural similarities between AYFYPEL 
and its related peptide, YFYPEL, which possesses the favorable features for 
opioid receptor binding, naloxone did not significantly affect the antihypertensive 
effect of the latter one. Although, to the best of our knowledge, the presence of 
Ala at N-terminal has not been reported as a favorable feature for opioid receptor 
binding, in this case it seemed to be crucial for the activity of AYFYPEL, and 
indeed, the absence of antagonism for YFYPEL.  
In addition, RYLGY and AYFYPEL were also found to have potent in vitro 
ACE-inhibitory activity (IC50 values of 0.71 µM ± 0.08 and 6.58 µM ± 0.50, 
respectively) and antioxidant activity (2.829 and 3.216 µmol equiv Trolox µmol-1 
peptide, respectively, determined by the method of oxygen radical absorbance 
capacity) (Contreras et al., 2009). The contribution of the ACE-inhibitory activity 
of food derived peptides has been extensively studied (Ricci-Cabello, Herrera, & 
Artacho, 2012; Korhonen, 2009). Moreover, it has been proposed the beneficial 
effects of food antioxidants in hypertension and cardiovascular disease (Schiffrin, 
2010). For instance, some studies have revealed that antioxidant vitamins reduce 
blood pressure and arterial stiffness in patients with diabetes (Mullan, Young, 
Fee, & McCance, 2002). In any case, although further studies focused on the 
contribution of other potential mechanisms are already in progress, our results 
demonstrated that the two previously identified active peptides (RYLGY and 
AYFYPEL) in the hydrolysate exert their effect mediated by the opioid system. 
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According to our results, the antihypertensive activity of YFYPEL did not seem to 
involve opioid receptors. The mechanism of action of this new antihypertensive 
peptide deserves further investigations. Under our trial conditions the activity of 
the hydrolysate is mediated by interaction with opioid receptors in a naloxone-
antagonizable manner. This would suggest that the contribution of the opioid 
mechanism in its activity is predominant over other pathways. 
Since the precursor casein of the hydrolysate showed no antihypertensive 
activity compared with the hydrolysate, a peptidomic analysis thereof and the 
precursor-casein digest was performed in order to understand the different 
behaviour. Some differences were revealed. Interestingly, αs1-casein f(90-94), 
RYLGY, present in the peptic casein hydrolysate, was not found after 
gastrointestinal digestion of the precursor casein, as revealed by the peptidomic 
analysis. On the contrary, peptides αs1-casein f(143-149), AYFYPEL, and αs1-
casein f(144-149), YFYPEL, were found in both samples among others [f(25-31), 
f(173-179) and f(165-172)]. Moreover, AYFYPEL had been previously found in 
calves’ stomach content after ingestion of whole casein (Yvon & Pelissier, 1987), 
and in human gastric effluents after ingestion of milk, although not in duodenum 
(Chabance et al., 1998). In this latter study, YFYPEL was found in duodenal 
effluents. In any case, this study confirms the antihypertensive activity of 
AYFYPEL, and reports for the first time that of YFYPEL after their individual oral 
administration to SHR, although the mechanism involved in the effect produced 
by the latter one deserves future investigations. Thus, the possible matrix effect 
and the synergism between peptides in the overall activity of the hydrolysate 
should not be discarded. 
Results 
 
230 
 
The peptidomic study of the casein-simulated gastrointestinal digest and the 
active hydrolysate showed that although the casein hydrolysate is produced by 
pepsin, a gastric enzyme, the nature of the peptides or their concentration within 
the hydrolysate is different than that generated during gastrointestinal digestion. 
These differences, between casein and the hydrolysate, are sufficient to elicit or 
not an antihypertensive effect when orally administered to SHR at the same 
dose.  
 
4. Conclusions 
These results provided evidence of involvement of the opioid receptors on 
the antihypertensive activity of a peptic casein hydrolysate. This suggested that 
several peptides present in this hydrolysate could exert antihypertensive activity 
related to the opioid system. The results obtained for peptide RYLGY and 
AYFYPEL showed that the opioid system is involved on their antihypertensive 
effect. In the case of YFYPEL, although its effect is mediated by other 
mechanism of action since there was no evidence of such implication under our 
trial conditions, the present work represents the first report on the 
antihypertensive activity of this peptide. In this respect, the involvement of other 
mechanisms of action deserves future investigations. In addition, the casein 
hydrolysate produced a significant decrease in SBP, while the precursor casein 
administered at the same dose did not. The peptidomic study showed that 
although there are similarities between the casein digest and the casein 
hydrolysate, the appearance of certain peptides under these conditions of 
hydrolysis with food-grade pepsin would explain the difference in activity. 
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In the last years, the effect of the in vivo processes undergone by the food 
components in the organism once ingested has been increasingly pointed out, since 
the resulting products may have subsequent health implications. In addition, the 
production of active sequences within food matrices has been widely studied by using 
enzymatic hydrolysis or fermentation with acid lactic bacteria. Part of the work included 
in this thesis is related to the analysis of food matrices by the application of peptidomic 
techniques targeted at active peptides or untargeted. In this regard, peptidomics was 
applied to the characterisation of casein hydrolysates produced by different strains of 
yeasts, focused on certain antihypertensive sequences (chapter I). Furthermore, the 
whole peptide profile of cheeses where different packaging technologies have been 
used, and its evolution during storage time, was studied in chapter II. Subsequently, 
the changes of milk proteins during gastrointestinal digestion and the generation of 
peptides through this process, focusing on bioactive sequences were evaluated in this 
thesis (chapter III and IV). In chapter III, the influence of the proteolytic state of two 
dairy matrices on the release of peptides during digestion was assessed. Likely, food 
processing, such as heat treatment, can affect the behavior of proteins and the 
formation of peptides through digestion, as shown in chapter IV. Moreover, in 
publication V the oral bioavailability and the pharmacokinetic parameters of an 
antihypertensive peptide derived from β-casein, f(134-138), have been estimated in a 
rat model. In this study, several fragments derived from metabolism of this peptide 
were detected in plasma. In order to confirm the possible derived fragments generated 
from this β-casein sequence, in vitro incubation of the synthetic peptide in plasma was 
performed, and the antihypertensive activity of the identified derived fragments was 
assayed (chapter VI). Finally, the involvement of the opioid system in the 
antihypertensive activity of a peptic casein hydrolysate produced by food-grade pepsin 
and three of its main peptides was evaluated in chapter VII.  
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3.1 Application of a peptidomic tools to the identification of peptides during 
production, shelf-life of the product and changes during digestion. 
Fermentation and enzymatic hydrolysis with food-grade enzymes has been 
widely used to produce bioactive peptides in dairy matrices. For instance, the 
antihypertensive sequences RYLGY and AYFYPEL from αs1-casein f(90-94) and f(143-
419), respectively, were previously identified by our group as two of the main peptides 
present in a casein hydrolysate produced with food-grade pepsin (Contreras et al., 
2009). Similarly, the group also identified the antihypertensive peptide f(133-138), 
LHLPLP, as one of the major peptides in fermented milk produced by Enterococcus 
faecalis (Quirós et al., 2007). However, the pathogenic risks of Enterococcus genus 
strains may limit their use in the food industry (Franz et al., 1999; Ogier & Serror, 
2008). Thus, an optimisation of enzymatic hydrolysis for the production of HLPLP was 
carried out (Quirós et al., 2012), since this penta-peptide was also shown to exert an  
antihypertensive effect, and it was released by the action of brush border enzymes 
(Quirós et al., 2008; Miguel et al., 2010). Recently, casein was demonstrated to be a 
suitable substrate for yeast strains such as Debariomyces hansenii, Kluyveromyces 
lactis and Kluyveromyces marxianus to produce antihypertensive hydrolysates (García-
Tejedor et al., 2013). This could represent a good alternative to fermentation with lactic 
acid bacteria as they are considered GRAS (Generally Recognised As Safe) 
microorganisms. These fermentation processes usually lead to complex peptide 
profiles. In this regard, in chapter I, the casein hydrolysates produced by different 
yeasts strains of D. hansenii, K. lactis and K. marxianus where ACE-inhibitory activity 
was observed, were analysed by MS-based techniques. This analysis was targeted at 
previously reported active peptides present in an enzymatic hydrolysate i.e RYLGY, 
AYFYPEL (Contreras et al., 2009), in fermented milk i.e. LHLPLP, and its derived 
peptide (HLPLP); and in sour milk i.e. VPP and IPP (Nakamura et al., 1995a). The 
peptides RYLGY, AYFYPEL, VPP and IPP could not be identified in any of the 
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hydrolysates produced by the yeasts strains used in chapter I. However, LHLPLP and 
HLPLP were present in two of the casein hydrolysates produced by strains of 
D.hansenii (Dh1 and Dh14) at concentrations of 15.6 and 52.7 µg/mg in Dh1 and 
Dh14, respectively in the case of the first sequence, and 43.5 and 46.4 µg/mg in Dh1 
and Dh14, respectively, for the latter peptide. In spite of these differences in the 
concentration of LHLPLP between the two hydrolysates, no significant differences in 
ACE-inhibitory values were found among the two hydrolysates.  These results suggest 
the implication of other sequences in the potency of ACE-inhibitory activity of the 
hydrolysates. Indeed, the zymography assay carried out on the hydrolysates to 
evaluate the extracellular proteolytic activity, indicated a different proteolytic profile for 
both hydrolysates, which was reflected on the peptidic profile. The β-casein region 
containing residues 128-140 gave rise to numerous peptides beside the active 
sequences LHLPLP and HLPLP, i.e. LHLPLPL and HLPLPL, among others. The two 
latter peptides have been also identified in Valdeón cheese digest (chapter III), and in 
jejunal content of humans after ingestion of casein (Boutrou et al., 2013). In spite of the 
absence of IPP in the hydrolysates produced by D. hansenii, several sequences 
identified shared some residues with this active peptide i.e IPPLT, IPPLTQT or 
IPPLTQTP. In this regard, gastrointestinal digestion could play an important role in the 
release of active fragments from some of these sequences, which deserves further 
investigations.  
In any case, the generation of the two sequences LHLPLP (f(133-138) and 
HLPLP (134-138) by yeasts within a casein matrix provides an alternative to the use of 
lactic acid bacteria for the production of active hydrolysates. The results provided by 
this work are relevant since this region of the β-casein (residues 128-140) is a well 
conserved domain between different species, and has been underlined as a resistant 
core of the protein to in vitro, static and dynamic, gastrointestinal digestion (chapter III 
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and IV), and the shorter fragment, HLPLP, was absorbed into blood circulation in rats 
(chapter V).  
On the other hand, technological processing leads to modifications in food 
components, which can ultimately affect the protein behavior and the nutritional value 
of food, as pointed out in previous sections. Once the production has been studied and 
optimised, as it could be the case of a fermented product or an active hydrolysate 
(chapter I), the packaging and the storage time of the final product is an important 
issue to take into account, especially for cheese (Pantaleão et al., 2007). Cheese 
undergoes proteolysis during ripening. In this regard, the application of MS-based 
techniques to study the proteolysis phenomena in cheese has been reported as a 
useful tool (Piraino et al., 2007). In addition, when cheese is packed in order to extend 
its life-time the impact of packaging on the ripening process should be assessed. 
However, to our knowledge, few comparative studies on the peptide profile of cheese 
in regard of the packaging technologies have been carried out. Thus, in chapter II, 
peptidomic analysis of semi-hard cheese packed with two different systems, vacuum 
packaging (VP), and modified atmosphere packaging (MAP) was studied. The 
evolution of the peptide profile along the storage time and their differences depending 
on the packaging systems were evaluated. The UV chromatograms were not different 
between VP and MAP cheeses. However, the MS profile revealed some differences. 
Numerous peptides from the N-terminal region of αs1-casein (i.e. residues 1-23) were 
found in both cheeses (VP and MAP). The peptide bond Phe23-Phe24 is susceptible of 
cleavage by chymosin, giving rise to two major fragments: αs1-casein f(1-23) and f(24-
199) (McSweeney & Fox, 1993). In this regard, the results obtained are in accordance 
to what it was reported for Emmental cheese (Gagnaire et al., 2001). However, in 
Valdeón cheese (chapter III) this trend at N-terminal was not observed before 
digestion; in contrast, more homogeneous distribution of the peptide profile throughout 
the protein was observed. This could be due to the different proteolysis phenomena 
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undergone by semi-hard and blue cheeses. Conversely to αs1-casein, the peptides 
derived from β-casein built up a profile homogenously distributed throughout the 
protein sequence in agreement to the results reported during Emmental cheese 
ripening (Gagnaire et al., 2001). Overall, although slight qualitative differences in the 
peptide profile from αs1-casein with respect of the packaging technology, no differences 
were found for β-casein. However, the relative abundance of some sequences was 
different in VP and MAP at 90 days of storage time. For instance αs1-casein f(24-32) 
and (25-32), and β-casein f(44-52) achieved greater intensities in VP. On the contrary, 
the relative abundance of αs1-casein f(1-16) and f(46-52) and f(74-82) was higher in 
MAP. While the behavior of β-casein peptides during the storage time was similar 
regardless of the packaging technology, differences could be detected for αs1-casein 
peptides among VP and MAP.  
In terms of bioactivity, some of the identified peptides in both semi-hard cheeses 
have been previously reported as active sequences. Among these sequences (nine), 
only three of them were common for both semi-hard and Valdeón blue cheese before 
digestion (chapter III). Nonetheless, out of those three sequences, only the ACE-
inhibitor β-casein f(47-52), DKIHPF (Gómez-Ruiz et al., 2004; 2006), survived 
gastrointestinal digestion of the blue cheese (chapter III), which is consistent with the 
identification of this sequence in vivo (Boutrou et al., 2013). However, the other two β-
casein sequences i.e. the opioid peptide f(60-68), YPFPGPIPN (β-CM 9) (Jinsmaa & 
Yoshikawa, 1999) and the antihypertensive sequence f(169-175), KVLPVPQ (Maeno et 
al., 1996), did not resist in vitro digestion of cheese (chapter III). Nevertheless, other 
active peptides, not identified in the peptidomic profiles of semi-hard or Valdeón 
cheese, were generated through gastrointestinal digestion, as in the case of the 
antihypertensive f(133-138), LHLPLP from β-casein (chapter III). In any case, great 
number of biologically active peptides could be found after gastrointestinal digestion 
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although it remains to be clarified if these are produced in vivo in a significant amount 
to exert a physiological effect.  
The important role of gastrointestinal digestion on the formation and 
bioavailability of peptides derived from milk proteins has been highlighted. The 
physiological changes that food undergoes upon ingestion determine their 
bioaccesibility, and ultimately their bioactivity (Fernández-García et al., 2009). Once 
the food matrices have been characterised, in terms of production of active sequences 
i.e. HLPLP and LHLPLP in yeasts hydrolysates, or the influence of packaging 
technologies and the storage time in the peptide profile of proteolised matrices, the 
next step was to study the impact of digestion on food proteins and on the stability or 
formation of peptides. In this respect, it is known that certain sequences that showed in 
vitro activity, did not exert any in vivo biological effect, and vice versa. In some cases, 
the explanation lies on the effect of digestion on the stability of these peptides. For 
instance the case of Lactokinin, which was not stable enough to digestion to maintain 
its activity (Walsh et al., 2004). In addition, some conditions may affect proteins and the 
subsequent release of peptides upon digestion, such as the free ends and cleavage 
sites which are determined by the proteolytic state of the matrix. Thus, in chapter III, 
Spanish blue cheese (Valdeón) and skimmed milk powder (SMP), two dairy matrices 
containing the same proteins but in different degree of proteolysis were digested using 
an in vitro static digestion model (Martos et al., 2010). In this work, the exhaustive 
peptidomic analysis of undigested cheese revealed the presence of several previously 
reported active sequences in cheese. Nevertheless, the simulated digestion process of 
both food matrices led to the release of a high number of peptide sequences, among 
them, previously reported active peptides, such as antihypertensive, antibacterial or 
antioxidant sequences. The total peptide homology estimated for the cheese before 
and after digestion (12%) and between cheese and SMP digests (19%) suggested that 
digestion process could bring closer the resulting products from certain regions of the 
Discussion 
 
245 
 
protein, even if the matrices and the proteolysis degree were initially different. For 
instance, the β-casein domains 60-93, 128-140 and 193-209 were found to be resistant 
in both, cheese and SMP digests, probably due to the presence of hydrophobic 
residues such as Pro (Vanhoof et al., 1995). The region comprised between residues 
128-140 was found to be especially resistant to hydrolysis during cheese ripening and 
digestion thereof, and also in SMP digest. This is consistent with results from in vitro 
dynamic gastric digestion of SMP (chapter IV), in vitro static digestion of β-casein 
(Dupont et al., 2010a) and also from humans studies after ingestion of casein (Boutrou 
et al., 2013). In this sense, these results are relevant since they highlight the resistance 
of this β-casein domain to in vitro (dynamic and static models) and in vivo digestion that 
hosts the active sequences LHLPLP and HLPLP.  
A higher number of peptides was found in cheese digest compared to SMP. This 
can be attributed to the extensive proteolysis phenomena undergone by blue cheese 
(Cantor et al., 2004;, Sousa et al., 2001; Diezhandino et al., 2013; Fresno et al., 2013), 
which exposes numerous cleavage sites to digestion enzymes. It has to be underlined 
that the αs1-casein sequence YFYPEL f(144-149), described as antioxidant (Suetsuna 
et al., 2000), mucin production stimulant  (Martínez-Maqueda et al., 2013) and 
antihypertensive (chapter VII), was found in cheese and SMP digests. However, its 
related peptide, the sequence AYFYPEL f(143-149), was not detected after digestion of 
SMP, but only in digested cheese. These results are interesting because both 
sequences (YFYPEL and AYFYPEL) are present in the active casein hydrolysate 
produced with food-grade pepsin used in chapter VII, and were both identified in SMP 
after gastric dynamic digestion (chapter IV). Likely, AYFYPEL was found in stomach 
effluents from calves after ingestion of milk, nevertheless YFYPEL was identified in 
duodenal contents in the same study (Chabance et al., 1998). These two sequences 
are formed in gastric phase by the action of pepsin, but it seems that YFYPEL can 
survive intestinal digestion. Since AYFYPEL could be found in blue cheese, but not in 
SMP after gastrointestinal simulation, this could suggest the influence of the food 
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matrix on the release of peptides during digestion. Likewise, the antihypertensive 
peptide LHLPLP f(133-138) from β-casein, was present in cheese digests, but not 
detected in digested SMP. This fact could be related to the need of a precursor 
sequence in the matrix in order to release this active peptide through digestion. 
Moreover, the presence of this peptide has been recently reported in jejunal effluents 
from humans after ingestion of casein (Boutrou et al., 2013). In this sense, fermented 
milk containing LHLPLP, the major responsible for its activity, caused blood depressor 
effect on SHR after long term intake compared to the fermented milk lacking LHLPLP, 
with no ACE activity, used as negative control (Miguel et al., 2005). Thus, this fact 
brings up the question whether the amount of this sequence released in vivo from 
casein could elicit appreciable biological effect.    
Dynamic digestion models are more realistic in terms of physiological parameters 
compared to the static ones (Guerra et al., 2012). Therefore, in this thesis, chapter IV 
represents a forward step in the study of digestion of milk proteins after the static in 
vitro model.  Some technological processes such as heat treatment may influence the 
behavior of milk proteins through digestion. Therefore, the impact of heat treatment on 
protein and the subsequent release of peptides during gastric dynamic digestion were 
evaluated in chapter IV.Heat treatment affected the behavior of proteins in different 
manner, as shown in the electrophoretic runs. The increase of the resistance to 
digestion observed for caseins was in accordance to previously reported results in 
caseins (Picariello et al., 2010), β-casein or in raw milk (Dupont et al., 2010a; 2010c). 
However, the β-Lg became more susceptible to hydrolysis by pepsin, even though it is 
known to be resistant to gastric digestion. Probably the heat-induced structural 
changes that led to the exposure of the cleavage sites made the protein more 
susceptible to the action of pepsin (Peram et al., 2013). The different behavior of these 
proteins through digestion of heated and unheated milk could also be explained by the 
heat-induced aggregates that may be formed between β-Lg and caseins (Guyomarc’h 
et al., 2003).  
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Although the impact of heat treatment on the behavior of milk proteins during 
digestion has been widely evaluated, the application of MS-based techniques to study 
peptide release has been less studied (Kopf-Bolanz et al., 2014; Dupont et al., 2010b; 
2010c). Heat treatments irreversibly affect conformational status and aggregation of the 
protein matrix. Therefore, peptidomes arising from digestion are expectedly divergent, 
at least to some extent (Nyemb et al., 2014). The peptidomic analysis in this work has 
permitted to evaluate the influence of heating on the final products resulting from milk 
protein digestion, focusing on the active sequences. The peptide homology calculated 
in this work allowed to highlight the difference in the pattern of peptide release at short 
times of digestion and the importance of the exposure time to enzymes on the release 
of peptides. Indeed, it is not after 50 min that digestion starts to bring closer the 
peptidome of certain regions of proteins from heated and unheated milk. Nevertheless, 
at the end of digestion only 48% of peptide homology was achieved, which points out 
the impact of the heat treatment on the identity of the peptides generated through 
digestion. The resistance of certain regions to gastrointestinal enzymes has been 
observed, and some of them were common for heated and unheated milk. This is the 
case of the β-casein domains comprised between residues 76-93, 128-140 or the C-
terminal part of the protein, as also reported in chapter III, and coincident with highly 
hydrophobic areas at low pH (Dupont et al., 2010c). The MS-analysis also revealed 
some differences between heated and unheated milk, not only in the identity of 
peptides but also in the pattern of release thereof. These differences could have health 
implications from the bioactivity point of view and also regarding the generation or 
resistance of epitopes. The region 76-93 of the protein hosts various binding epitopes, 
for instance f(82-93), still identified at 405 min of digestion in unheated milk, and 
previously described as an IgE binding fragment (Benedé et al., 2014). With respect to 
the time of peptide release some sequences had different hydrolysis rate in heated and 
non-heated milk. This fact could represent an important aspect to consider in terms of 
nutritional and physiological efficiency, since the absorption rate and the postprandrial 
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N utilization is related to this issue (Lacroix et al., 2006b, c; Deglaire et al., 2009a). The 
gastric step plays a key role in digestion since the peptides generated during this 
phase will be delivered to duodenum, where they can be further hydrolysed, be 
absorbed or interact with intestinal receptors in situ (Langerholc et al., 2011; Shimizu et 
al., 2010). Both, the absorption rate of these products as well as the interaction with 
receptors at intestinal epithelium may be affected by the hydrolysis rate of peptides 
during digestion. Some examples of the identified active sequences with different rate 
of hydrolysis in heated and unheated milk are αs1-casein f(25-32) (VAPFPEVF), αs1-
casein f(90-94) (RYLGY) or β-casein f(94-105) (GVSKVKEAMAPK), β-casein f(132-
140) (NLHLPLPLL), αs1-casein f(144-149) (YFYPEL), among others. The two latter 
peptides were also found in chapter III, in cheese and SMP digests. In addition, these 
sequences could be detected in intestinal effluents of humans after ingestion of casein 
(Boutrou et al., 2013) and milk (Chabance et al., 1998), respectively. These results 
indicate that they may be formed at gastric phase (chapter IV), and they can resist 
intestinal digestion in vivo, regardless of the matrix ingested, a protein fraction (casein) 
or milk. Likely, bioactive peptides from other proteins could be found in heated or 
unheated milk, for instance, αs2-casein f(183-206) and f(183-207), reported as 
antibacterial (Recio et al., 1999), and also identified in effluents gathered from mini-pigs 
after ingestion of milk (Barbé et al., 2014). These results imply the identification of 
several peptide sequences during dynamic gastric digestion that are also generated in 
vivo, which in sufficient amount may elicit a biological effect, and in some cases also 
correlate with their formation in vitro. Altogether, these results suggest the importance 
of digestion in the formation or resistance of bioactive peptides.  
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3.2 Bioavailability of food-derived peptides. ADME studies 
Once the resistance of some peptides to digestion has been assessed by the 
application of gastrointestinal digestion models, it is important to establish their 
bioavailability. Little information is available on the absorption of hypotensive food-
derived peptides, which is essential to determine their mechanism of action and a 
cause-effect relationship. Previous works of our group had identified the β-casein 
peptide LHLPLP in fermented milk produced by different strains of E. faecalis (Quirós 
et al., 2007). chapter I, shows that this peptide can be also produced with similar 
efficiency by food-grade yeasts. In fact, LHLPLP was specifically proven to be resistant 
to gastrointestinal digestion (Quirós et al., 2009), although it was further hydrolysed by 
brush border enzymes, releasing the penta-peptide, HLPLP, which was transported 
through Caco-2 monolayer (Quirós et al., 2008). The penta-peptide retained 
hypertensive activity (Miguel et al., 2010).  In addition, the β-casein domain 128-140, 
where these sequences are included, was found to be resistant to digestion as 
previously discussed (chapter s III and IV). This background brought up the question 
about the ability of the penta-peptide HLPLP to reach blood circulation, since generally 
only amino acids, di- or tri-peptides derived from food had been previously 
demonstrated to be absorbed in plasma. For instance IPP, LPP and VPP from casein 
reported in pigs (van der Pijl et al., 2008) and in humans (Foltz et al., 2007). In chapter 
V, the peptide f(134-138), HLPLP, from β-casein was identified in plasma samples 
collected from rats fed the synthetic peptide, using an UPLC coupled to a Q-TOF 
instrument. This is the first report of the absorption and of the pharmacokinetic 
parameters for a food-derived penta-peptide (HLPLP) in rats fed the synthetic peptide. 
In addition, several derived fragments from HLPLP could be detected in blood stream 
as a result of the action of plasmatic peptidases on this peptide. The MS-based 
analytical method developed after the exhaustive optimisation of the parameters was 
shown to be sensitive enough to detect and quantify the penta-peptide in plasma with a 
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detection limit of 0.03 nmol/L (0.02 ng/mL). It has to be underlined that the oral 
bioavailability obtained for HLPLP (5.18%), was greater than that observed for the tri-
peptides above mentioned, estimated at 0.059-0.077%  in a pig model (van der Pijl et 
al., 2008).  
Two derived fragments from β-casein i.e f(135-138), LPLP and f(134-137), HLPL, 
were detected in plasma after intravenous administration of HLPLP. After oral 
administration they could also be detected, although not quantified, because they were 
under the LOQ of the analytical method. After intravenous administration, the peptides 
LPLP and HLPL represented 206.7% and 21.8%, respectively, of the precursor 
peptide, which suggest a wide biotransformation of HLPLP by plasma peptidases. The 
formation of LPLP could be predominant compared to HLPL, or the latter might 
undergo faster degradation, which would lead to a lower concentration of HLPL in 
either case. Probably, the cleavage at His-Leu from HLPLP is favored compared to 
Leu-Pro, since the Pro confers more resistance to peptidases (Vanhoof et al., 1995). 
Moreover, the two Pro residues present in the sequence LPLP may have impaired its 
further degradation. Keeping in mind the metabolism of HLPLP after oral and 
intravenous administration, the oral bioavailability calculated for this sequence could 
have been underestimated, since this parameter was established only considering the 
intact amount of the penta-peptide, and not any of its derived fragments. These results 
represent relevant and valuable information since these derived fragments generated 
in vivo by plasmatic peptidases have influence on the pharmacokinetic behavior of 
HLPLP and might affect the in vivo physiological effect produced by this peptide.  
In chapter VI, the in vivo metabolism of HLPLP was confirmed by in vitro 
incubation thereof in rat plasma. The analytical method used in chapter V was adapted 
to achieve the best conditions focused on the possible fragments derived from HLPLP 
metabolism. After in vitro incubation of the peptide HLPLP in plasma the fragments 
LPLP, HLPL and HLP were identified. The tri-peptide HLP could not be detected in 
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vivo, nor after intravenous neither after oral administration of the penta-peptide 
(chapter V). Probably, this fact was a matter of concentration that precludes its 
detection in vivo. Matsui et al. (2000) conducted an in vitro incubation of the peptide 
IVY in rat and human plasma that resulted in the identification of VY and Y. Although 
the hydrolysis of the parent sequence occurred faster in human plasma compared to 
rat, both in vitro incubations resulted in the formation of the same derived fragments. 
Therefore, as the in vitro incubation in rat plasma was similar to that in human in 
qualitative terms, it could be considered a suitable approach to confirm the generation 
of the derived fragments, as in the case of our work.  
The sequences derived from HLPLP metabolism were orally administered to 
SHR to evaluate their antihypertensive activity. All the peptide fragments identified after 
in vitro incubation of HLPLP in plasma (LPLP, HLPL and HLP) retained 
antihypertensive activity after oral administration to SHR. These results are important 
because the effective absorption of HLPLP was estimated only considering the parent 
peptide, and this work demonstrates the hypotensive effect of its derived fragments 
when orally administered. Thus, the in vivo effect of HLPLP is influenced by the 
generation of these peptide fragments. Furthermore, two additional peptide fragments 
that could possibly be generated from HLPLP in plasma were also tested in SHR i.e 
LPL and PLP, and showed antihypertensive activity. Indeed, PLP, which has Pro 
residues at ultimate and penultimate position, meets structural features that favour the 
binding to ACE (Cheung et al., 1980; Rohrbach et al., 1981), and also confer 
resistance to peptidases. In this regard, this work provides a novel tri-peptide from β-
casein (PLP) that could derive from metabolism of the penta-peptide in plasma, which 
showed long-lasting hypotensive effect even at 24h post-administration.  
Considering the T1/2a (2.79 min) and the time to reach maximum concentration 
(Tmax, 11.88 min) estimated for HLPLP in chapter V, the peptide was rapidly absorbed, 
and the maximum SBP decrease was observed at 2h post-administration (chapter VI). 
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This value of T1/2a was similar to that found for IPP (3.3 min) and for VPP (4.6 min); 
although their Tmax 8.6 and 8.9 min, respectively, (van der Pijl et al., 2008), were lower 
than that observed for HLPLP. Interestingly, the maximum decrease on SBP produced 
by IPP and VPP was recorded at 8 and 4h after their respective administration 
(Nakamura et al., 1995). In the case of HLPLP, the further degradation in plasma into 
smaller fragments seems to influence its in vivo effect that reaches its maximum 
decrease at 2h post-administration, and afterwards starts to recover. This could 
suggest the importance of establishing the suitable pharmacokinetic criteria, not only in 
regard of absorption, distribution and elimination of peptides, but also of their further 
metabolism, that correlate to the subsequent effect.   
 
3.3 Evaluation of alternative mechanisms of action of food-derived peptides 
The blood depressor effect of food-derived peptides has been widely studied, 
however, their mechanism of action is still a controversial issue. Some of the known 
antihypertensive peptides have shown ACE-inhibitory activity, nevertheless, the 
correspondence between the effect in vivo and in vitro has only been demonstrated in 
few cases, in rats after single oral administration (Nakamura et al., 1995b), or after 
long-term intake (Sipola et al., 2001), and in humans (Seppo et al., 2003). This 
discrepancy could be due to further degradation of the compound during 
gastrointestinal digestion or because other mechanisms of action different from ACE 
are implicated (Martinez-Maqueda et al., 2012). The involvement of endogenous opioid 
peptides in the regulation of blood pressure has been demonstrated (Siren et al., 1992; 
Czapla et al., 1998). Indeed, the decrease on mean arterial pressure produced by a 
quimeric opioid peptide (YPFPFRTic-NH2) based on morphiceptin and the 
neuropeptide FF, were antagonised by the co-administration of naloxone, and it was 
suggested the implication of endothelial NO pathway in the response (Li et al., 2013). 
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However, the implication of opioid receptors in the antihypertensive effect of food-
derived peptides has only been demonstrated in few cases, for instance α-Lactorphin 
(Nurminen et al., 2000). Moreover, this peptide was shown to improve endothelial 
function associated to NO (Sipola et al., 2002b).  
One of the objectives of this thesis was to evaluate the implication of opioid 
receptors on the antihypertensive activity of peptides RYLGY, AYFYPEL and YFYPEL, 
and the casein hydrolysate containing the same, by the co-administration of naloxone. 
In previous works of our group, the production of a hypotensive casein hydrolysate 
using food-grade pepsin was developed, where two of the main peptides from αs1-
casein showed antihypertensive effect i.e. RYLGY [f(90-95)] and AYFYPEL [f(143-
149)] (Contreras et al., 2009). They were also demonstrated to inhibit ACE in vitro and 
to exert antioxidant activity. Later on, Sanchez et al. (2011) reported an improvement of 
aorta and mesenteric acetylcholine relaxation after the administration of this 
hydrolysate to SHR during 6 weeks, in addition to an increase on eNOS gene 
expression in aorta. Interestingly, in chapter VII, the results provided evidence of the 
involvement of opioid receptors in the casein hydrolysate effect and for two of the main 
peptides (RYLGY and AYFYPEL), although not for YFYPEL. Two sequences similar to 
RYLGY, i.e. RYLGYL and RYLGYLE, had been previously reported as opioid peptides 
(Loukas et al., 1983). In addition, the Tyr at N-terminal end of the sequence and the 
presence of Phe and Tyr at third or fourth position have been described as favourable 
structural features for opioid receptor binding, except for αs1-casein opioids that could 
present Arg at N-terminal (Meisel et al., 1997).  The peptide AYFYPEL, whose 
structure does not contain Tyr at N-terminal, showed antagonism with naloxone. 
Conversely, YFYPEL, which displayed the structural traits favourable for the interaction 
with opioid receptors, did not show any evidence of such antagonism. Although the 
presence of Ala in first position at N-terminal end has not been described as an 
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important structural trait for the interaction with opioid receptors, it seemed to be crucial 
for the antihypertensive activity of AYFYPEL that involved opioid receptors. 
The antagonism of the hydrolysate when co-administered with naloxone indicates 
the implication of opioid receptors in its effect. These results suggest the contribution of 
both sequences (RYLGY and AYFYPEL) to the overall effect of the hydrolysate. 
Moreover, the antihypertensive effect of the peptide YFYPEL, present in the 
hydrolysate is reported for the first time. However, the possibility of synergic effect with 
other active peptides present in the hydrolysate should not be discarded.  
Furthermore, the differences on the peptide profile between the casein 
hydrolysate and the precursor casein, suggested that even though the hydrolysate was 
produced with a gastric enzyme, food-grade pepsin, the pattern of peptide release and 
probably the amount thereof differs from that generated during gastrointestinal 
digestion. These differences could explain the absence of biological effect in the casein 
preparation and the significant antihypertensive effect of the peptic casein hydrolysate 
after their oral administration to SHR, as shown in results. Thus, the importance of 
gastrointestinal digestion on the biological effect of food matrices was pointed out. 
The results derived from this work provide important information since they 
demonstrate the implication of opioid receptors in the antihypertensive effect of two 
milk-derived peptides present in a casein hydrolysate, for which such implication was 
also evidenced. Furthermore, the antihypertensive activity of YFYPEL was 
demonstrated for the first time, although its mechanism of action deserves future 
investigations. Therefore, this work highlights the contribution of other mechanisms of 
action different to ACE-inhibition in the in vivo antihypertensive effect.  
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CONCLUSIONS 
1. Two strains of Debaryomyces hansenii, isolated from ewe’s and goat’s milk 
cheese, are able to produce the β-casein-derived antihypertensive sequences 
f(133-138), LHLPLP, and f(134-138), HLPLP, by fermentation of commercial 
casein.  
 
2. The packaging technology, vacuum or modified atmosphere, does not lead to 
differences in the qualitative peptide profile of semi-hard cheese in the course of 
storage time, although it affects the relative abundance of the peptides.  
 
3. β-casein domains comprised between residues 60-93, 126-140 and 190-209, are 
resistant to simulated gastrointestinal digestion regardless of the dairy matrix: 
blue cheese, skim milk powder or heated and unheated milk, and of the in vitro 
digestion model used (static or dynamic). These regions are well conserved 
between species and host several bioactive sequences. The proteolytic state of 
food-stuffs is a determinant factor in the presence of these sequences’ 
precursors. 
 
4. Heat treatment of milk induces an increase in the resistance of caseins to 
hydrolysis by pepsin, in contrast to β-Lg, which becomes more susceptible to 
dynamic simulated gastric digestion. The pattern of peptides released is also 
affected by the heat treatment applied, being only 48% of peptide homology 
among heated and non-heated milk samples.  
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5. The absorption of the penta-peptide from β-casein f(134-138), HLPLP, into blood 
circulation in rats was demonstrated for the first time. The total effective 
absorption reached was 5.18%. The peptide was further hydrolysed by the action 
of plasma peptidases in vivo giving rise to the fragments HLPL, f(134-137) and 
LPLP, f(135-138). 
 
6. The in vivo metabolism of the penta-peptide in plasma was confirmed in vitro by 
incubation, giving rise to the two fragments generated in vivo, and in addition to 
the tri-peptide HLP, f(134-136). These three peptide fragments, as well as 
f(135-137), LPL and f(136-138), PLP, show a potent antihypertensive activity in 
spontaneously hypertensive rats.  
 
7. Opioid receptors could be involved in the mechanism of action of the 
antihypertensive αs1-casein peptides f(90-94), RYLGY and f(143-149), 
AYFYPEL and the casein hydrolysate comprising both, since their activity is 
antagonised by naloxone.  
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CONCLUSIONES 
1. Dos cepas de Debaryomyces hansenii, aisladas de quesos de leche de cabra y 
oveja, son capaces de liberar las secuencias antihipertensivas derivadas de la 
β-caseína, LHLPLP, f(133-138) y HLPLP, f(134-138), mediante la fermentación 
de caseína comercial. 
 
2. En queso semicurado, el tipo de envasado, al vacío o en atmósfera modificada, 
no da lugar a diferencias cualitativas en el perfil peptídico durante el tiempo de 
almacenamiento, aunque sí en la abundancia relativa de los péptidos.  
 
3. Los dominios de la β-caseína comprendidos entre los residuos 60-93, 126-140 y 
190-209 son resistentes al proceso de simulación de la digestión gastrointestinal 
independientemente del producto lácteo digerido: queso azul, leche en polvo, 
leche tratada y no tratada térmicamente y del modelo de digestión utilizado, bien 
estático o dinámico. Estas regiones están bien conservadas entre especies y 
albergan numerosas secuencias bioactivas. El estado proteolítico del alimento es 
un factor determinante en la presencia de los precursores de estas secuencias. 
 
4. El tratamiento térmico de la leche provoca un aumento de la resistencia de las 
caseínas a la digestión por pepsina mientras que la β-Lg resulta más susceptible 
a la digestión gástrica dinámica. El calentamiento al que se somete la leche 
afecta al patrón de liberación de péptidos de los digeridos, alcanzándose sólo un 
48% de homología entre los péptidos presentes en las muestras de leche con 
diferente tratamiento térmico.  
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5. Se demuestra por primera vez la absorción de un penta-péptido derivado de la β-
caseína, f(134-138), HLPLP, llegando intacto al torrente sanguíneo de rata tras 
su administración oral. Su valor de absorción efectiva fue de 5.18%. El péptido 
se hidroliza in vivo en el plasma dando lugar a los fragmentos HLPL, f(134-137) y 
LPLP, f(135-138).  
 
6. El metabolismo in vivo del penta-péptido fue confirmado in vitro en plasma dando 
lugar a los dos fragmentos identificados in vivo, y además encontrándose el tri-
peptido HLP, f(134-136). Estos tres fragmentos, así como f(135-137), LPL y 
f(136-138), PLP, muestran una potente actividad antihipertensiva en ratas 
espontáneamente hipertensas. 
 
7. Los receptores opioides podrían estar involucrados en el mecanismo de acción 
de los péptidos antihipertensivos αs1-caseína f(90-94), RYLGY, y αs1-caseína 
f(143-149), AYFYPEL, así como del hidrolizado que los contiene, dado que su 
actividad antihipertensiva se antagoniza con la coadministración de naloxona.  
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